Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
1_CD
._.
Accounting_GER
policies_NN
Accounting_GER
convention_NOMZ
The_DT
financial_JJ
statements_NOMZ
are_VPRT [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
cost_NN
convention_NOMZ
and_CC
in_PIN
accordance_NN
with_PIN
applicable_JJ
accounting_GER
standards_NN
._.
Basis_NN
of_PIN
consolidation_NOMZ
The_DT
consolidated_JJ
accounts_NN
include_VPRT
the_DT
results_NN
of_PIN
the_DT
Company_NN
and_CC
all_QUAN
of_PIN
its_PIT
subsidiary_NN
undertakings_GER
._.
No_SYNE
profit_NN
and_PHC
loss_NN
account_NN
is_VPRT [PASS]
presented_VBN
for_PIN
Celltech_NN
Group_NN
plc_NN
,_,
as_IN
provided_VBN
by_PIN
section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
The_DT
results_NN
of_PIN
businesses_NOMZ
acquired_VBN [WZPAST]
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
accounts_NN
from_PIN
their_TPP3
date_NN
of_PIN
acquisition_NOMZ
unless_COND
they_TPP3
are_VPRT [PASS]
held_VBN [PRIV]
for_PIN
immediate_JJ
disposal_NN
._.
Income_NN
recognition_NOMZ
Revenue_NN
from_PIN
product_NN
sales_NN
is_VPRT [PASS]
recorded_VBN
as_IN
turnover_NN
at_PIN
the_DT
invoiced_JJ
amount_NN
excluding_VBG [WZPRES]
sales_NN
and_PHC
value_NN
added_VBD [PUBV]
taxes_NN
less_JJ
estimated_JJ
provisions_NN
for_PIN
product_NN
returns_NN
,_,
wholesale_JJ
chargebacks_NN
and_PHC
rebates_NN
given_VBN [WZPAST]
to_PIN
Medicaid_NN
,_,
managed_VBD
care_NN
and_CC
other_JJ
customers_NN
._.
Cash_NN
discounts_NN
for_PIN
prompt_JJ
payment_NOMZ
are_VPRT [SPAU] [PASS]
also_RB
deducted_VBN
from_PIN
sales_NN
on_PIN
an_DT
accrual_NN
basis_NN
._.
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
title_NN
passes_VPRT
,_,
which_WDT [SERE]
is_VPRT
usually_RB
either_RB
on_PIN
shipment_NOMZ
or_CC
on_PIN
receipt_NN
of_PIN
goods_NN
by_PIN
the_DT
customer_NN
,_,
depending_VBG [PRESP]
on_PIN
local_JJ
trading_GER
terms_NN
._.
Royalties_NN
are_VPRT [PASS]
recorded_VBN
as_IN
turnover_NN
and_CC
recognized_VBN [PRIV]
on_PIN
a_DT
time_NN
accrual_NN
basis_NN
unless_COND
there_EX
remains_VPRT
uncertainty_NN
over_IN
their_TPP3
collection_NOMZ
,_,
in_PIN
which_WDT [PIRE]
case_NN
recognition_NOMZ
is_VPRT [PASS]
deferred_VBN
until_IN
such_JJ
uncertainties_NN
are_VPRT [PASS]
removed_VBN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
typically_RB
on_PIN
cash_NN
receipt_NN
._.
Revenue_NN
under_IN
research_NN
and_PHC
development_NOMZ
reimbursement_NOMZ
contracts_NN
,_,
where_RB
there_EX
is_VPRT
no_SYNE
obligation_NOMZ
to_TO
repay_VB
such_JJ
amounts_NN
,_,
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
the_DT
related_JJ
costs_NN
are_VPRT [PASS]
incurred_VBN
and_PHC
is_VPRT [PASS]
recorded_VBN
as_IN
a_DT
credit_NN
to_PIN
research_NN
and_PHC
development_NOMZ
expenditure_NN
._.
Income_NN
associated_VBN [WZPAST]
with_PIN
performance_NN
milestones_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
based_VBN
upon_PIN
the_DT
occurrence_NN
of_PIN
the_DT
event_NN
that_TSUB
triggers_VPRT
the_DT
milestone_NN
payment_NOMZ
,_,
as_IN
defined_VBN
in_PIN
the_DT
respective_JJ
agreements_NOMZ
,_,
and_ANDC
is_VPRT [PASS]
recorded_VBN
as_IN
Other_JJ
income_NN
._.
Other_JJ
payments_NOMZ
received_VBD
,_,
such_JJ
as_IN
licence_NN
fees_NN
,_,
are_VPRT [PASS]
assessed_VBN
on_PIN
a_DT
case-by-case_JJ
basis_NN
,_,
taking_VBG [PRESP]
into_PIN
account_NN
the_DT
nature_NN
of_PIN
the_DT
payment_NOMZ
and_CC
the_DT
ongoing_JJ
collaboration_NOMZ
,_,
if_COND
any_QUAN
,_,
with_PIN
the_DT
third_JJ
party_NN
and_CC
any_QUAN
possible_JJ
related_VBN
continuing_VBG
obligations_NOMZ
._.
Depending_VBG [PRESP]
on_PIN
the_DT
nature_NN
of_PIN
the_DT
arrangement_NOMZ
,_,
amounts_NN
received_VBD
may_POMD
be_VB [PASS]
recognized_VBN [PRIV]
immediately_TIME
as_IN
a_DT
component_NN
of_PIN
Other_JJ
income_NN
or_CC
deferred_VBN
over_IN
the_DT
development_NOMZ
or_CC
other_JJ
appropriate_JJ
period_NN
._.
Goodwill_NN
Goodwill_NN
represents_VPRT
the_DT
excess_NN
of_PIN
consideration_NOMZ
paid_VBN
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
net_JJ
separable_JJ
assets_NN
acquired_VBN [WZPAST]
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
Goodwill_NN
arising_VBG [WZPRES]
after_IN
1_CD
January_NN
1998_CD
is_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
its_PIT
useful_JJ
economic_JJ
life_NN
,_,
normally_RB
not_XX0
exceeding_VBG
20_CD
years_NN
,_,
on_PIN
a_DT
straight-line_JJ
basis_NN
._.
Prior_RB
to_PIN
1_CD
January_NN
1998_CD
,_,
goodwill_NN
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
directly_RB
to_PIN
reserves_NN
and_CC
upon_PIN
disposal_NN
would_PRMD
be_VB [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Intangibles_NN
Intangible_NN
assets_NN
represent_VPRT
acquired_VBN
licences_NN
,_,
patents_NN
,_,
platform_NN
technologies_NN
and_PHC
marketing_GER
rights_NN
,_,
where_RB
these_DEMP
relate_VPRT
to_PIN
specific_JJ
compounds_NN
,_,
products_NN
or_CC
know-how_NN
that_TSUB
are_VPRT
being_VBG [PASS]
developed_VBN
or_CC
used_VBN
for_PIN
commercial_JJ
applications_NOMZ
._.
Intangible_JJ
assets_NN
acquired_VBN [WZPAST]
separately_RB
from_PIN
a_DT
business_NOMZ
are_VPRT [PASS]
capitalized_VBN
at_PIN
cost_NN
._.
Intangible_JJ
assets_NN
acquired_VBN
as_IN
part_NN
of_PIN
a_DT
business_NOMZ
are_VPRT [PASS]
capitalized_VBN
separately_RB
where_RB
their_TPP3
value_NN
can_POMD
be_VB [PASS]
measured_VBN
reliably_RB
:_:
otherwise_CONJ
they_TPP3
are_VPRT [PASS]
treated_VBN
as_IN
part_NN
of_PIN
goodwill_NN
acquired_VBN [WZPAST]
with_PIN
that_DEMO
business_NOMZ
._.
Separately_NN
capitalized_VBD
intangible_JJ
assets_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
less_JJ
provision_NN
for_PIN
amortisation_NOMZ
._.
Intangible_JJ
assets_NN
in_PIN
relation_NOMZ
to_PIN
licences_NN
,_,
patents_NN
and_PHC
marketing_GER
rights_NN
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
to_TO
match_VB
the_DT
sales_NN
of_PIN
the_DT
related_JJ
products_NN
or_CC
,_,
where_RB
this_DEMP
is_VPRT
not_XX0
readily_RB
identifiable_PRED
,_,
on_PIN
a_DT
straight-line_JJ
basis_NN
._.
Estimated_VBN [PRIV] [THATD]
useful_JJ
lives_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
and_CC
are_VPRT [SPAU] [PASS]
generally_RB
presumed_VBN [PRIV]
not_XX0
to_TO
exceed_VB
20_CD
years_NN
._.
Platform_NN
technologies_NN
supporting_VBG [WZPRES]
the_DT
Groups_NN
discovery_NN
research_NN
strategy_NN
are_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB
an_DT
indefinite_JJ
life_NN
and_ANDC
consequently_CONJ
are_VPRT [BEMA]
subject_PRED
to_PIN
annual_JJ
reviews_NN
and_CC
amortised_VBN
as_RB
necessary_JJ
if_COND
impairment_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
have_VB [PEAS]
taken_VBN
place_NN
._.
Research_NN
and_PHC
Development_NOMZ
Research_NN
and_PHC
development_NOMZ
expenses_NN
include_VPRT
related_VBN
salaries_NN
,_,
contractor_NN
fees_NN
,_,
building_VBG
costs_NN
,_,
utilities_NOMZ
and_PHC
allocations_NOMZ
of_PIN
appropriate_JJ
administrative_JJ
overheads_NN
._.
Research_NN
and_PHC
development_NOMZ
costs_NN
also_RB
include_VPRT
activities_NOMZ
such_JJ
as_IN
product_NN
registration_NOMZ
and_CC
regulatory_JJ
costs_NN
._.
All_QUAN
such_JJ
costs_NN
are_VPRT [PASS]
charged_VBN
to_PIN
research_NN
and_PHC
development_NOMZ
expenditure_NN
as_IN
incurred_VBN
._.
Depreciation_NOMZ
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
all_QUAN
fixed_VBN
assets_NN
at_PIN
rates_NN
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
the_DT
cost_NN
of_PIN
each_QUAN
asset_NN
down_IN
to_TO
estimated_VBN [PRIV]
residual_JJ
values_NN
evenly_RB
over_IN
its_PIT
expected_VBN [PRIV]
useful_JJ
life_NN
,_,
as_IN
follows_VPRT
:_:
Leasehold_VB
properties_NN
and_PHC
improvements_NOMZ
the_DT
shorter_JJ
of_PIN
20_CD
years_NN
or_CC
the_DT
lease_NN
term_NN
Freehold_NN
buildings_GER
50_CD
years_NN
Freehold_NN
land_NN
no_SYNE
depreciation_NOMZ
Plant_NN
and_PHC
machinery_NN
2_CD
to_PIN
10_CD
years_NN
Celltech_NN
Annual_JJ
Report_NN
2003_CD
53_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
1_CD
._.
Accounting_GER
policies_NN
continued_VBD
Stocks_NN
Stock_NN
of_PIN
material_NN
for_PIN
use_NN
in_PIN
scheduled_VBN
clinical_JJ
trials_NN
is_VPRT [PASS]
written_VBN [PUBV]
off_PIN
to_PIN
investment_NOMZ
in_PIN
research_NN
and_PHC
development_NOMZ
upon_PIN
use_NN
or_CC
at_PIN
termination_NOMZ
of_PIN
the_DT
trial_NN
._.
Other_JJ
stocks_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Leased_JJ
assets_NN
Assets_NN
acquired_VBN
under_IN
finance_NN
leasing_VBG [WZPRES]
arrangements_NOMZ
are_VPRT [PASS]
capitalized_VBN
at_PIN
cost_NN
upon_PIN
inception_NOMZ
and_CC
depreciated_VBN
over_IN
their_TPP3
expected_VBN [PRIV]
useful_JJ
lives_NN
._.
The_DT
interest_NN
element_NOMZ
of_PIN
the_DT
rental_JJ
obligations_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
period_NN
of_PIN
the_DT
lease_NN
and_CC
represents_VPRT
a_DT
constant_JJ
proportion_NOMZ
of_PIN
the_DT
balance_NN
of_PIN
capital_NN
repayments_NOMZ
outstanding_JJ
._.
Outstanding_JJ
future_JJ
lease_NN
obligations_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
Creditors_NN
._.
Rentals_NN
paid_VBN
under_IN
operating_VBG
leases_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
they_TPP3
accrue_VPRT
._.
Foreign_NN
currencies_NN
The_DT
profit_NN
and_PHC
loss_NN
accounts_NN
and_PHC
cash_NN
flows_NN
of_PIN
overseas_PLACE
subsidiaries_NN
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
at_PIN
the_DT
average_JJ
rates_NN
of_PIN
exchange_NN
,_,
other_JJ
than_PIN
substantial_JJ
exceptional_JJ
items_NN
which_WDT [WHSUB]
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
rate_NN
on_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
._.
The_DT
adjustment_NOMZ
to_TO
closing_VBG
rates_NN
for_PIN
the_DT
year_NN
is_VPRT [PASS]
taken_VBN
to_PIN
reserves_NN
._.
Balance_NN
sheets_NN
are_VPRT [PASS]
translated_VBN
at_PIN
closing_GER
rates_NN
._.
Exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
the_DT
re-translation_NOMZ
at_PIN
closing_GER
rates_NN
of_PIN
the_DT
opening_GER
balance_NN
sheets_NN
of_PIN
overseas_PLACE
subsidiaries_NN
are_VPRT [PASS]
taken_VBN
to_PIN
reserves_NN
,_,
less_JJ
exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
related_VBN
foreign_JJ
currency_NN
borrowings_GER
._.
Tax_NN
charges_NN
and_PHC
credits_NN
arising_VBG [WZPRES]
on_PIN
such_JJ
items_NN
are_VPRT [SPAU] [PASS]
also_RB
taken_VBN
to_PIN
reserves_NN
._.
Other_JJ
exchange_NN
differences_NN
are_VPRT [PASS]
taken_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Transactions_NOMZ
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
transaction_NOMZ
or_CC
,_,
if_COND
hedged_VBN
forward_RB
,_,
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
under_IN
the_DT
related_VBN
foreign_JJ
currency_NN
contract_NN
._.
Monetary_NN
amounts_VPRT
denominated_VBN
in_PIN
a_DT
foreign_JJ
currency_NN
are_VPRT [PASS]
translated_VBN
at_PIN
closing_GER
rates_NN
at_PIN
the_DT
year_NN
end_NN
._.
Preference_NN
share_NN
dividends_NN
Accumulated_VBN
unpaid_JJ
preference_NN
share_NN
dividends_NN
have_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
reserves_NN
accrual_NN
._.
During_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
the_DT
preference_NN
shares_NN
in_PIN
existence_NN
were_VBD [PASS]
redeemed_VBN
see_VPRT [PRIV]
note_NN
24_CD
._.
Pensions_NN
The_DT
Group_NN
operates_VPRT
contributory_NN
and_CC
non-contributory_JJ
defined_VBN
benefit_NN
and_CC
defined_VBN
contribution_NOMZ
pension_NN
schemes_NN
covering_VBG [WZPRES]
the_DT
majority_NOMZ
of_PIN
its_PIT
employees_NN
._.
The_DT
scheme_NN
funds_NN
of_PIN
the_DT
defined_VBN
benefit_NN
plans_NN
are_VPRT [BYPA]
administered_VBN
by_PIN
trustees_NN
and_CC
are_VPRT [BEMA]
independent_PRED
of_PIN
the_DT
Groups_NN
finances_NN
._.
Contributions_NOMZ
are_VPRT [PASS]
paid_VBN
to_PIN
the_DT
schemes_NN
in_PIN
accordance_NN
with_PIN
the_DT
recommendations_NOMZ
of_PIN
independent_JJ
actuaries_NN
._.
The_DT
Groups_NN
contributions_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
so_RB
as_IN
to_TO
spread_VB
the_DT
costs_NN
of_PIN
pensions_NN
over_IN
employees_NN
working_VBG [WZPRES]
lives_NN
with_PIN
the_DT
Group_NN
._.
As_IN
permitted_VBN
by_PIN
SSAP_NN
24_CD
,_,
and_ANDC
as_IN
indicated_VBN [PRIV]
in_PIN
note_NN
27_CD
,_,
the_DT
defined_VBN
benefit_NN
schemes_NN
of_PIN
certain_JJ
overseas_PLACE
subsidiaries_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
local_JJ
GAAP_NN
due_JJ
to_PIN
the_DT
difficulties_NN
and_PHC
cost_NN
of_PIN
obtaining_VBG
the_DT
necessary_JJ
actuarial_JJ
information_NOMZ
._.
Payments_NOMZ
to_TO
defined_VBN
contributions_NOMZ
schemes_NN
are_VPRT [PASS]
expensed_VBN
as_IN
incurred_VBN
._.
Equity_NOMZ
investments_NOMZ
Current_JJ
asset_NN
equity_NOMZ
investments_NOMZ
are_VPRT [PASS]
valued_VBN
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
In_PIN
determining_VBG [SUAV] [PRIV]
net_JJ
realisable_JJ
values_NN
,_,
market_NN
values_NN
are_VPRT [PASS]
used_VBN
in_PIN
the_DT
case_NN
of_PIN
listed_VBN
investments_NOMZ
and_PHC
Directors_NN
estimates_NN
are_VPRT [PASS]
used_VBN
in_PIN
the_DT
case_NN
of_PIN
unlisted_JJ
investments_NOMZ
._.
Deferred_JJ
taxation_NOMZ
Deferred_VBN
taxation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
timing_NN
differences_NN
that_TSUB
have_VPRT [PEAS]
originated_VBN
but_CC
not_XX0
reversed_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
except_PIN
as_IN
otherwise_CONJ
required_VBN [SUAV]
by_PIN
FRS_NN
19_CD
on_PIN
a_DT
non-discounted_JJ
basis_NN
._.
Deferred_JJ
taxation_NOMZ
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
only_DWNT
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
there_EX
will_PRMD
be_VB
suitable_JJ
taxable_JJ
profits_NN
from_PIN
which_WDT [PIRE]
future_JJ
reversals_NN
of_PIN
the_DT
underlying_VBG
timing_NN
difference_NN
can_POMD
be_VB [PASS]
deducted_VBN
._.
Contingent_JJ
liabilities_NOMZ
The_DT
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
certain_JJ
legal_JJ
proceedings_GER
arising_VBG [WZPRES]
in_PIN
the_DT
normal_JJ
course_NN
of_PIN
its_PIT
business_NOMZ
,_,
as_IN
discussed_VBN
in_PIN
the_DT
contingent_JJ
liabilities_NOMZ
note_VPRT [PRIV]
to_PIN
the_DT
financial_JJ
statements_NOMZ
see_VPRT [PRIV]
note_NN
28_CD
._.
Provision_NN
is_VPRT [PASS]
made_VBN
in_PIN
the_DT
accounts_NN
for_PIN
all_QUAN
liabilities_NOMZ
which_WDT [WHSUB]
might_POMD
be_VB [SPAU] [PASS]
reasonably_RB
expected_VBN [PRIV]
to_TO
materialise_VB
from_PIN
these_DEMO
claims_NN
._.
Financial_NN
instruments_NOMZ
The_DT
Group_NN
uses_VPRT
financial_JJ
instruments_NOMZ
,_,
in_CONJ
particular_NULL
forward_RB
exchange_NN
contracts_NN
,_,
to_TO
manage_VB
the_DT
financial_JJ
risks_NN
associated_VBN [WZPAST]
with_PIN
the_DT
Groups_NN
underlying_VBG [WZPRES]
business_NOMZ
activities_NOMZ
and_CC
the_DT
financing_GER
of_PIN
those_DEMO
foreign_JJ
activities_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
undertake_VB
any_QUAN
trading_GER
activity_NOMZ
in_PIN
financial_JJ
instruments_NOMZ
._.
A_DT
discussion_NN
of_PIN
how_RB
the_DT
Group_NN
manages_VPRT
its_PIT
financial_JJ
risks_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
Financial_NN
Review_NN
and_CC
in_PIN
note_NN
21_CD
._.
The_DT
primary_JJ
financial_JJ
instruments_NOMZ
used_VBN [WZPAST]
by_PIN
the_DT
Group_NN
are_VPRT
forward_RB
exchange_NN
contracts_NN
which_WDT [WHSUB]
are_VPRT [PASS]
used_VBN
to_TO
hedge_VB
foreign_JJ
exchange_NN
exposures_NN
arising_VBG [WZPRES]
on_PIN
forecast_NN
receipts_NN
in_PIN
foreign_JJ
currencies_NN
._.
As_IN
the_DT
hedges_NN
are_VPRT [PASS]
not_XX0
absolutely_AMP
matched_VBN
to_PIN
specific_JJ
receivables_NN
,_,
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
until_IN
such_JJ
time_NN
as_IN
they_TPP3
have_VPRT [PEAS]
been_VBN [PASS]
realized_VBN [PRIV]
._.
The_DT
aggregate_JJ
fair_JJ
values_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
of_PIN
the_DT
hedging_GER
instruments_NOMZ
described_VBN
above_PLACE
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
note_NN
21_CD
to_PIN
the_DT
accounts_NN
._.
Analysis_NN
of_PIN
turnover_NN
,_,
profit_NN
and_CC
net_JJ
assets_NN
Turnover_NN
is_VPRT [BYPA]
represented_VBN
by_PIN
product_NN
sales_NN
and_PHC
royalties_NN
receivable_JJ
during_PIN
the_DT
year_NN
._.
Income_NN
receivable_NN
as_IN
milestones_NN
arising_VBG [WZPRES]
from_PIN
research_NN
and_PHC
development_NOMZ
collaborations_NOMZ
is_VPRT [PASS]
treated_VBN
as_IN
other_JJ
operating_GER
income_NN
._.
2003_CD
2002_CD
i_FPP1
Turnover_NN
by_PIN
geographical_JJ
destination_NOMZ
m_NN
m_NN
USA_NN
243.7_CD
231.8_CD
UK_NN
51.1_CD
41.9_CD
Rest_VPRT
of_PIN
Europe_NN
51.1_CD
48.5_CD
Rest_VPRT
of_PIN
world_NN
7.4_CD
7.4_CD
Total_JJ
353.3_CD
329.6_CD
Turnover_NN
comprises_VPRT
259.2_CD
million_CD
2002_CD
:_:
252.9_CD
million_CD
of_PIN
product_NN
sales_NN
and_CC
94.1_CD
million_CD
2002_CD
:_:
76.7_CD
million_CD
of_PIN
royalty_NN
income_NN
._.
Royalty_NN
income_NN
includes_VPRT
10.5_CD
million_CD
of_PIN
forward_RB
hedging_VBG
exchange_NN
gains_NN
._.
In_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
foreign_JJ
exchange_NN
gains_NN
of_PIN
3.7_CD
million_CD
are_VPRT [PASS]
included_VBN
in_PIN
cost_NN
of_PIN
sales_NN
._.
The_DT
Group_NN
considers_VPRT [PRIV]
that_THVC
the_DT
revised_VBN
2003_CD
presentation_NOMZ
reflects_VPRT [PRIV]
more_EMPH
appropriately_RB
the_DT
nature_NN
of_PIN
the_DT
hedging_VBG
transaction_NOMZ
._.
ii_FW
Segmental_JJ
analysis_NN
by_PIN
country_NN
of_PIN
origin_NN
Operating_GER
profit_NN
loss_NN
Loss_NN
on_PIN
ordinary_JJ
before_IN
goodwill_NN
and_PHC
activities_NOMZ
Turnover_NN
exceptional_JJ
items_NN
before_IN
interest_NN
Net_JJ
assets_NN
2003 2002 2003 2002_CD
2003 2002 2003 2002_CD
m_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
USA_NN
168.4_CD
162.5_CD
52.3_CD
41.5_CD
17.4_CD
18.1_CD
234.1_CD
313.2_CD
UK_NN
132.0_CD
116.2_CD
11.7_CD
3.2_CD
57.1_CD
24.9_CD
216.8_CD
186.0_CD
Rest_VPRT
of_PIN
Europe_NN
52.9_CD
50.9_CD
8.9_CD
10.7_CD
10.7_CD
1.7_CD
55.0_CD
65.2_CD
Total_JJ
353.3_CD
329.6_CD
49.5_CD
49.0_CD
85.2_CD
44.7_CD
505.9_CD
564.4_CD
Substantially_NN
all_QUAN
of_PIN
the_DT
turnover_NN
and_CC
operating_VBG
profits_NN
are_VPRT [PASS]
generated_VBN
from_PIN
the_DT
Groups_NN
principal_JJ
activity_NOMZ
,_,
being_VBG [PRESP] [BEMA]
the_DT
research_NN
and_PHC
development_NOMZ
of_PIN
novel_NN
therapeutic_JJ
products_NN
for_PIN
human_JJ
use_NN
and_CC
the_DT
development_NOMZ
,_,
manufacture_NN
and_PHC
sale_NN
of_PIN
prescription_NOMZ
pharmaceutical_JJ
products_NN
._.
Other_JJ
income_NN
2003_CD
2002_CD
m_NN
m_NN
Pfizer_NN
CDP870_NN
milestone_NN
6.4_CD
Other_JJ
milestone_NN
income_NN
1.5_CD
1.7_CD
Disposal_NN
of_PIN
product_NN
licences_NN
0.5_CD
Other_JJ
collaboration_NOMZ
income_NN
0.5_CD
Total_JJ
2.5_CD
8.1_CD
During_PIN
the_DT
year_NN
Pfizer_NN
gave_VBD
notice_NN
of_PIN
their_TPP3
intention_NOMZ
to_TO
terminate_VB
their_TPP3
participation_NOMZ
in_PIN
the_DT
development_NOMZ
of_PIN
CDP870_CD
from_PIN
February_NN
2004_CD
,_,
consequently_CONJ
no_SYNE
further_JJ
income_NN
will_PRMD
be_VB [PASS]
received_VBN
from_PIN
Pfizer_NN
with_PIN
regard_NN
to_PIN
this_DEMO
collaboration_NOMZ
._.
An_DT
amount_NN
of_PIN
4.8_CD
million_CD
2002_CD
:_:
5.4_CD
million_CD
is_VPRT [PASS]
held_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
within_PIN
accruals_NN
and_CC
deferred_JJ
income_NN
,_,
in_PIN
respect_NN
of_PIN
Pfizers_NN
upfront_NN
contribution_NOMZ
to_PIN
the_DT
development_NOMZ
of_PIN
CDP870_NN
in_PIN
the_DT
Crohns_NN
disease_NN
indication_NOMZ
._.
This_DEMO
amount_NN
has_VPRT [PEAS]
been_VBN [PASS]
deferred_VBN
and_PHC
is_VPRT
being_VBG [PASS]
taken_VBN
to_PIN
income_NN
over_IN
the_DT
remaining_VBG
development_NOMZ
period_NN
,_,
in_PIN
order_NN
to_TO
match_VB
the_DT
revenue_NN
with_PIN
the_DT
associated_VBN
cost_NN
._.
Research_NN
and_PHC
development_NOMZ
expenditure_NN
in_PIN
2003_CD
is_VPRT [PASS]
shown_VBN [PRIV]
net_NN
of_PIN
the_DT
0.6_CD
million_CD
2002_CD
:_:
3.7_CD
million_CD
of_PIN
the_DT
upfront_JJ
contribution_NOMZ
utilised_VBN [WZPAST]
during_PIN
the_DT
year_NN
._.
Celltech_NN
Annual_JJ
Report_NN
2003_CD
55_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
4_CD
._.
Operating_VBG
loss_NN
The_DT
operating_GER
loss_NN
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
charging_VBG
:_:
2003_CD
2002_CD
m_NN
m_NN [PASS]
Depreciation_NOMZ
owned_VBN
assets_NN
13.5_CD
12.8_CD
Depreciation_NOMZ
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_VPRT
0.4_CD
0.5_CD
Amortisation_NOMZ
intangibles_VPRT
3.2_CD
1.0_CD
Operating_GER
lease_NN
rentals_NN
plant_NN
and_PHC
machinery_NN
1.1_CD
1.4_CD
Operating_GER
lease_NN
rentals_NN
other_JJ
6.3_CD
6.4_CD
Administrative_JJ
expenses_NN
corporate_JJ
and_PHC
general_JJ
administrative_JJ
31.3_CD
26.8_CD
Depreciation_NOMZ
exceptional_JJ
items_NN
18.9_CD
Depreciation_NOMZ
goodwill_NN
94.2_CD
93.7_CD
In_PIN
2003_CD
the_DT
operating_GER
loss_NN
is_VPRT [SPAU] [PASS]
also_RB
stated_VBN [PUBV]
after_IN
the_DT
following_VBG
material_NN
items_NN
discussed_VBD
elsewhere_RB
in_PIN
this_DEMO
report_NN
:_:
10.5_CD
million_CD
2002_CD
:_:
3.7_CD
million_CD
of_PIN
exchange_NN
gains_NN
on_PIN
hedging_VBG
instruments_NOMZ
note_VPRT [PRIV]
2_CD
and_CC
3.0_CD
million_CD
2002_CD
:_:
2.9_CD
million_CD
establishment_NOMZ
of_PIN
new_JJ
provisions_NN
for_PIN
self_NN
insurance_NN
note_NN
20_CD
._.
In_CONJ
addition_NULL
in_PIN
2002_CD
,_,
there_EX
was_VBD
a_DT
provision_NN
release_NN
of_PIN
3.1_CD
million_CD
note_NN
20_CD
and_CC
a_DT
0.9_CD
million_CD
loss_NN
on_PIN
the_DT
disposal_NN
of_PIN
equity_NOMZ
investments_NOMZ
note_VPRT [PRIV]
16_CD
._.
Fees_NN
paid_VBD
to_PIN
auditors_NN
The_DT
following_JJ
summarises_NN
the_DT
audit_NN
and_CC
non-audit_JJ
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
auditor_NN
,_,
KPMG_NN
Audit_NN
Plc_NN
:_:
2003_CD
2002_CD
m_NN
m_NN
Audit_NN
services_NN
0.4_CD
0.3_CD
Further_JJ
assurance_NN
services_NN
0.3_CD
0.1_CD
Tax_NN
services_NN
compliance_NN
0.2_CD
0.2_CD
Tax_NN
services_NN
advisory_JJ
0.1_CD
0.2_CD
Total_JJ
1.0_CD
0.8_CD
The_DT
Company_NN
audit_NN
fee_NN
amounted_VBD
to_PIN
25,000_CD
2002_CD
:_:
25,000_CD
._.
There_EX
are_VPRT
no_SYNE
fees_NN
charged_VBN [WZPAST]
to_PIN
the_DT
Company_NN
for_PIN
other_JJ
services_NN
._.
Exceptional_JJ
items_NN
2003_CD
2002_CD
m_NN
m_NN [BEMA]
European_JJ
sales_NN
force_NN
restructuring_GER
9.0_CD
Write-off_PIN
CDP571_CD
stocks_NN
7.5_CD
Development_NOMZ
restructuring_GER
1.5_CD
Thiemann_NN
asset_NN
write-down_NN
0.9_CD
Operating_GER
exceptional_JJ
charge_NN
18.9_CD
Loss_NN
on_PIN
the_DT
termination_NOMZ
of_PIN
operations_NOMZ
14.6_CD
Provision_NN
against_PIN
fixed_VBN
asset_NN
investment_NOMZ
7.0_CD
Exceptional_JJ
items_NN
before_IN
taxation_NOMZ
40.5_CD
Exceptional_JJ
tax_NN
items_NN
note_VPRT [PRIV]
8_CD
31.7_CD
Exceptional_JJ
items_NN
8.8_CD
Of_PIN
the_DT
total_JJ
exceptional_JJ
charge_NN
of_PIN
40.5_CD
million_CD
before_IN
taxation_NOMZ
,_,
20.0_CD
million_CD
will_PRMD
result_VB
in_PIN
a_DT
cash_NN
outflow_NN
for_PIN
the_DT
Group_NN
and_CC
20.5_CD
million_CD
represents_VPRT
asset_NN
write-downs_NN
._.
The_DT
non-cash_JJ
items_NN
are_VPRT [BEMA]
the_DT
write-off_PIN
of_PIN
the_DT
investment_NOMZ
in_PIN
Neogenesis_NN
and_PHC
CDP571_NN
stocks_NN
together_RB
totalling_VBG
14.5_CD
million_CD
,_,
tangible_JJ
fixed_JJ
asset_NN
impairments_NOMZ
of_PIN
4.5_CD
million_CD
see_VPRT [PRIV]
note_NN
12_CD
and_CC
1.5_CD
million_CD
of_PIN
inventory_NN
write-downs_NN
at_PIN
the_DT
Santa_NN
Ana_NN
manufacturing_VBG [WZPRES]
facility_NOMZ
._.
The_DT
total_JJ
cash_NN
expenditure_NN
on_PIN
exceptional_JJ
items_NN
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
was_VBD [BEMA]
8.9_CD
million_CD
8.7_CD
million_CD
of_PIN
items_NN
booked_VBN [WZPAST]
in_PIN
the_DT
current_JJ
year_NN
and_CC
0.2_CD
million_CD
of_PIN
prior_JJ
year_NN
items_NN
,_,
leaving_VBG [PRESP]
a_DT
balance_NN
of_PIN
11.3_CD
million_CD
to_TO
be_VB [PASS]
spent_VBN
primarily_RB
during_PIN
2004_CD
._.
The_DT
total_JJ
cash_NN
cost_NN
of_PIN
20.0_CD
million_CD
includes_VPRT
14.5_CD
million_CD
of_PIN
redundancy_NN
and_CC
related_JJ
costs_NN
._.
Operating_VBG
exceptional_JJ
items_NN
European_JJ
sales_NN
force_NN
restructuring_GER
During_PIN
the_DT
year_NN
the_DT
UK_NN
,_,
French_NN
,_,
German_NN
and_CC
Spanish_JJ
sales_NN
forces_NN
have_VPRT [PEAS]
been_VBN [PASS]
restructured_VBN
from_PIN
primary_JJ
care_NN
to_PIN
specialist_NN
focus_NN
._.
The_DT
majority_NOMZ
of_PIN
the_DT
costs_NN
in_PIN
all_QUAN
locations_NOMZ
relate_VPRT
to_PIN
provisions_NN
for_PIN
redundancy_NN
and_CC
related_VBN
expenditure_NN
._.
As_IN
at_PIN
31_CD
December_NN
,_,
2003_CD
,_,
4.8_CD
million_CD
of_PIN
this_DEMO
provision_NN
remained_VBD
to_TO
be_VB [PASS]
utilised_VBN
._.
Exceptional_JJ
items_NN
continued_VBD
Write-off_PIN
of_PIN
CDP571_CD
stocks_NN
Following_VBG [WZPRES]
a_DT
review_NN
of_PIN
CDP571_CD
undertaken_VBN
during_PIN
2003_CD
,_,
it_PIT
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
that_THVC
the_DT
commercial_JJ
opportunities_NOMZ
for_PIN
this_DEMO
product_NN
,_,
including_VBG [PRESP]
its_PIT
use_NN
on_PIN
a_DT
named_VBN
patient_NN
basis_NN
,_,
would_PRMD
not_XX0
be_VB [SPAU] [PASS]
actively_RB
pursued_VBN
._.
Consequently_CONJ
,_,
the_DT
stock_NN
of_PIN
CDP571_CD
held_VBD [PRIV]
as_RB
at_PIN
31_CD
December_NN
2002_CD
7.5_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
down_RP
to_PIN
nil_NN
._.
Development_NOMZ
restructuring_GER
These_DEMO
costs_NN
relate_VPRT
primarily_RB
to_PIN
the_DT
Groups_NN
announced_VBD [PUBV]
reorganisation_NOMZ
of_PIN
the_DT
development_NOMZ
functions_NOMZ
of_PIN
the_DT
Group_NN
based_VBN [WZPAST]
in_PIN
Slough_NN
and_PHC
Cambridge_NN
._.
The_DT
charge_NN
relates_VPRT
to_PIN
provision_NN
for_PIN
redundancy_NN
costs_NN
and_CC
external_JJ
consulting_GER
costs_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
0.9_CD
million_CD
of_PIN
the_DT
total_JJ
provision_NN
remained_VBD
to_TO
be_VB [PASS]
utilised_VBN
._.
Thiemann_NN
asset_NN
write-down_NN
With_PIN
the_DT
acquisition_NOMZ
of_PIN
Thiemann_NN
in_PIN
2001_CD
,_,
the_DT
Group_NN
inherited_VBD
a_DT
freehold_NN
building_GER
in_PIN
Waltrop_NN
in_PIN
north-east_PLACE
Germany_NN
._.
During_PIN
2002_CD
,_,
Celltechs_NN
German_NN
operations_NOMZ
relocated_VBD
to_PIN
new_JJ
leased_VBN
offices_NN
in_PIN
the_DT
Essen_NN
area_NN
of_PIN
Germany_NN
._.
The_DT
charge_NN
in_PIN
2003_CD
reflects_VPRT [PRIV]
a_DT
write-down_NN
to_PIN
net_JJ
realisable_JJ
value_NN
of_PIN
the_DT
Waltrop_NN
site_NN
._.
Loss_NN
on_PIN
termination_NOMZ
of_PIN
operations_NOMZ
The_DT
table_NN
below_PLACE
sets_NN
out_PIN
the_DT
loss_NN
on_PIN
termination_NOMZ
of_PIN
operations_NOMZ
:_:
m_VB
Closure_NN
of_PIN
Seattle_NN
research_NN
operations_NOMZ
5.6_CD
Closure_NN
of_PIN
Santa_NN
Ana_NN
manufacturing_VBG [WZPRES]
facility_NOMZ
4.5_CD
OGS_NN
closure_NN
costs_VPRT
4.5_CD
Total_JJ
14.6_CD
Closure_NN
of_PIN
Seattle_NN
research_NN
operation_NOMZ
Following_VBG [WZPRES]
a_DT
review_NN
of_PIN
Celltechs_NN
long-term_JJ
research_NN
and_PHC
development_NOMZ
needs_NN
,_,
the_DT
decision_NN
was_VBD [PASS]
made_VBN
to_TO
close_VB
its_PIT
Seattle_NN
research_NN
facility_NOMZ
._.
This_DEMO
closure_NN
has_VPRT [PEAS]
resulted_VBN
in_PIN
an_DT
exceptional_JJ
charge_NN
of_PIN
5.6_CD
million_CD
,_,
reflecting_VBG [PRIV]
provision_NN
for_PIN
redundancy_NN
costs_NN
,_,
short-term_JJ
lease_NN
commitments_NOMZ
and_CC
writing_VBG [PUBV]
down_RP
the_DT
remaining_VBG
book_NN
value_NN
of_PIN
the_DT
facility_NOMZ
to_PIN
nil_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
3.4_CD
million_CD
of_PIN
the_DT
provision_NN
remained_VBD
to_TO
be_VB [PASS]
utilised_VBN
._.
Closure_NN
of_PIN
Santa_NN
Ana_NN
manufacturing_VBG [WZPRES]
facility_NOMZ
On_PIN
3_CD
June_NN
2003_CD
Celltech_NN
announced_VBD [PUBV]
the_DT
closure_NN
of_PIN
its_PIT
manufacturing_GER
facility_NOMZ
in_PIN
Santa_NN
Ana_NN
,_,
California_NN
._.
The_DT
site_NN
produced_VBD
various_JJ
methylphenidate_NN
products_NN
._.
Production_NOMZ
associated_VBN [WZPAST]
with_PIN
the_DT
tableting_GER
and_PHC
packaging_GER
of_PIN
these_DEMO
products_NN
has_VPRT [PEAS]
been_VBN [PASS]
transferred_VBN
to_PIN
the_DT
Groups_NN
facility_NOMZ
in_PIN
Rochester_NN
,_,
New_NN
York_NN
._.
The_DT
provision_NN
for_PIN
closure_NN
costs_NN
relates_VPRT
primarily_RB
to_PIN
redundancies_NN
,_,
lease_NN
commitments_NOMZ
and_PHC
asset_NN
write-downs_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
0.5_CD
million_CD
of_PIN
the_DT
provision_NN
remained_VBD
to_TO
be_VB [PASS]
utilised_VBN
._.
OGS_NN
closure_NN
costs_NN
Following_VBG [WZPRES]
Celltechs_NN
acquisition_NOMZ
of_PIN
OGS_NN
,_,
a_DT
substantial_JJ
restructuring_GER
of_PIN
the_DT
operations_NOMZ
was_VBD [PASS]
undertaken_VBN
._.
The_DT
charge_NN
relates_VPRT
primarily_RB
to_PIN
provision_NN
for_PIN
redundancy_NN
costs_NN
for_PIN
staff_NN
and_PHC
development_NOMZ
spend_VPRT
on_PIN
projects_NN
to_TO
be_VB [PASS]
discontinued_VBN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
1.7_CD
million_CD
of_PIN
the_DT
provision_NN
remained_VBD
to_TO
be_VB [PASS]
utilised_VBN
._.
Provision_NN
against_PIN
fixed_VBN
asset_NN
investment_NOMZ
Neogenesis_NN
investment_NOMZ
write-off_PIN
In_PIN
view_NN
of_PIN
the_DT
current_JJ
environment_NOMZ
for_PIN
biotechnology_NN
IPOs_NN
,_,
the_DT
Directors_NN
have_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
the_DT
estimated_VBN [PRIV]
net_JJ
realisable_JJ
value_NN
of_PIN
Celltechs_NN
investment_NOMZ
in_PIN
Neogenesis_NN
in_PIN
the_DT
event_NN
of_PIN
a_DT
trade_NN
sale_NN
is_VPRT
nil_NN
,_,
leading_VBG [PRESP]
to_PIN
a_DT
write-down_NN
of_PIN
7.0_CD
million_CD
see_VPRT [PRIV]
note_NN
13_CD
._.
Net_JJ
interest_NN
receivable_NN
2003_CD
2002_CD
m_NN
m_NN
Bank_NN
interest_NN
receivable_NN
3.5_CD
1.4_CD
Interest_NN
on_PIN
PowderJect_NN
convertible_JJ
loan_NN
note_NN
receivable_JJ
1.8_CD
2.2_CD
Tillotts_NN
loan_NN
note_NN
0.1_CD
0.1_CD
5.4_CD
3.7_CD
Interest_NN
payable_JJ
on_PIN
$_$
50m_CD
senior_JJ
debt_NN
1.9_CD
2.2_CD
Interest_NN
payable_JJ
on_PIN
revolving_VBG
credit_NN
facility_NOMZ
0.6_CD
Interest_NN
paid_VBN [WZPAST]
on_PIN
finance_NN
leases_VPRT
0.1_CD
0.1_CD
Other_JJ
0.1_CD
2.7_CD
2.3_CD
Net_JJ
interest_NN
receivable_NN
2.7_CD
1.4_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
57_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
7_CD
._.
Staff_NN
costs_NN
i_FPP1
Staff_NN
costs_NN
,_,
including_VBG [PRESP]
the_DT
emoluments_NOMZ
of_PIN
the_DT
Executive_NN
Directors_NN
,_,
amounted_VBD
to_TO
:_:
2003_CD
2002_CD
m_NN
m_NN
Salaries_NN
81.9_CD
79.4_CD
Social_NN
security_NOMZ
costs_NN
8.0_CD
7.4_CD
Other_JJ
costs_NN
including_VBG [WZPRES]
pensions_NN
9.4_CD
10.8_CD
Total_JJ
99.3_CD
97.6_CD
The_DT
above_PLACE
costs_NN
exclude_VPRT
redundancy_NN
and_CC
related_JJ
charges_NN
made_VBN [WZPAST]
during_PIN
the_DT
year_NN
of_PIN
14.5_CD
million_CD
see_VPRT [PRIV]
note_NN
5_CD
._.
ii_FW
The_DT
average_JJ
number_NN
of_PIN
staff_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
,_,
including_VBG
Executive_NN
Directors_NN
,_,
during_PIN
the_DT
year_NN
was_VBD
:_:
2003_CD
2002_CD
Number_NN
Number_NN
Production_NOMZ
556_CD
569_CD
Sales_NN
and_PHC
distribution_NOMZ
560_CD
679_CD
General_NN
and_PHC
administration_NOMZ
162_CD
176_CD
Research_NN
and_CC
technical_JJ
661_CD
613_CD
Total_JJ
1,939_CD
2,037_CD
iii_FW
Details_NN
of_PIN
the_DT
remuneration_NOMZ
of_PIN
each_QUAN
Director_NN
,_,
compensation_NOMZ
for_PIN
loss_NN
of_PIN
office_NN
,_,
pension_NN
entitlements_NOMZ
and_PHC
share_NN
options_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
Taxation_NOMZ
2003_CD
2002_CD
m_NN
m_NN
UK_NN
corporation_NOMZ
tax_NN
at_PIN
30_CD
%_NN
2002_CD
:_:
30_CD
%_NN
1.3_CD
0.7_CD
Utilisation_NOMZ
of_PIN
tax_NN
losses_NN
1.3_CD
0.7_CD
UK_NN
corporation_NOMZ
tax_NN
Overseas_PLACE
federal_JJ
and_CC
state_NN
tax_NN
7.6_CD
4.7_CD
Overseas_PLACE
deferred_JJ
tax_NN
31.5_CD
2.9_CD
Overseas_PLACE
taxation_NOMZ
23.9_CD
7.6_CD
Deferred_JJ
tax_NN
credit_NN
on_PIN
goodwill_NN
4.7_CD
5.1_CD
Taxation_NOMZ
charge_NN
28.6_CD
2.5_CD
The_DT
table_NN
below_PLACE
reconciles_NN
the_DT
actual_JJ
current_JJ
tax_NN
charge_NN
to_PIN
the_DT
expected_VBN [PRIV]
tax_NN
rate_NN
,_,
computed_VBN [PASTP]
by_PIN
applying_VBG
the_DT
UK_NN
tax_NN
rate_NN
of_PIN
30_CD
%_NN
2002_CD
:_:
30_CD
%_NN
to_PIN
the_DT
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
:_:
2003_CD
2002_CD
m_NN [PASS]
m_NN [PASS]
Expected_VBN [PRIV]
tax_NN
credit_NN
at_PIN
UK_NN
corporation_NOMZ
tax_NN
rate_NN
24.8_CD
13.0_CD
Permanent_JJ
difference_NN
on_PIN
goodwill_NN
24.5_CD
23.3_CD
Restructuring_GER
costs_NN
see_VPRT [PRIV]
below_PLACE
9.5_CD
4.7_CD
Difference_NN
in_PIN
local_JJ
tax_NN
rates_NN
0.1_CD
0.3_CD
Utilisation_NOMZ
of_PIN
losses_NN
1.3_CD
Other_JJ
1.5_CD
0.1_CD
Current_JJ
taxation_NOMZ
charge_NN
7.6_CD
4.7_CD
The_DT
deferred_VBN
taxation_NOMZ
provision_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
2003_CD
2002_CD
m_NN [PASS]
m_NN [PASS]
Accelerated_VBD
capital_NN
allowances_NN
2.2_CD
3.6_CD
Goodwill_NN
deferred_VBN
tax_NN
asset_NN
4.7_CD
Other_JJ
non-current_JJ
tax_NN
liabilities_NOMZ
22.8_CD
53.7_CD
Deferred_JJ
taxation_NOMZ
provision_NN
20.3_CD
57.3_CD
58_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
8_CD
._.
Taxation_NOMZ
continued_VBD
The_DT
movement_NOMZ
in_PIN
the_DT
provision_NN
in_PIN
the_DT
year_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
note_NN
20_CD
._.
There_EX
are_VPRT
taxation_NOMZ
losses_NN
of_PIN
approximately_RB
289_CD
million_CD
2002_CD
:_:
291_CD
million_CD
which_WDT
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
._.
Exceptional_JJ
and_CC
goodwill_NN
items_NN
2003_CD
m_NN
Tax_NN
credit_NN
on_PIN
exceptional_JJ
items_NN
3.2_CD
Release_NN
of_PIN
other_JJ
non-current_JJ
tax_NN
liabilities_NOMZ
28.5_CD
Total_JJ
exceptional_JJ
tax_NN
items_NN
31.7_CD
FRS_NN
19_CD
deferred_JJ
tax_NN
credit_NN
on_PIN
goodwill_NN
4.7_CD
Exceptional_JJ
tax_NN
and_PHC
goodwill_NN
items_NN
36.4_CD
Tax_NN
credits_NN
on_PIN
exceptional_JJ
items_NN
arising_VBG [WZPRES]
during_PIN
the_DT
year_NN
are_VPRT [BEMA]
primarily_RB
in_PIN
respect_NN
of_PIN
restructuring_GER
charges_NN
outside_PLACE
the_DT
UK_NN
._.
Where_RB
restructuring_GER
charges_NN
have_VPRT [PEAS]
led_VBN
to_PIN
an_DT
increase_NN
in_PIN
taxation_NOMZ
losses_NN
,_,
the_DT
benefit_NN
of_PIN
such_JJ
losses_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
._.
In_CONJ
addition_NULL
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
Group_NN
resolving_VBG [SUAV] [WZPRES]
a_DT
number_NN
of_PIN
outstanding_JJ
tax_NN
issues_NN
with_PIN
various_JJ
tax_NN
authorities_NOMZ
during_PIN
the_DT
course_NN
of_PIN
the_DT
year_NN
,_,
an_DT
amount_NN
of_PIN
28.5_CD
million_CD
held_VBN [PRIV]
primarily_RB
by_PIN
Medeva_NN
at_PIN
January_NN
2000_CD
has_VPRT [PEAS]
been_VBN [PASS]
released_VBN
as_IN
an_DT
exceptional_JJ
credit_NN
._.
FRS_NN
19_CD
Deferred_NN
Tax_NN
requires_VPRT [SUAV]
that_THVC
the_DT
Group_NN
recognizes_VPRT [PRIV]
deferred_JJ
tax_NN
assets_NN
in_PIN
respect_NN
of_PIN
the_DT
timing_NN
difference_NN
associated_VBN [WZPAST]
with_PIN
goodwill_NN
._.
This_DEMP
has_VPRT [PEAS]
resulted_VBN
in_PIN
the_DT
Group_NN
recognizing_VBG [PRIV] [WZPRES]
a_DT
deferred_JJ
tax_NN
asset_NN
of_PIN
4.7_CD
million_CD
in_PIN
the_DT
year_NN
._.
It_PIT
is_VPRT [PASS]
anticipated_VBN [PRIV]
that_THVC
additional_JJ
deferred_JJ
tax_NN
assets_NN
will_PRMD
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
subsequent_JJ
years_NN
before_IN
reversing_VBG
in_PIN
accordance_NN
with_PIN
the_DT
nature_NN
of_PIN
the_DT
timing_NN
difference_NN
._.
Earnings_GER
per_PIN
share_NN
The_DT
basic_JJ
loss_NN
per_PIN
share_NN
is_VPRT [PASS]
based_VBN
upon_PIN
a_DT
loss_NN
of_PIN
54.0_CD
million_CD
2002_CD
:_:
loss_NN
of_PIN
46.0_CD
million_CD
after_IN
deduction_NOMZ
of_PIN
preference_NN
share_NN
dividends_NN
of_PIN
0.1_CD
million_CD
2002_CD
:_:
0.2_CD
million_CD
and_CC
a_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
of_PIN
276.4_CD
million_CD
2002_CD
:_:
275.4_CD
million_CD
._.
The_DT
earnings_GER
per_PIN
share_NN
before_IN
goodwill_NN
and_CC
exceptional_JJ
items_NN
is_VPRT [PASS]
provided_VBN
based_VBN
on_PIN
a_DT
profit_NN
of_PIN
44.3_CD
million_CD
2002_CD
:_:
profit_NN
of_PIN
42.6_CD
million_CD
._.
This_DEMP
is_VPRT [PASS]
reconciled_VBN
to_PIN
the_DT
loss_NN
of_PIN
54.0_CD
million_CD
2002_CD
:_:
loss_NN
of_PIN
46.0_CD
million_CD
as_IN
set_VBN
out_PIN
below_PLACE
:_:
2003_CD
2002_CD
m_NN
m_NN [BEMA]
Attributable_JJ
loss_NN
54.0_CD
46.0_CD
Goodwill_NN
amortisation_NOMZ
note_NN
11_CD
94.2_CD
93.7_CD
Exceptional_JJ
items_NN
note_VPRT [PRIV]
5_CD
40.5_CD
Tax_NN
on_PIN
goodwill_NN
and_CC
exceptional_JJ
tax_NN
items_NN
note_VPRT [PRIV]
8_CD
36.4_CD
5.1_CD
Adjusted_JJ
profit_NN
44.3_CD
42.6_CD
The_DT
Directors_NN
believe_VPRT [PRIV]
that_THVC
earnings_GER
per_PIN
share_NN
based_VBN [WZPAST]
on_PIN
the_DT
adjusted_JJ
profit_NN
provides_VPRT
useful_JJ
additional_JJ
information_NOMZ
for_PIN
shareholders_NN
._.
The_DT
diluted_JJ
earnings_GER
loss_NN
per_PIN
share_NN
takes_VPRT
into_PIN
account_NN
the_DT
dilutive_JJ
effect_NN
of_PIN
share_NN
options_NOMZ
and_CC
convertible_JJ
preference_NN
shares_NN
._.
A_DT
reconciliation_NOMZ
between_PIN
the_DT
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
the_DT
calculation_NOMZ
of_PIN
the_DT
basic_JJ
and_PHC
diluted_JJ
earnings_GER
loss_NN
per_PIN
share_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
below_PLACE
:_:
2003_CD
2002_CD
Number_NN
Number_NN
m_FW
m_FW [BEMA]
Basic_JJ
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
276.4_CD
275.4_CD
Share_NN
options_NOMZ
1.1_CD
0.6_CD
Convertible_JJ
preference_NN
shares_NN
0.5_CD
1.9_CD
Diluted_NN
number_NN
of_PIN
shares_NN
278.0_CD
277.9_CD
Due_JJ
to_PIN
the_DT
loss-making_JJ
position_NOMZ
of_PIN
the_DT
Group_NN
,_,
the_DT
exercise_NN
of_PIN
share_NN
options_NOMZ
and_PHC
conversion_NN
of_PIN
preference_NN
shares_NN
do_VPRT
not_XX0
increase_VB
the_DT
basic_JJ
loss_NN
per_PIN
share_NN
and_ANDC
therefore_CONJ
,_,
according_VBG [PRESP]
to_PIN
FRS_NN
14_CD
the_DT
basic_JJ
and_PHC
diluted_JJ
loss_NN
per_PIN
share_NN
remain_VPRT
the_DT
same_JJ
._.
The_DT
2003_CD
and_CC
2002_CD
earnings_GER
per_PIN
share_NN
before_IN
goodwill_NN
and_CC
exceptional_JJ
items_NN
and_CC
the_DT
preference_NN
share_NN
dividend_NN
have_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
for_PIN
the_DT
dilutive_JJ
effect_NN
._.
Profit_NN
attributable_JJ
to_PIN
members_NN
of_PIN
the_DT
holding_VBG [PRIV]
company_NN
In_PIN
accordance_NN
with_PIN
the_DT
exemption_NOMZ
allowed_VBN [SUAV] [WZPAST]
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
the_DT
Company_NN
has_VPRT [PEAS]
not_XX0
presented_VBN
its_PIT
own_JJ
profit_NN
and_PHC
loss_NN
account_NN
._.
The_DT
profit_NN
in_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Company_NN
was_VBD [BEMA]
4.9_CD
million_CD
2002_CD
:_:
profit_NN
6.8_CD
million_CD
._.
Celltech_NN
Annual_JJ
Report_NN
2003_CD
59_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
11_CD
._.
Intangible_JJ
fixed_JJ
assets_NN
Goodwill_NN
Intangible_NN
assets_NN
Group_NN
m_FW
m_FW
m_FW
Cost_NN
At_PIN
1_CD
January_NN
2003_CD
1,011.7_CD
48.1_CD
1,059.8_CD
Additions_NOMZ
1.8_CD
1.8_CD
Acquisition_NOMZ
of_PIN
OGS_NN
8.1_CD
8.1_CD
Exchange_NN
1.0_CD
1.0_CD
At_PIN
31_CD
December_NN
2003_CD
1,019.8_CD
48.9_CD
1,068.7_CD
Provisions_NN
for_PIN
amortisation_NOMZ
At_PIN
1_CD
January_NN
2003_CD
618.9_CD
1.0_CD
619.9_CD
Amortisation_NOMZ
charged_VBN [WZPAST]
in_PIN
the_DT
year_NN
94.2_CD
3.2_CD
97.4_CD
At_PIN
31_CD
December_NN
2003_CD
713.1_CD
4.2_CD
717.3_CD
Net_JJ
book_NN
value_NN
At_PIN
31_CD
December_NN
2003_CD
306.7_CD
44.7_CD
351.4_CD
At_PIN
31_CD
December_NN
2002_CD
392.8_CD
47.1_CD
439.9_CD
The_DT
goodwill_NN
amortisation_NOMZ
charge_NN
reflects_VPRT [PRIV]
a_DT
full_JJ
year_NN
of_PIN
ownership_NN
of_PIN
Medeva_NN
88.3_CD
million_CD
,_,
Cistron_NN
0.7_CD
million_CD
and_CC
Thiemann_NN
4.7_CD
million_CD
and_CC
an_DT
eight-month_JJ
charge_NN
in_PIN
respect_NN
of_PIN
OGS_NN
of_PIN
0.5_CD
million_CD
see_VPRT [PRIV]
note_NN
22_CD
._.
Medeva_NN
and_PHC
Thiemann_NN
goodwill_NN
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
seven_CD
years_NN
._.
Cistron_NN
and_PHC
OGS_NN
goodwill_NN
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
10_CD
years_NN
._.
Included_VBN [PASTP]
within_PIN
intangible_JJ
assets_NN
is_VPRT [BEMA]
a_DT
payment_NOMZ
of_PIN
11.8_CD
million_CD
to_PIN
Abgenix_NN
for_PIN
extensive_JJ
access_NN
to_PIN
its_PIT
SLAM_NN
Selective_NN
Lymphocyte_NN
Antibody_NN
Method_NN
technology_NN
._.
Amortisation_NOMZ
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
charged_VBN
on_PIN
this_DEMO
in_PIN
the_DT
year_NN
as_IN
the_DT
Directors_NN
consider_VPRT [PRIV]
that_THVC
it_PIT
has_VPRT
an_DT
indefinite_JJ
life_NN
._.
As_IN
required_VBN [SUAV]
by_PIN
FRS_NN
10_CD
,_,
Goodwill_NN
and_PHC
Intangible_NN
Assets_NN
,_,
the_DT
Directors_NN
have_VPRT [PEAS]
undertaken_VBN
an_DT
impairment_NOMZ
review_NN
to_TO
support_VB
the_DT
carrying_VBG
value_NN
._.
The_DT
SLAM_NN
technology_NN
has_VPRT [PEAS]
been_VBN [PASS]
combined_VBN
with_PIN
the_DT
Groups_NN
existing_VBG [WZPRES]
antibody_NN
technologies_NN
in_PIN
order_NN
to_TO
expand_VB
the_DT
breadth_NN
of_PIN
the_DT
antibody_NN
pipeline_NN
and_CC
extend_VB
the_DT
repertoire_NN
of_PIN
drug_NN
targets_NN
._.
The_DT
technology_NN
is_VPRT [PASS]
seen_VBN [PRIV]
as_IN
core_NN
to_PIN
Celltechs_NN
research_NN
activities_NOMZ
and_CC
will_PRMD
continue_VB
to_TO
benefit_VB
the_DT
Group_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
,_,
accordingly_RB
Celltech_NN
has_VPRT [PEAS]
rebutted_VBN
the_DT
presumption_NOMZ
that_TOBJ
useful_JJ
economic_JJ
life_NN
should_NEMD
be_VB
no_RB
longer_RB
than_PIN
20_CD
years_NN
as_IN
permitted_VBN
by_PIN
FRS_NN
10_CD
,_,
Goodwill_NN
and_PHC
Intangible_NN
Assets_NN
._.
As_IN
required_VBN [SUAV]
by_PIN
FRS_NN
10_CD
,_,
this_DEMO
matter_NN
will_PRMD
be_VB [PASS]
kept_VBN
under_IN
review_NN
and_PHC
SLAM_NN
technology_NN
will_PRMD
be_VB [BEMA]
subject_PRED
to_PIN
an_DT
annual_JJ
impairment_NOMZ
review_NN
._.
In_PIN
July_NN
2002_CD
,_,
the_DT
Group_NN
announced_VBD [PUBV]
that_THVC
it_PIT
had_VBD [PEAS]
entered_VBN
into_PIN
arrangements_NOMZ
with_PIN
Pharmacia_NN
now_TIME
part_NN
of_PIN
Pfizer_NN
to_TO
access_VB
its_PIT
product_NN
Dipentum_NN
in_PIN
the_DT
US_FPP1
and_CC
European_JJ
markets_NN
._.
The_DT
European_JJ
product_NN
rights_NN
were_VBD [PASS]
acquired_VBN
outright_RB
for_PIN
$_$
20_CD
million_CD
._.
The_DT
US_FPP1
agreement_NOMZ
provided_VBD
Celltech_NN
with_PIN
exclusive_JJ
sales_NN
,_,
marketing_GER
and_PHC
distribution_NOMZ
rights_NN
until_IN
January_NN
2005_CD
,_,
at_PIN
which_WDT [PIRE]
time_NN
Celltech_NN
can_POMD
acquire_VB
the_DT
product_NN
outright_RB
at_PIN
its_PIT
option_NOMZ
for_PIN
$_$
5_CD
million_CD
._.
The_DT
substance_NN
of_PIN
the_DT
US_FPP1
transaction_NOMZ
is_VPRT
that_DEMO
of_PIN
an_DT
outright_JJ
acquisition_NOMZ
settled_VBD
through_PIN
a_DT
series_NN
of_PIN
payments_NOMZ
which_WDT [WHSUB]
are_VPRT
capital_NN
in_PIN
nature_NN
over_IN
the_DT
period_NN
to_PIN
January_NN
2005_CD
,_,
followed_VBN [PASTP]
by_PIN
the_DT
$_$
5_CD
million_CD
exercise_NN
element_NOMZ
._.
In_PIN
accordance_NN
with_PIN
FRS_NN
5_CD
,_,
Reporting_GER
the_DT
Substance_NN
of_PIN
Transactions_NOMZ
,_,
the_DT
Group_NN
has_VPRT [PEAS]
capitalized_VBN
the_DT
total_NN
of_PIN
these_DEMO
payments_NOMZ
of_PIN
$_$
35.4_CD
million_CD
._.
The_DT
total_JJ
capitalized_JJ
for_PIN
the_DT
European_JJ
and_CC
US_FPP1
rights_NN
is_VPRT
thus_CONJ
$_$
55.4_CD
million_CD
35.3_CD
million_CD
._.
The_DT
total_JJ
capital_NN
payments_NOMZ
made_VBN [WZPAST]
during_PIN
2003_CD
amounted_VBD
to_PIN
11.7_CD
million_CD
._.
The_DT
Dipentum_NN
asset_NN
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
15_CD
years_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
Directors_NN
estimate_NN
of_PIN
the_DT
products_NN
useful_JJ
economic_JJ
life_NN
._.
In_PIN
estimating_VBG [PRIV]
the_DT
useful_JJ
life_NN
the_DT
Directors_NN
have_VPRT [PEAS]
had_VBN
regard_NN
to_PIN
market_NN
projections_NOMZ
,_,
barriers_NN
to_PIN
entry_NN
and_PHC
risk_NN
of_PIN
generic_JJ
products_NN
and_PHC
substitutes_NN
._.
Dipentum_NN
sales_NN
recorded_VBN [WZPAST]
by_PIN
the_DT
Group_NN
in_PIN
2003_CD
are_VPRT [BEMA]
17.1_CD
million_CD
2002_CD
:_:
4.6_CD
million_CD
part_NN
year_NN
only_DWNT
._.
The_DT
Group_NN
has_VPRT
assets_NN
in_PIN
the_DT
course_NN
of_PIN
construction_NOMZ
or_CC
commissioning_VBG
which_WDT
are_VPRT [PASS]
not_XX0
depreciated_VBN
of_PIN
9.6_CD
million_CD
2002_CD
:_:
18.4_CD
million_CD
._.
Of_PIN
the_DT
9.6_CD
million_CD
,_,
6.2_CD
million_CD
are_VPRT [PASS]
included_VBN
within_PIN
the_DT
long_JJ
leasehold_NN
category_NN
and_CC
3.4_CD
million_CD
are_VPRT [BEMA]
within_PIN
plant_NN
and_PHC
machinery_NN
._.
The_DT
assets_NN
in_PIN
the_DT
course_NN
of_PIN
construction_NOMZ
relate_VPRT
primarily_RB
to_PIN
the_DT
expansion_NN
of_PIN
the_DT
laboratory_NN
facilities_NOMZ
at_PIN
Slough_NN
and_CC
an_DT
upgrade_NN
to_PIN
the_DT
manufacturing_GER
facility_NOMZ
at_PIN
Ashton_NN
._.
Capital_NN
expenditure_NN
of_PIN
16.2_CD
million_CD
in_PIN
the_DT
year_NN
took_VBD
place_NN
principally_RB
on_PIN
the_DT
UK_NN
Research_NN
and_PHC
Development_NOMZ
facilities_NOMZ
based_VBN [WZPAST]
in_PIN
Slough_NN
7.7_CD
million_CD
,_,
the_DT
Ashton_NN
manufacturing_GER
site_NN
1.3_CD
million_CD
and_CC
the_DT
Rochester_NN
manufacturing_GER
site_NN
3.1_CD
million_CD
._.
The_DT
freehold_JJ
land_NN
and_PHC
building_GER
addition_NOMZ
of_PIN
$_$
2_CD
million_CD
1.1_CD
million_CD
relates_VPRT
to_PIN
the_DT
property_NN
acquired_VBN [WZPAST]
from_PIN
Dr_NN
Ando_NN
in_PIN
a_DT
related_JJ
party_NN
transaction_NOMZ
note_NN
25_CD
._.
Of_PIN
the_DT
total_JJ
expenditure_NN
of_PIN
16.2_CD
million_CD
,_,
1.2_CD
million_CD
was_VBD [PASS]
accrued_VBN
at_PIN
the_DT
year_NN
end_NN
relating_VBG [WZPRES]
to_TO
spend_VB
at_PIN
Slough_NN
and_PHC
Ashton_NN
._.
Transfers_NN
relate_VPRT
to_PIN
certain_JJ
assets_NN
in_PIN
the_DT
course_NN
of_PIN
construction_NOMZ
which_WDT [WHSUB]
were_VBD [SPAU] [PASS]
initially_TIME
capitalized_VBN
within_PIN
freehold_NN
buildings_GER
,_,
but_CC
which_WDT
have_VPRT [PEAS]
been_VBN [PASS]
transferred_VBN
to_PIN
plant_NN
and_PHC
machinery_NN
once_TIME
commissioned_VBN
._.
On_PIN
the_DT
disposal_NN
of_PIN
fixed_JJ
assets_NN
no_SYNE
material_NN
profit_NN
nor_SYNE
loss_NN
arose_VBD
._.
Investments_NOMZ
Long-term_JJ
investments_NOMZ
Group_NN
Company_NN
2003 2002 2003 2002_CD
m_FW
m_FW
m_FW
m_FW
Loan_NN
notes_VPRT [PRIV]
1.9_CD
32.9_CD
Investment_NOMZ
in_PIN
Neogenesis_NN
7.0_CD
Investment_NOMZ
in_PIN
OGS_NN
107.3_CD
Investments_NOMZ
in_PIN
subsidiary_NN
undertakings_GER
199.3_CD
199.3_CD
Loans_NN
to_PIN
subsidiary_NN
undertakings_GER
4.3_CD
93.6_CD
Own_NN
shares_NN
held_VBD [PRIV]
0.9_CD
0.3_CD
0.6_CD
At_PIN
31_CD
December_NN
2003_CD
2.8_CD
40.2_CD
311.5_CD
292.9_CD
The_DT
Company_NN
investment_NOMZ
in_PIN
OGS_NN
of_PIN
107.3_CD
million_CD
reflects_VPRT [PRIV]
a_DT
receipt_NN
of_PIN
1.2_CD
million_CD
in_PIN
cash_NN
in_PIN
respect_NN
of_PIN
share_NN
options_NOMZ
received_VBN [WZPAST]
in_PIN
OGS_NN
._.
The_DT
net_JJ
figure_NN
of_PIN
106.1_CD
million_CD
is_VPRT [BEMA]
the_DT
Group_NN
investment_NOMZ
in_PIN
OGS_NN
as_IN
shown_VBN [PRIV]
in_PIN
note_NN
22_CD
._.
Loans_NN
to_PIN
subsidiary_NN
undertakings_GER
have_VPRT [PEAS]
been_VBN [BYPA]
subordinated_VBN
by_PIN
Celltech_NN
Group_NN
plc_NN
in_PIN
favor_NN
of_PIN
any_QUAN
third_JJ
party_NN
liabilities_NOMZ
that_TSUB
may_POMD
accrue_VB
._.
Celltech_NN
Annual_JJ
Report_NN
2003_CD
61_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
13_CD
._.
Investments_NOMZ
continued_VBD
Movements_NOMZ
in_PIN
investments_NOMZ
during_PIN
the_DT
year_NN
are_VPRT
as_IN
follows_VPRT
:_:
Group_NN
Company_NN
m_FW
m_FW [BEMA]
At_PIN
1_CD
January_NN
2003_CD
40.2_CD
292.9_CD
PowderJect_NN
loan_NN
notes_NN
repaid_VBN
31.0_CD
Acquisition_NOMZ
of_PIN
own_JJ
shares_NN
1.4_CD
1.4_CD
Accrual_NN
for_PIN
deferred_VBN
bonus_NN
scheme_NN
0.8_CD
0.8_CD
Write-down_NN
of_PIN
Neogenesis_NN
investment_NOMZ
7.0_CD
Movement_NOMZ
in_PIN
loans_NN
to_PIN
subsidiary_NN
undertakings_GER
89.3_CD
Acquisition_NOMZ
of_PIN
OGS_NN
107.3_CD
At_PIN
31_CD
December_NN
2003_CD
2.8_CD
311.5_CD
ESOPs_NN
Employee_NN
share_NN
schemes_NN
set_VBN
up_RP
as_IN
trusts_NN
hold_VPRT [PRIV]
Celltech_NN
Group_NN
plc_NN
ordinary_JJ
shares_NN
to_TO
meet_VB
potential_JJ
obligations_NOMZ
under_IN
the_DT
schemes_NN
._.
Options_NOMZ
are_VPRT [BYPA]
satisfied_VBN
by_PIN
the_DT
transfer_NN
of_PIN
shares_NN
held_VBN [PRIV] [WZPAST]
in_PIN
trust_NN
where_RB
newly_RB
issued_VBN
shares_NN
are_VPRT [PASS]
not_XX0
used_VBN
._.
The_DT
Chiroscience_NN
1994_CD
Share_NN
Ownership_NN
Plan_NN
Trust_NN
holds_VPRT [PRIV]
255,346_CD
shares_NN
at_PIN
31_CD
December_NN
2003_CD
,_,
of_PIN
which_WDT [PIRE]
43,806_CD
are_VPRT
to_TO
meet_VB
options_NOMZ
vested_VBN
but_CC
not_XX0
yet_RB
exercised_VBN
under_IN
the_DT
Chiroscience_NN
1997_CD
All_QUAN
Employee_NN
Share_NN
Option_NOMZ
Scheme_NN
._.
It_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
intention_NOMZ
that_TOBJ
the_DT
shares_NN
over_IN
and_CC
above_PLACE
those_DEMP
required_VBN [SUAV]
to_TO
meet_VB
the_DT
43,806_CD
granted_VBN [SUAV]
and_PHC
vested_VBN
options_NOMZ
will_PRMD
be_VB [PASS]
used_VBN
to_TO
meet_VB
obligations_NOMZ
under_IN
other_JJ
schemes_NN
in_PIN
the_DT
future_NN
._.
On_PIN
13_CD
January_NN
2003_CD
,_,
the_DT
Celltech_NN
Group_NN
Employee_NN
Share_NN
Trust_NN
purchased_VBD
400,000_CD
shares_NN
with_PIN
funds_NN
gifted_JJ
by_PIN
Celltech_NN
Group_NN
plc._NN
._.
At_PIN
the_DT
year_NN
end_NN
the_DT
Celltech_NN
Group_NN
Employee_NN
Share_NN
Trust_NN
holds_VPRT [PRIV]
551,756_CD
shares_NN
,_,
of_PIN
which_WDT [PIRE]
77,718_CD
are_VPRT
to_TO
meet_VB
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Deferred_NN
Bonus_NN
Plan_NN
which_WDT [WHSUB]
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
exercised_VBN
but_CC
have_VPRT [PEAS]
vested_VBN
,_,
and_ANDC
377,632_CD
which_WDT
have_VPRT [PEAS]
not_XX0
yet_RB
vested_VBN
._.
The_DT
book_NN
value_NN
of_PIN
all_QUAN
Company_NN
shares_NN
held_VBN [PRIV] [WZPAST]
in_PIN
trust_NN
has_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
down_RP
by_PIN
0.3_CD
million_CD
,_,
being_VBG [PRESP] [BEMA]
the_DT
cost_NN
of_PIN
shares_NN
over_IN
which_WDT
options_NOMZ
have_VPRT [PEAS]
vested_VBN
._.
The_DT
cost_NN
of_PIN
shares_NN
over_IN
which_WDT
options_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
granted_VBN [SUAV]
but_CC
not_XX0
vested_VBN
at_PIN
31_CD
December_NN
2003_CD
is_VPRT [PASS]
accrued_VBN
over_IN
the_DT
period_NN
to_TO
vesting_VBG
._.
At_PIN
the_DT
year_NN
end_NN
the_DT
accrual_NN
is_VPRT [BEMA]
0.5_CD
million_CD
._.
In_PIN
total_JJ
,_,
the_DT
amount_NN
accrued_VBN
or_CC
written_VBN [PUBV]
down_RP
is_VPRT [BEMA]
0.8_CD
million_CD
,_,
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
table_NN
above_PLACE
._.
The_DT
total_JJ
market_NN
value_NN
of_PIN
the_DT
Companys_NN
shares_NN
held_VBD [PRIV]
in_PIN
trust_NN
at_PIN
31_CD
December_NN
2003_CD
is_VPRT [BEMA]
3.1_CD
million_CD
,_,
based_VBN [PASTP]
on_PIN
the_DT
year-end_JJ
price_NN
of_PIN
3.78_CD
._.
Other_JJ
investments_NOMZ
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
has_VPRT
one_CD
remaining_VBG
loan_NN
note_NN
due_RB
from_PIN
Tillotts_NN
Pharma_NN
AG_NN
._.
This_DEMO
loan_NN
note_NN
was_VBD [PASS]
issued_VBN
to_PIN
Medeva_NN
PLC_NN
on_PIN
26_CD
April_NN
1999_CD
._.
The_DT
loan_NN
note_NN
bears_VPRT
interest_NN
at_PIN
4_CD
%_NN
per_PIN
annum_NN
and_CC
is_VPRT [BEMA]
repayable_PRED
in_PIN
annual_JJ
instalments_NOMZ
dependent_JJ
on_PIN
the_DT
underlying_VBG
adjusted_JJ
profits_NN
of_PIN
Tillotts_NN
Pharma_NN
AG_NN
,_,
or_CC
at_PIN
the_DT
latest_JJ
by_PIN
31_CD
December_NN
2011_CD
._.
In_PIN
2001_CD
,_,
Celltech_NN
acquired_VBD
a_DT
minority_NOMZ
interest_NN
in_PIN
Neogenesis_NN
for_PIN
$_$
10_CD
million_CD
7.0_CD
million_CD
._.
With_PIN
the_DT
acquisition_NOMZ
of_PIN
OGS_NN
the_DT
Group_NN
inherited_VBD
a_DT
further_JJ
4.3_CD
million_CD
stake_NN
in_PIN
Neogenesis_NN
._.
The_DT
total_JJ
investment_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
down_RP
to_TO
nil_VB
as_RB
at_PIN
31_CD
December_NN
2003_CD
,_,
based_VBN [PASTP]
on_PIN
the_DT
expected_VBN [PRIV]
realisable_JJ
value_NN
._.
This_DEMP
is_VPRT [BEMA]
due_PRED
to_PIN
the_DT
shareholder_NN
structure_NN
which_WDT [WHSUB]
allows_VPRT [SUAV]
series_NN
A-D_NN
shareholders_NN
to_TO
recover_VB
their_TPP3
investment_NOMZ
before_IN
series_NN
E_NN
investors_NN
._.
Both_DT
the_DT
initial_JJ
Celltech_NN
holding_GER
and_CC
that_DEMP
inherited_VBN
with_PIN
OGS_NN
are_VPRT
part_NN
of_PIN
the_DT
series_NN
E_NN
shares_NN
._.
Celltech_NN
and_CC
other_JJ
series_NN
E_NN
shareholders_NN
would_PRMD [SPAU]
only_DWNT
recover_VB
their_TPP3
investment_NOMZ
if_COND
the_DT
sales_NN
proceeds_NN
of_PIN
Neogenesis_NN
exceeded_VBD
$_$
33.0_CD
million_CD
._.
For_PIN
the_DT
reasons_NN
set_VBN [WZPAST]
out_PIN
in_PIN
note_NN
5_CD
,_,
the_DT
Celltech_NN
Directors_NN
do_VPRT
not_XX0
consider_VB [PRIV]
this_DEMO
likely_JJ
._.
The_DT
existing_VBG
Celltech_NN
holding_GER
has_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
as_IN
an_DT
exceptional_JJ
item_NN
in_PIN
the_DT
period_NN
,_,
whereas_OSUB
the_DT
OGS_NN
holding_GER
was_VBD [PASS]
written_VBN [PUBV]
off_PIN
as_IN
a_DT
fair_JJ
value_NN
adjustment_NOMZ
to_PIN
the_DT
acquired_VBN
assets_NN
of_PIN
that_DEMO
company_NN
._.
Investments_NOMZ
continued_VBD
The_DT
following_VBG
information_NOMZ
relates_VPRT
to_PIN
the_DT
Companys_NN
principal_JJ
subsidiary_NN
undertakings_GER
Proportion_NOMZ
held_VBD [PRIV]
at_PIN
Country_NN
of_PIN
31_CD
December_NN
Name_NN
of_PIN
Company_NN
incorporation_NOMZ
Holding_VBG [PRIV] [WZPRES]
2003_CD
Nature_NN
of_PIN
Business_NOMZ
Celltech_NN
R&D_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Darwin_NN
Discovery_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Chiroscience_NN
R&D_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Oxford_NN
GlycoSciences_NN
UK_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Research_NN
and_PHC
Development_NOMZ
Confirmant_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Celltech_NN
R&D_NN
Inc_NN
USA_NN
Common_NN
stock_NN
100_CD
%_NN
Cistron_NN
Biotechnology_NN
,_,
Inc_NN
USA_NN
Common_NN
stock_NN
100_CD
%_NN
Darwin_NN
Molecular_NN
Corporation_NOMZ
USA_NN
Common_NN
stock_NN
100_CD
%_NN
Holding_VBG [PRIV] [WZPRES]
company_NN
Oxford_NN
GlycoSciences_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Celltech_NN
Pharma_NN
GmbH_NN
&_CC
Co_NN
KG_NN
Germany_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Celltech_NN
Pharmaceuticals_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Celltech_NN
Manufacturing_GER
Services_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
International_NN
Medication_NOMZ
Systems_NN
UK_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Manufacture_NN
and_PHC
sale_NN
of_PIN
a_DT
range_NN
Celltech_NN
Pharma_NN
SA_NN
Spain_NN
Ordinary_NN
shares_NN
100_CD
%_NN
of_PIN
branded_JJ
specialty_NN
and_CC
generic_JJ
Celltech_NN
Pharma_NN
SA_NN
France_NN
Ordinary_NN
shares_NN
100_CD
%_NN
pharmaceutical_JJ
products_NN
Celltech_NN
Pharma_NN
SA_NN
Belgium_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Celltech_NN
Nordic_NN
ApS_NN
Denmark_NN
Common_NN
stock_NN
100_CD
%_NN
Medeva_NN
Pharma_NN
Schweiz_NN
AG_NN
Switzerland_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Owns_VPRT
intellectual_JJ
property_NN
relating_VBG [WZPRES]
to_PIN
pharmaceutical_JJ
products_NN
Celltech_NN
Manufacturing_GER
CA_NN
,_,
Inc_NN
USA_NN
Common_NN
stock_NN
100_CD
%_NN
Celltech_NN
Pharmaceuticals_NN
,_,
Inc_NN
USA_NN
Common_NN
stock_NN
100_CD
%_NN
Manufacture_NN
and_PHC
sale_NN
of_PIN
a_DT
range_NN
of_PIN
Celltech_NN
Manufacturing_GER
,_,
Inc_NN
USA_NN
Common_NN
stock_NN
100_CD
%_NN
branded_VBD
specialty_NN
and_CC
generic_JJ
Upstate_NN
Pharma_NN
,_,
LLC_NN
USA_NN
Common_NN
stock_NN
100_CD
%_NN
pharmaceutical_JJ
products_NN
Celltech_NN
Technologies_NN
,_,
Inc_NN
USA_NN
Common_NN
stock_NN
100_CD
%_NN
Leasing_GER
operations_NOMZ
Celltech_NN
US_FPP1
,_,
Inc_NN
USA_NN
Common_NN
stock_NN
100_CD
%_NN
Holding_VBG [PRIV] [WZPRES]
companies_NN
Celltech_NN
Holdings_GER
,_,
Inc_NN
USA_NN
Common_NN
stock_NN
100_CD
%_NN
Celltech_NN
Pharma_NN
Europe_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Holding_VBG [PRIV] [THATD] [WZPRES]
company_NN
Owns_VPRT
licences_NN
and_CC
other_JJ
intellectual_JJ
property_NN
relating_VBG [WZPRES]
to_PIN
pharmaceutical_JJ
products_NN
Medeva_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Holding_VBG [PRIV] [WZPRES]
company_NN
Celltech_NN
Limited_NN
England_NN
Ordinary_NN
shares_NN
100_CD
%_NN
Treasury_NN
operations_NOMZ
Celltech_NN
Reinsurance_NN
Ireland_NN
Limited_NN
Ireland_NN
Common_NN
stock_NN
100_CD
%_NN
Insurance_NN
operations_NOMZ
Celltech_NN
Insurance_NN
Ireland_NN
Limited_NN
Ireland_NN
Common_NN
stock_NN
100_CD
%_NN
Directly_RB
held_VBD [PRIV]
A_DT
full_JJ
list_NN
of_PIN
subsidiaries_NN
will_PRMD
be_VB [PASS]
annexed_VBN
to_PIN
the_DT
Companys_NN
next_JJ
annual_JJ
return_NN
filed_VBN [WZPAST]
with_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
._.
Stock_NN
Group_NN
2003_CD
2002_CD
m_NN
m_NN
Raw_NN
materials_NN
and_CC
consumables_VPRT
6.1_CD
5.8_CD
Clinical_JJ
trials_NN
material_NN
2.7_CD
7.9_CD
Work_NN
in_PIN
progress_NN
7.7_CD
10.6_CD
Finished_VBN
goods_NN
and_PHC
goods_NN
for_PIN
resale_NN
19.9_CD
19.1_CD
Total_JJ
36.4_CD
43.4_CD
The_DT
clinical_JJ
trials_NN
material_NN
amount_NN
comprises_VPRT
2.5_CD
million_CD
2002_CD
:_:
nil_NN
of_PIN
CDP484_CD
stock_NN
and_CC
0.2_CD
million_CD
2002_CD
:_:
0.4_CD
million_CD
of_PIN
other_JJ
materials_NN
._.
During_PIN
the_DT
year_NN
,_,
the_DT
Group_NN
wrote_VBD [PUBV]
off_PIN
7.5_CD
million_CD
of_PIN
CDP571_CD
stocks_NN
which_WDT [WHSUB]
were_VBD [PASS]
held_VBN [PRIV]
at_PIN
31_CD
December_NN
2002_CD
._.
Celltech_NN
Annual_JJ
Report_NN
2003_CD
63_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
15_CD
._.
Debtors_NN
Group_NN
2003_CD
2002_CD
m_NN
m_NN
Trade_NN
debtors_NN
43.7_CD
50.0_CD
Other_JJ
debtors_NN
10.3_CD
13.7_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
23.5_CD
12.9_CD
Total_JJ
77.5_CD
76.6_CD
Debtors_NN
include_VPRT
9.3_CD
million_CD
2002_CD
:_:
5.9_CD
million_CD
which_WDT
is_VPRT [BEMA]
recoverable_PRED
in_PIN
more_EMPH
than_PIN
one_CD
year_NN
._.
Equity_NOMZ
investments_NOMZ
Group_NN
2003_CD
Dec_NN
2002_CD
m_NN
m_NN
Equity_NOMZ
investments_NOMZ
0.8_CD
The_DT
equity_NOMZ
investments_NOMZ
held_VBN [PRIV] [WZPAST]
at_PIN
31_CD
December_NN
2003_CD
relate_VPRT
to_PIN
1.3_CD
million_CD
shares_NN
held_VBN [PRIV] [WZPAST]
in_PIN
BioInvent_NN
,_,
a_DT
company_NN
listed_VBN [WZPAST]
on_PIN
the_DT
Danish_JJ
stock_NN
market_NN
._.
The_DT
investment_NOMZ
was_VBD [PASS]
inherited_VBN
as_IN
part_NN
of_PIN
the_DT
OGS_NN
acquisition_NOMZ
._.
The_DT
market_NN
value_NN
of_PIN
the_DT
Groups_NN
holding_VBG [PRIV] [WZPRES]
as_RB
at_PIN
31_CD
December_NN
2003_CD
was_VBD [BEMA]
1.1_CD
million_CD
._.
During_PIN
2002_CD
,_,
the_DT
Group_NN
completed_VBD
the_DT
process_NN
of_PIN
disposing_VBG
of_PIN
the_DT
equity_NOMZ
investments_NOMZ
which_WDT [WHSUB]
had_VBD [PEAS]
been_VBN [PASS]
inherited_VBN
as_IN
part_NN
of_PIN
the_DT
Medeva_NN
acquisition_NOMZ
and_ANDC
which_WDT
had_VBD [PEAS]
been_VBN [BYPA]
held_VBN [PRIV]
by_PIN
that_DEMO
company_NN
due_JJ
to_PIN
its_PIT
research_NN
and_PHC
development_NOMZ
relationships_NN
._.
In_PIN
total_JJ
during_PIN
2002_CD
the_DT
Group_NN
disposed_VBD
of_PIN
937,000_CD
shares_NN
in_PIN
Targeted_NN
Genetics_NN
Corporation_NOMZ
and_CC
207,500_CD
shares_NN
in_PIN
Matrix_NN
Pharmaceuticals_NN
Inc._NN
._.
The_DT
disposals_NN
generated_VBD
cash_NN
of_PIN
1.1_CD
million_CD
and_CC
resulted_VBD
in_PIN
a_DT
loss_NN
of_PIN
0.9_CD
million_CD
which_WDT
was_VBD [PASS]
recorded_VBN
within_PIN
research_NN
and_PHC
development_NOMZ
expenditure_NN
._.
Cash_NN
and_CC
liquid_JJ
resources_NN
Celltech_NN
manages_VPRT
its_PIT
funds_NN
in_PIN
a_DT
portfolio_NN
of_PIN
cash_NN
,_,
short-term_JJ
bank_NN
deposits_NN
and_CC
liquid_JJ
resources_NN
,_,
with_PIN
maturities_NOMZ
chosen_VBN
to_TO
meet_VB
its_PIT
shortand_JJ
medium-term_JJ
requirements_NOMZ
._.
The_DT
liquid_JJ
resources_NN
are_VPRT [BEMA]
in_PIN
fully_AMP
negotiable_JJ
instruments_NOMZ
,_,
including_VBG
treasury_NN
bills_NN
,_,
certificates_NN
of_PIN
deposit_NN
,_,
bills_NN
of_PIN
exchange_NN
and_CC
commercial_JJ
paper_NN
,_,
and_ANDC
are_VPRT [BYPA]
managed_VBN
by_PIN
Royal_NN
London_NN
Cash_NN
Management_NOMZ
and_PHC
Royal_NN
Bank_NN
of_PIN
Scotland_NN
._.
Group_NN
Company_NN
2003 2002 2003 2002_CD
m_FW
m_FW
m_FW
m_FW
Cash_NN
38.5_CD
81.1_CD
0.2_CD
22.3_CD
Liquid_NN
resources_NN
116.5_CD
24.0_CD
8.7_CD
Total_JJ
cash_NN
and_CC
liquid_JJ
resources_NN
155.0_CD
105.1_CD
8.9_CD
22.3_CD
As_IN
at_PIN
31_CD
December_NN
2002_CD
,_,
Celltech_NN
held_VBD [PRIV]
within_PIN
cash_NN
and_CC
liquid_JJ
resources_NN
7.2_CD
million_CD
of_PIN
restricted_VBN
funds_NN
in_PIN
respect_NN
of_PIN
financing_VBG
arrangements_NOMZ
with_PIN
regard_NN
to_PIN
the_DT
self_NN
insurance_NN
of_PIN
methylphenidate_NN
the_DT
alternative_NN
financing_GER
arrangements_NOMZ
._.
Following_VBG
termination_NOMZ
of_PIN
the_DT
alternative_JJ
financing_GER
arrangements_NOMZ
for_PIN
methylphenidate_NN
during_PIN
2003_CD
,_,
the_DT
Group_NN
received_VBD
2.7_CD
million_CD
in_PIN
respect_NN
of_PIN
the_DT
insurance_NN
deposit_NN
2002_CD
:_:
2.7_CD
million_CD
included_VBD
as_IN
a_DT
liquid_JJ
resource_NN
._.
This_DEMO
amount_NN
was_VBD [PASS]
returned_VBN
to_PIN
the_DT
Group_NN
net_NN
of_PIN
interest_NN
and_PHC
fees_NN
._.
In_CONJ
addition_NULL
,_,
an_DT
amount_NN
of_PIN
4.5_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
released_VBN
from_PIN
a_DT
segregated_VBN
fund_NN
previously_TIME
held_VBN [PRIV]
in_PIN
the_DT
name_NN
of_PIN
the_DT
Company_NN
and_CC
managed_VBN
by_PIN
one_CD
of_PIN
the_DT
Groups_NN
fund_NN
managers_NN
in_PIN
respect_NN
of_PIN
the_DT
alternative_JJ
financing_GER
arrangement_NOMZ
._.
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
Group_NN
2003_CD
2002_CD
m_NN
m_NN
Accruals_NN
and_CC
deferred_JJ
income_NN
69.6_CD
53.0_CD
Trade_NN
creditors_NN
32.6_CD
24.5_CD
Sales_NN
rebates_NN
and_PHC
wholesaler_NN
charge_NN
backs_VPRT
29.6_CD
18.2_CD
Other_JJ
creditors_NN
9.5_CD
15.7_CD
Senior_JJ
loan_NN
notes_NN
31.2_CD
Deferred_JJ
consideration_NOMZ
5.3_CD
11.7_CD
Leasing_GER
obligations_NOMZ
0.6_CD
0.8_CD
Corporation_NOMZ
taxes_NN
2.7_CD
5.0_CD
Total_JJ
149.9_CD
160.1_CD
The_DT
senior_JJ
loan_NN
notes_NN
were_VBD [PASS]
repaid_VBN
on_PIN
17_CD
December_NN
2003_CD
._.
They_TPP3
were_VBD [BEMA]
unsecured_PRED
and_CC
carried_VBD
a_DT
fixed_VBN
coupon_NN
rate_NN
of_PIN
6.51_CD
%_NN
._.
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Group_NN
2003_CD
2002_CD
m_NN
m_NN [BEMA]
Deferred_JJ
consideration_NOMZ
2.8_CD
8.9_CD
Other_JJ
creditors_NN
2.5_CD
2.9_CD
Leasing_GER
obligations_NOMZ
0.4_CD
0.9_CD
Total_JJ
5.7_CD
12.7_CD
The_DT
deferred_VBN
consideration_NOMZ
amounts_NN
disclosed_VBN [PUBV] [WZPAST]
in_PIN
both_DT
current_JJ
and_PHC
long-term_JJ
creditors_NN
for_PIN
2003_CD
and_CC
2002_CD
relate_VPRT
to_PIN
the_DT
amounts_NN
payable_JJ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
rights_NN
to_PIN
Dipentum_NN
in_PIN
the_DT
US_FPP1
and_PHC
Europe_NN
see_VPRT [PRIV]
note_NN
11_CD
._.
Other_JJ
long-term_JJ
creditors_NN
of_PIN
2.5_CD
million_CD
2002_CD
:_:
2.9_CD
million_CD
relate_VPRT
to_PIN
pension_NN
obligations_NOMZ
in_PIN
the_DT
US_FPP1
see_VB [PRIV]
note_NN
27_CD
,_,
Pension_NN
fund_NN
deficit_NN
._.
Obligations_NOMZ
under_IN
finance_NN
and_CC
operating_VBG
leases_NN
Group_NN
2003_CD
2002_CD
Finance_NN
leases_VPRT
m_NN
m_NN
Amounts_NN
payable_JJ
:_:
Within_PIN
one_CD
year_NN
0.6_CD
0.8_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
0.5_CD
1.1_CD
Less_RB
interest_NN
element_NOMZ
0.1_CD
0.2_CD
Finance_NN
lease_NN
obligations_NOMZ
1.0_CD
1.7_CD
Operating_GER
leases_VPRT
The_DT
Group_NN
has_VPRT
annual_JJ
commitments_NOMZ
under_IN
noncancellable_JJ
operating_GER
leases_NN
as_IN
follows_VPRT
:_:
Land_NN
and_PHC
buildings_GER
Other_JJ
2003 2002 2003 2002_CD
m_FW
m_FW
m_FW
m_FW
Operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
Within_PIN
one_CD
year_NN
0.7_CD
0.8_CD
0.1_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
0.5_CD
1.0_CD
0.6_CD
1.4_CD
Over_IN
five_CD
years_NN
4.6_CD
5.0_CD
Total_JJ
annual_JJ
commitment_NOMZ
5.8_CD
6.0_CD
1.4_CD
1.5_CD
The_DT
Company_NN
has_VPRT
no_SYNE
commitments_NOMZ
under_IN
operating_GER
or_CC
finance_NN
leases_NN
._.
Celltech_NN
Annual_JJ
Report_NN
2003_CD
65_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
20_CD
._.
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
Restructuring_GER
,_,
Deferred_NN
tax_NN
integration_NOMZ
and_CC
other_JJ
Noninsured_NN
claims_VPRT [PUBV]
Fair_NN
value_NN
Group_NN
note_NN
8_CD
i_FPP1
ii_FW
iii_FW
Total_JJ
m_NN
m_FW
m_FW
m_FW
m_FW
Balance_NN
at_PIN
1_CD
January_NN
2003_CD
57.3_CD
3.0_CD
2.9_CD
63.2_CD
Profit_NN
and_PHC
loss_NN
account_NN
credit_NN
charge_NN
36.2_CD
20.0_CD
3.0_CD
13.2_CD
On_PIN
OGS_NN
acquisition_NOMZ
34.2_CD
34.2_CD
Profit_NN
and_PHC
loss_NN
account_NN
release_NN
0.2_CD
0.2_CD
Utilised_VBN
in_PIN
year_NN
11.0_CD
22.5_CD
33.5_CD
Currency_NN
translation_NOMZ
4.5_CD
4.5_CD
Transferred_VBN
from_PIN
to_PIN
creditors_NN
3.7_CD
3.7_CD
At_PIN
31_CD
December_NN
2003_CD
20.3_CD
11.8_CD
5.9_CD
11.7_CD
49.7_CD
i_FPP1
The_DT
remaining_VBG
provision_NN
relates_VPRT
to_TO
restructuring_VBG
charges_NN
booked_VBN [WZPAST]
during_PIN
2003_CD
as_IN
described_VBN
in_PIN
note_NN
5_CD
of_PIN
11.3_CD
million_CD
,_,
along_IN
with_PIN
other_JJ
provisions_NN
of_PIN
0.5_CD
million_CD
._.
The_DT
opening_GER
provision_NN
of_PIN
3.0_CD
million_CD
included_VBD
2.0_CD
million_CD
relating_VBG
to_PIN
ML_NN
Laboratories_NN
see_VPRT [PRIV]
below_PLACE
and_CC
other_JJ
provisions_NN
of_PIN
1.0_CD
million_CD
._.
The_DT
profit_NN
and_PHC
loss_NN
account_NN
charge_NN
is_VPRT [BEMA]
the_DT
cash_NN
element_NOMZ
of_PIN
the_DT
exceptional_JJ
items_NN
see_VPRT [PRIV]
note_NN
5_CD
._.
The_DT
utilisation_NOMZ
is_VPRT [BEMA]
the_DT
spend_VPRT
on_PIN
exceptional_JJ
items_NN
of_PIN
8.9_CD
million_CD
,_,
along_IN
with_PIN
2.0_CD
million_CD
paid_VBN
to_PIN
ML_NN
Laboratories_NN
and_CC
0.1_CD
million_CD
of_PIN
other_JJ
._.
In_PIN
2002_CD
,_,
Celltech_NN
negotiated_VBD
a_DT
settlement_NOMZ
to_TO
terminate_VB
certain_JJ
co-development_NOMZ
relationships_NN
with_PIN
Innovata_NN
Biomed_NN
,_,
a_DT
subsidiary_NN
of_PIN
ML_NN
Laboratories_NN
which_WDT [WHSUB]
had_VBD [PEAS]
been_VBN [PASS]
inherited_VBN
with_PIN
the_DT
Medeva_NN
acquisition_NOMZ
._.
The_DT
terms_NN
of_PIN
the_DT
termination_NOMZ
included_VBD
a_DT
4.0_CD
million_CD
payment_NOMZ
to_PIN
ML_NN
Laboratories_NN
of_PIN
which_WDT [PIRE]
the_DT
final_JJ
2.0_CD
million_CD
was_VBD [PASS]
paid_VBN
in_PIN
January_NN
2003_CD
._.
In_PIN
total_JJ
,_,
the_DT
settlement_NOMZ
of_PIN
this_DEMO
liability_NOMZ
resulted_VBD
in_PIN
a_DT
credit_NN
of_PIN
3.1_CD
million_CD
to_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_VPRT
taken_VBN
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
._.
ii_FW
Since_OSUB
20_CD
September_NN
2001_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
been_VBN [PASS]
required_VBN [SUAV]
to_TO
increase_VB
its_PIT
levels_NN
of_PIN
self_NN
insurance_NN
in_PIN
respect_NN
of_PIN
methylphenidate_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
to_TO
retain_VB
a_DT
level_NN
of_PIN
self_NN
insurance_NN
in_PIN
respect_NN
of_PIN
all_QUAN
product_NN
liability_NOMZ
up_IN
to_PIN
an_DT
annual_JJ
limit_NN
of_PIN
$_$
13.5_CD
million_CD
,_,
as_RB
well_RB
as_IN
self_NN
insurance_NN
in_PIN
respect_NN
of_PIN
methylphenidate_NN
of_PIN
up_RB
to_TO
$_$
20_CD
million_CD
._.
Whilst_OSUB
no_SYNE
methylphenidate_NN
claims_NN
have_VPRT [PEAS]
been_VBN [PASS]
received_VBN
since_OSUB
20_CD
September_NN
2001_CD
,_,
as_RB
at_PIN
31_CD
December_NN
2003_CD
the_DT
Group_NN
has_VPRT [PEAS]
provided_VBN
5.4_CD
million_CD
based_VBN
on_PIN
an_DT
external_JJ
review_NN
of_PIN
the_DT
likely_JJ
liability_NOMZ
associated_VBN [WZPAST]
with_PIN
incidents_NN
that_TSUB
may_POMD
arise_VB
from_PIN
past_JJ
sales_NN
of_PIN
methylphenidate_NN
prior_RB
to_PIN
20_CD
September_NN
2003_CD
and_CC
across_PLACE
all_QUAN
products_NN
after_IN
19_CD
September_NN
2003_CD
._.
A_DT
further_JJ
0.5_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
for_PIN
product_NN
recall_NN
and_CC
other_JJ
liabilities_NOMZ
for_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT
no_SYNE
external_JJ
insurance_NN
._.
iii_FW
On_PIN
the_DT
acquisition_NOMZ
of_PIN
OGS_NN
the_DT
Group_NN
provided_VBD
for_PIN
certain_JJ
onerous_JJ
obligations_NOMZ
._.
These_DEMP
relate_VPRT
primarily_RB
to_TO
lease_VB
obligations_NOMZ
,_,
committed_JJ
development_NOMZ
spend_VPRT
on_PIN
non-valuable_JJ
projects_NN
and_CC
other_JJ
contractual_JJ
obligations_NOMZ
see_VPRT [PRIV]
note_NN
22_CD
._.
There_EX
are_VPRT
no_SYNE
provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
in_PIN
the_DT
Company_NN
._.
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
The_DT
disclosures_NN
below_PLACE
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
currency_NN
exposures_NN
,_,
exclude_VPRT
short-term_JJ
debtors_NN
and_PHC
creditors_NN
where_RB
permissible_JJ
under_IN
FRS_NN
13_CD
._.
The_DT
following_VBG
categories_NN
of_PIN
short-term_JJ
creditor_NN
are_VPRT [PASS]
included_VBN
below_PLACE
:_:
borrowing_GER
and_PHC
leasing_GER
obligations_NOMZ
and_CC
foreign_JJ
currency_NN
denominated_VBD
deferred_VBN
consideration_NOMZ
._.
The_DT
main_JJ
risks_NN
arising_VBG [WZPRES]
from_PIN
the_DT
Groups_NN
use_NN
of_PIN
financial_JJ
instruments_NOMZ
and_CC
the_DT
strategy_NN
for_PIN
managing_VBG
these_DEMP
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
Interest_NN
rate_NN
risk_NN
The_DT
Group_NN
repaid_VBD
the_DT
private_JJ
placement_NOMZ
fixed_VBN
borrowings_GER
of_PIN
31.2_CD
million_CD
US$_$
50_CD
million_CD
in_PIN
December_NN
2003_CD
._.
Liquidity_NOMZ
risk_NN
The_DT
Group_NN
ensures_VPRT [SUAV] [PRIV]
that_THVC
it_PIT
has_VPRT
sufficient_JJ
long-term_JJ
funding_GER
and_CC
committed_JJ
bank_NN
facilities_NOMZ
to_TO
meet_VB
foreseeable_JJ
peak_NN
borrowing_GER
requirements_NOMZ
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
Group_NN
had_VBD
75_CD
million_CD
of_PIN
committed_JJ
facilities_NOMZ
2002_CD
:_:
107.2_CD
million_CD
of_PIN
which_WDT [PIRE]
75_CD
million_CD
were_VBD [BEMA]
undrawn_PRED
2002_CD
:_:
76.0_CD
million_CD
see_VPRT [PRIV]
section_NOMZ
iv_NN
of_PIN
note_NN
below_PLACE
._.
Foreign_JJ
currency_NN
risk_NN
Approximately_RB
23_CD
%_NN
2002_CD
:_:
50_CD
%_NN
of_PIN
the_DT
Group_NN
net_JJ
assets_NN
excluding_VBG [WZPRES]
goodwill_NN
are_VPRT [BEMA]
in_PIN
the_DT
US_FPP1
._.
The_DT
Group_NN
does_VPRT
not_XX0
currently_RB
actively_RB
hedge_VB
against_PIN
the_DT
effect_NN
of_PIN
exchange_NN
rate_NN
differences_NN
resulting_VBG [WZPRES]
from_PIN
the_DT
translation_NOMZ
of_PIN
foreign_JJ
currency_NN
earnings_GER
,_,
but_CC
does_VPRT [PROD]
,_,
where_RB
appropriate_JJ
,_,
seek_VB
to_TO
hedge_VB
significant_JJ
transaction_NOMZ
exposures_NN
,_,
which_WDT [SERE]
includes_VPRT
hedging_VBG
material_NN
surplus_NN
balances_VPRT
not_XX0
denominated_VBN
in_PIN
the_DT
functional_JJ
currency_NN
of_PIN
the_DT
operating_VBG
unit_NN
._.
The_DT
Group_NN
uses_VPRT
financial_JJ
derivatives_NN
,_,
in_CONJ
particular_NULL
forward_JJ
currency_NN
contracts_NN
,_,
to_TO
manage_VB
the_DT
financial_JJ
risks_NN
associated_VBN [WZPAST]
with_PIN
the_DT
Groups_NN
underlying_VBG [WZPRES]
business_NOMZ
activity_NOMZ
._.
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
Credit_NN
risk_NN
A_DT
large_JJ
number_NN
of_PIN
major_JJ
international_JJ
financial_JJ
institutions_NOMZ
are_VPRT
counterparties_NN
to_PIN
the_DT
foreign_JJ
exchange_NN
contracts_NN
and_PHC
deposits_NN
transacted_VBN [WZPAST]
by_PIN
the_DT
Group_NN
._.
Counterparties_NN
for_PIN
such_JJ
transactions_NOMZ
entered_VBD
into_PIN
during_PIN
the_DT
year_NN
have_VPRT
a_DT
long-term_JJ
credit_NN
rating_NN
of_PIN
A_DT
or_CC
better_JJ
._.
The_DT
Group_NN
monitors_VPRT
its_PIT
credit_NN
exposure_NN
to_PIN
its_PIT
counterparties_NN
,_,
together_RB
with_PIN
their_TPP3
credit_NN
ratings_GER
,_,
and_ANDC
,_,
by_PIN
policy_NN
,_,
limits_VPRT
the_DT
amount_NN
of_PIN
agreements_NOMZ
or_CC
contracts_NN
it_PIT
enters_VPRT
into_PIN
with_PIN
any_QUAN
one_CD
party_NN
._.
The_DT
notional_JJ
amounts_NN
of_PIN
financial_JJ
instruments_NOMZ
used_VBN [WZPAST]
in_PIN
interest_NN
rate_NN
and_CC
foreign_JJ
exchange_NN
management_NOMZ
do_VPRT
not_XX0
represent_VB
the_DT
credit_NN
risk_NN
arising_VBG [WZPRES]
through_PIN
the_DT
use_NN
of_PIN
these_DEMO
instruments_NOMZ
._.
The_DT
immediate_JJ
credit_NN
risk_NN
of_PIN
these_DEMO
instruments_NOMZ
is_VPRT [BYPA]
represented_VBN
by_PIN
the_DT
fair_JJ
value_NN
of_PIN
contracts_NN
with_PIN
a_DT
positive_JJ
value_NN
._.
Cash_NN
at_PIN
bank_NN
and_CC
liquid_JJ
resources_NN
principally_RB
comprise_VPRT
money_NN
market_NN
deposits_NN
,_,
commercial_JJ
paper_NN
and_PHC
investments_NOMZ
._.
The_DT
investments_NOMZ
are_VPRT [BEMA]
with_PIN
counterparties_NN
having_VBG [WZPRES]
strong_JJ
credit_NN
ratings_GER
._.
The_DT
Group_NN
considers_VPRT [PRIV]
the_DT
possibility_NOMZ
of_PIN
material_JJ
loss_NN
in_PIN
the_DT
event_NN
of_PIN
non-performance_JJ
by_PIN
a_DT
financial_JJ
counterparty_NN
or_CC
the_DT
non-payment_NOMZ
of_PIN
an_DT
account_NN
receivable_NN
to_TO
be_VB [BEMA]
unlikely_PRED
,_,
other_JJ
than_PIN
as_IN
already_RB
provided_VBN
for_PIN
in_PIN
the_DT
accounts_NN
._.
i_FPP1
Interest_NN
rate_NN
risk_NN
At_PIN
fixed_VBN
InterestGroup_NN
At_PIN
fixed_VBN
InterestGroup_NN
interest_NN
free_JJ
Total_JJ
interest_NN
free_JJ
Total_JJ
2003 2003 2003 2002_CD
2002_CD
2002_CD
Interest_NN
rate_NN
risk_NN
profile_NN
of_PIN
financial_JJ
liabilities_NOMZ
m_VPRT
m_FW
m_FW
m_FW
m_FW
m_FW
Sterling_GER
1.0_CD
1.0_CD
1.7_CD
1.7_CD
US_FPP1
dollar_NN
10.6_CD
10.6_CD
31.2_CD
23.5_CD
54.7_CD
Preference_NN
shares_NN
3.4_CD
2.4_CD
5.8_CD
Total_JJ
1.0_CD
10.6_CD
11.6_CD
36.3_CD
25.9_CD
62.2_CD
Weighted_VBN
average_JJ
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
interest_NN
rates_NN
period_NN
for_PIN
which_WDT [PIRE]
interest_NN
rates_NN
period_NN
for_PIN
which_WDT [PIRE]
rates_NN
are_VPRT [PASS]
fixed_VBN
rates_NN
are_VPRT [PASS]
fixed_VBN
2003 2003 2002 2002_CD
Fixed_VBN
rate_NN
financial_JJ
liabilities_NOMZ
%_NN
Months_NN
%_NN
Months_NN
Sterling_GER
6.7_CD
23_CD
6.7_CD
35_CD
US_FPP1
dollars_NN
6.5_CD
12_CD
Preference_NN
shares_NN
6.9_CD
3_CD
Total_JJ
6.7_CD
23_CD
6.6_CD
12_CD
The_DT
interest-free_JJ
liabilities_NOMZ
are_VPRT [BEMA]
in_PIN
relation_NOMZ
to_PIN
Dipentum_NN
deferred_VBN
consideration_NOMZ
and_PHC
pension_NN
obligations_NOMZ
provided_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
._.
The_DT
Group_NN
has_VPRT
no_DT
floating_VBG
rate_NN
financial_JJ
liabilities_NOMZ
2002_CD
:_:
nil_NN
._.
The_DT
financial_JJ
liabilities_NOMZ
of_PIN
the_DT
Group_NN
comprised_VBD
:_:
2003_CD
2002_CD
m_NN
m_NN
Borrowings_GER
31.2_CD
Finance_NN
leases_NN
1.0_CD
1.7_CD
Deferred_JJ
consideration_NOMZ
8.1_CD
20.6_CD
Other_JJ
creditors_NN
2.5_CD
2.9_CD
Preference_NN
shares_NN
5.8_CD
Total_JJ
11.6_CD
62.2_CD
At_PIN
fixed_VBN
At_PIN
floating_VBG
Interestinterest_NN
rates_NN
interest_NN
rates_NN
free_JJ
Total_JJ
Interest_NN
rate_NN
risk_NN
profile_NN
of_PIN
financial_JJ
assets_NN
m_VPRT
m_FW
m_FW
m_FW
Sterling_GER
98.1_CD
5.6_CD
103.7_CD
US_FPP1
dollar_NN
43.1_CD
3.7_CD
46.8_CD
Euro_NN
13.6_CD
13.6_CD
Swiss_JJ
francs_NN
1.9_CD
0.2_CD
2.1_CD
At_PIN
31_CD
December_NN
2003_CD
1.9_CD
155.0_CD
9.3_CD
166.2_CD
Sterling_GER
31.0_CD
32.5_CD
1.9_CD
65.4_CD
US_FPP1
Dollar_NN
59.8_CD
11.0_CD
70.8_CD
Euro_NN
12.7_CD
12.7_CD
Swiss_JJ
francs_NN
1.9_CD
0.1_CD
2.0_CD
At_PIN
31_CD
December_NN
2002_CD
32.9_CD
105.1_CD
12.9_CD
150.9_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
67_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
21_CD
._.
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
Floating_VBG
rate_NN
financial_JJ
assets_NN
comprise_VPRT
cash_NN
deposits_NN
in_PIN
the_DT
money_NN
market_NN
,_,
certificates_NN
of_PIN
deposit_NN
and_CC
commercial_JJ
paper_NN
._.
These_DEMP
include_VPRT
deposits_NN
where_RB
the_DT
interest_NN
rate_NN
is_VPRT [PASS]
fixed_VBN
until_IN
maturity_NOMZ
but_CC
,_,
as_IN
the_DT
original_JJ
maturity_NOMZ
is_VPRT [BEMA]
less_PRED
than_PIN
one_CD
year_NN
,_,
they_TPP3
are_VPRT [PASS]
classified_VBN
as_IN
floating_VBG
rate_NN
financial_JJ
instruments_NOMZ
._.
Fixed_VBN
rate_NN
deposits_NN
comprise_VPRT
1.9_CD
million_CD
2002_CD
:_:
32.9_CD
million_CD
of_PIN
convertible_JJ
loan_NN
notes_NN
see_VPRT [PRIV]
note_NN
13_CD
for_PIN
duration_NOMZ
carrying_VBG [WZPRES]
a_DT
weighted_JJ
average_JJ
interest_NN
rate_NN
to_PIN
maturity_NOMZ
of_PIN
4_CD
%_NN
2002_CD
:_:
6.8_CD
%_NN
._.
The_DT
interest-free_JJ
assets_NN
relate_VPRT
to_PIN
long-term_JJ
debtors_NN
see_VPRT [PRIV]
note_NN
15_CD
._.
In_PIN
2002_CD
the_DT
interest-free_JJ
assets_NN
related_VBN [WZPAST]
to_PIN
the_DT
investment_NOMZ
in_PIN
Neogenesis_NN
see_VPRT [PRIV]
note_NN
13_CD
and_CC
long-term_JJ
debtors_NN
see_VPRT [PRIV]
note_NN
15_CD
._.
ii_FW
Currency_NN
exposures_NN
The_DT
table_NN
below_PLACE
shows_NN
the_DT
Groups_NN
transactional_JJ
currency_NN
exposures_NN
that_TSUB
give_VPRT
rise_VB
to_PIN
net_JJ
currency_NN
gains_NN
and_PHC
losses_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Such_JJ
exposures_NN
comprise_VPRT
the_DT
monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
Group_NN
that_TSUB
are_VPRT [PASS]
not_XX0
denominated_VBN
in_PIN
the_DT
functional_JJ
currency_NN
of_PIN
the_DT
operating_VBG
unit_NN
involved_VBN
._.
Net_JJ
monetary_JJ
assets_NN
liabilities_NOMZ
US_FPP1
$_$
Euro_NN
Other_JJ
Total_NN
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
31_CD
December_NN
2003_CD
15.5_CD
4.1_CD
0.2_CD
11.6_CD
At_PIN
31_CD
December_NN
2002_CD
5.9_CD
6.8_CD
0.2_CD
0.7_CD
iii_FW
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
The_DT
maturity_NOMZ
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
as_IN
at_PIN
31_CD
December_NN
2003_CD
was_VBD
as_IN
follows_VPRT
:_:
2003_CD
m_NN [BEMA]
In_PIN
one_CD
year_NN
or_CC
less_JJ
5.9_CD
In_PIN
more_EMPH
than_PIN
one_CD
year_NN
but_CC
not_XX0
more_EMPH
than_PIN
two_CD
years_NN
3.2_CD
In_PIN
more_EMPH
than_PIN
five_CD
years_NN
2.5_CD
Total_JJ
11.6_CD
iv_NN
Committed_VBN
borrowing_GER
facilities_NOMZ
The_DT
facilities_NOMZ
available_JJ
as_IN
at_PIN
31_CD
December_NN
2003_CD
were_VBD
as_IN
follows_VPRT
:_:
Committed_VBN
Undrawn_JJ
2003_CD
2003_CD
m_NN
m_NN
Revolving_VBG [WZPRES]
credit_NN
facility_NOMZ
65.0_CD
65.0_CD
Overdraft_NN
facility_NOMZ
10.0_CD
10.0_CD
Total_JJ
75.0_CD
75.0_CD
Expiring_GER
in_PIN
less_JJ
than_PIN
one_CD
year_NN
10.0_CD
10.0_CD
Expiring_VBG
in_PIN
more_EMPH
than_PIN
one_CD
year_NN
but_CC
not_XX0
more_EMPH
than_PIN
two_CD
years_NN
65.0_CD
65.0_CD
The_DT
committed_JJ
bank_NN
facility_NOMZ
is_VPRT [BEMA]
subject_PRED
to_PIN
certain_JJ
financial_JJ
covenants_NN
which_WDT [WHSUB]
are_VPRT [PASS]
tested_VBN
twice_RB
annually_RB
._.
The_DT
Group_NN
currently_RB
has_VPRT
no_SYNE
reason_NN
to_TO
believe_VB [PRIV]
that_THVC
it_PIT
will_PRMD
not_XX0
be_VB [BEMA]
able_PRED
to_TO
continue_VB
to_TO
meet_VB
the_DT
requirements_NOMZ
of_PIN
these_DEMO
covenants_NN
._.
The_DT
undrawn_JJ
revolving_JJ
credit_NN
facility_NOMZ
is_VPRT [BEMA]
available_PRED
until_IN
December_NN
2005_CD
._.
v_NN
Fair_NN
value_NN
of_PIN
financial_JJ
instruments_NOMZ
Book_NN
value_NN
Fair_NN
value_NN
2003 2002 2003 2002_CD
m_FW
m_FW
m_FW
m_FW [BEMA]
Primary_JJ
financial_JJ
instruments_NOMZ
:_:
Cash_NN
and_CC
short-term_JJ
deposits_NN
155.0_CD
105.1_CD
155.0_CD
105.1_CD
Convertible_JJ
loan_NN
notes_VPRT [PRIV]
1.9_CD
32.9_CD
1.9_CD
32.9_CD
Investment_NOMZ
in_PIN
Neogenesis_NN
7.0_CD
7.0_CD
Long-term_JJ
debtors_NN
9.3_CD
5.9_CD
9.3_CD
5.7_CD
Other_JJ
creditors_NN
2.5_CD
2.9_CD
2.5_CD
2.9_CD
Finance_NN
leases_NN
1.0_CD
1.7_CD
1.0_CD
1.7_CD
Senior_JJ
loan_NN
notes_NN
31.2_CD
31.2_CD
Deferred_JJ
consideration_NOMZ
8.1_CD
20.6_CD
8.1_CD
20.6_CD
Equity_NOMZ
investments_NOMZ
0.8_CD
1.1_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
forward_RB
exchange_NN
contracts_NN
5.8_CD
8.8_CD
Preference_NN
shares_NN
5.8_CD
6.7_CD
Total_JJ
155.4_CD
88.7_CD
161.5_CD
96.4_CD
68_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
21_CD
._.
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
Market_NN
values_NN
have_VPRT [PEAS]
been_VBN [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
short-term_JJ
deposits_NN
,_,
equity_NOMZ
investments_NOMZ
and_CC
the_DT
derivative_JJ
financial_JJ
instruments_NOMZ
._.
Neogenesis_NN
is_VPRT [BEMA]
an_DT
unlisted_JJ
company_NN
and_CC
the_DT
total_JJ
investment_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
down_RP
to_TO
nil_VB
as_RB
at_PIN
31_CD
December_NN
2003_CD
see_VPRT [PRIV]
note_NN
13_CD
._.
The_DT
market_NN
value_NN
of_PIN
the_DT
Groups_NN
holding_VBG [PRIV] [WZPRES]
in_PIN
BioInvent_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
is_VPRT [BEMA]
1.1_CD
million_CD
see_VPRT [PRIV]
note_NN
16_CD
._.
In_PIN
2002_CD
,_,
the_DT
Groups_NN
share_VPRT
price_NN
as_IN
of_PIN
31_CD
December_NN
2002_CD
was_VBD [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
preference_NN
shares_NN
._.
Other_JJ
amounts_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
to_TO
be_VB [BEMA]
equal_PRED
to_PIN
their_TPP3
book_NN
values_NN
._.
vi_FW
Gains_NN
and_PHC
losses_NN
on_PIN
hedges_NN
No_SYNE
financial_JJ
instruments_NOMZ
were_VBD [PASS]
held_VBN [PRIV]
for_PIN
the_DT
purposes_NN
of_PIN
dealing_VBG
or_CC
other_JJ
financial_JJ
instrument_NOMZ
trading_GER
activities_NOMZ
._.
Gains_NN
and_PHC
losses_NN
on_PIN
instruments_NOMZ
used_VBN [WZPAST]
for_PIN
hedging_VBG
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
until_IN
the_DT
exposure_NN
that_DEMP
is_VPRT
being_VBG [PASS]
hedged_VBN
is_VPRT [BEMA] [PASS]
itself_PIT
recognized_VBN [PRIV]
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT
unrecognised_JJ
gains_NN
on_PIN
financial_JJ
instruments_NOMZ
._.
2003_CD
2002_CD
m_NN
m_NN [BEMA]
Unrecognised_JJ
gains_NN
at_PIN
1_CD
January_NN
8.8_CD
1.9_CD
Additional_JJ
gains_NN
on_PIN
unrecognised_JJ
positions_NOMZ
at_PIN
1_CD
January_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
year_NN
1.7_CD
2.4_CD
Total_JJ
gains_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
year_NN
10.5_CD
3.7_CD
Unrecognised_JJ
gains_NN
in_PIN
the_DT
year_NN
on_PIN
hedges_NN
taken_VBN [WZPAST]
out_PIN
in_PIN
2001_CD
3.2_CD
Unrecognised_JJ
gains_NN
in_PIN
the_DT
year_NN
on_PIN
hedges_NN
taken_VBN [WZPAST]
out_PIN
in_PIN
2002_CD
5.0_CD
Unrecognised_JJ
gains_NN
in_PIN
the_DT
year_NN
on_PIN
hedges_NN
taken_VBN [WZPAST]
out_PIN
in_PIN
2003_CD
5.8_CD
Total_JJ
unrecognised_JJ
gains_NN
at_PIN
31_CD
December_NN
5.8_CD
8.8_CD
All_QUAN
the_DT
unrecognised_JJ
gains_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
during_PIN
2004_CD
._.
Acquisition_NOMZ
of_PIN
subsidiary_NN
undertakings_GER
OGS_NN
Fair_NN
value_NN
On_PIN
26_CD
February_NN
2003_CD
,_,
Celltech_NN
announced_VBD [PUBV]
the_DT
terms_NN
of_PIN
a_DT
Cash_NN
Offer_NN
for_PIN
the_DT
entire_JJ
issued_VBN
and_CC
to_TO
be_VB [PASS]
issued_VBN
share_NN
capital_NN
of_PIN
OGS_NN
._.
On_PIN
11_CD
April_NN
2003_CD
,_,
the_DT
Board_NN
of_PIN
OGS_NN
recommended_VBD [SUAV]
that_THVC
shareholders_NN
accept_VPRT [PRIV]
the_DT
Offer_NN
by_PIN
Celltech_NN
and_CC
by_PIN
the_DT
14_CD
April_NN
2003_CD
the_DT
Group_NN
held_VBD [PRIV]
more_EMPH
than_PIN
50_CD
%_NN
of_PIN
the_DT
shares_NN
of_PIN
the_DT
entity_NOMZ
._.
The_DT
Offer_NN
of_PIN
1.82_CD
for_PIN
each_QUAN
OGS_NN
share_NN
,_,
valued_VBN
the_DT
company_NN
at_PIN
102.3_CD
million_CD
56_CD
million_CD
issued_VBN
shares_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
,_,
plus_PIN
a_DT
further_JJ
0.9_CD
million_CD
of_PIN
subsequent_JJ
option_NOMZ
exercises_NN
at_PIN
1.82_CD
,_,
less_CC
1.2_CD
million_CD
in_PIN
option_NOMZ
receipts_NN
._.
On_PIN
4_CD
June_NN
2003_CD
,_,
Celltech_NN
announced_VBD [PUBV]
that_THVC
it_PIT
had_VBD [PEAS]
purchased_VBN
or_CC
received_VBN
valid_JJ
acceptances_NN
in_PIN
respect_NN
of_PIN
90.3_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
OGS_NN
,_,
and_ANDC
had_VBD [PEAS]
commenced_VBN
the_DT
procedure_NN
for_PIN
the_DT
compulsory_JJ
acquisition_NOMZ
of_PIN
the_DT
remaining_VBG
OGS_NN
shares_NN
._.
On_PIN
18_CD
July_NN
2003_CD
,_,
the_DT
process_NN
was_VBD [PASS]
completed_VBN
,_,
and_ANDC
OGS_NN
was_VBD [PASS]
fide-listed_VBN
from_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
on_PIN
21_CD
July_NN
2003_CD
._.
The_DT
total_JJ
cost_NN
of_PIN
the_DT
OGS_NN
acquisition_NOMZ
was_VBD [BEMA]
106.1_CD
million_CD
which_WDT
includes_VPRT
3.8_CD
million_CD
of_PIN
expenses_NN
._.
The_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
OGS_NN
acquired_VBD
are_VPRT
as_IN
follows_VPRT
:_:
Business_NOMZ
held_VBD [PRIV]
Fair_NN
value_NN
Total_JJ
fair_JJ
Book_NN
value_NN
for_PIN
resale_NN
adjustments_NOMZ
value_NN
m_NN
m_FW
m_FW
m_FW [PASS]
Fixed_VBN
assets_NN
a_DT
13.6_CD
8.0_CD
5.6_CD
Investments_NOMZ
b_NN
11.3_CD
5.8_CD
4.7_CD
0.8_CD
Stocks_NN
0.2_CD
0.2_CD
Debtors_NN
c_NN
9.4_CD
2.9_CD
2.9_CD
3.6_CD
Cash_NN
and_CC
liquid_JJ
resources_NN
126.6_CD
126.6_CD
Creditors_NN
d_SYM
8.5_CD
0.7_CD
3.5_CD
4.3_CD
Provisions_NN
e_SYM
34.2_CD
34.2_CD
Deferred_JJ
income_NN
8.2_CD
8.2_CD
Businesses_NOMZ
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
and_PHC
acquisition_NOMZ
of_PIN
Confirmant_NN
f_SYM
8.0_CD
2.5_CD
5.5_CD
Net_JJ
assets_NN
acquired_VBN
144.4_CD
46.4_CD
98.0_CD
Total_JJ
consideration_NOMZ
106.1_CD
Goodwill_NN
8.1_CD
Fair_NN
value_NN
adjustments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
to_PIN
the_DT
book_NN
value_NN
of_PIN
the_DT
assets_NN
and_PHC
liabilities_NOMZ
to_TO
adjust_VB
,_,
where_RB
applicable_JJ
,_,
the_DT
carrying_VBG
value_NN
of_PIN
certain_JJ
assets_NN
and_PHC
liabilities_NOMZ
._.
The_DT
above_PLACE
fair_JJ
values_NN
are_VPRT [BEMA]
preliminary_PRED
and_CC
will_PRMD
be_VB [BEMA]
further_PRED
reviewed_VBN
based_VBN
on_PIN
additional_JJ
information_NOMZ
available_JJ
at_PIN
30_CD
June_NN
2004_CD
and_CC
31_CD
December_NN
2004_CD
._.
Based_VBN [PASTP]
on_PIN
the_DT
preliminary_JJ
fair_JJ
value_NN
,_,
8.1_CD
million_CD
of_PIN
goodwill_NN
arises_VPRT
on_PIN
this_DEMO
transaction_NOMZ
._.
The_DT
goodwill_NN
has_VPRT [PEAS]
been_VBN [PASS]
capitalized_VBN
and_PHC
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
10_CD
years_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
Directors_NN
estimate_NN
of_PIN
useful_JJ
economic_JJ
life_NN
._.
Celltech_NN
Annual_JJ
Report_NN
2003_CD
69_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
22_CD
._.
Acquisition_NOMZ
of_PIN
subsidiary_NN
undertakings_GER
continued_VBD
The_DT
material_NN
fair_JJ
value_NN
adjustments_NOMZ
to_PIN
the_DT
net_JJ
assets_NN
of_PIN
OGS_NN
were_VBD [PASS]
determined_VBN [SUAV] [PRIV]
as_IN
follows_VPRT
:_:
a_DT
Tangible_JJ
fixed_JJ
assets_NN
have_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
off_PIN [STPR]
,_,
as_IN
they_TPP3
will_PRMD
not_XX0
be_VB [BYPA]
used_VBN
by_PIN
Celltech_NN
and_CC
recoverable_JJ
values_NN
are_VPRT [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
negligible_PRED
._.
Intangible_JJ
assets_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
capitalized_VBN
separately_RB
from_PIN
goodwill_NN
as_IN
the_DT
value_NN
of_PIN
the_DT
business_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
primarily_RB
in_PIN
early-stage_JJ
oncology_NN
research_NN
projects_NN
._.
Celltech_NN
does_VPRT
not_XX0
consider_VB [PRIV]
that_THVC
a_DT
reliable_JJ
valuation_NOMZ
can_POMD
be_VB [PASS]
made_VBN
of_PIN
such_JJ
projects_NN
suitable_JJ
for_PIN
capitalization_NOMZ
separate_JJ
from_PIN
goodwill_NN
._.
b_NN
Investments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
down_RP
to_PIN
recoverable_JJ
value_NN
based_VBN [WZPAST]
on_PIN
market_NN
value_NN
and_CC
have_VPRT [PEAS]
been_VBN [PASS]
classified_VBN
on_PIN
the_DT
Celltech_NN
balance_NN
sheet_NN
as_IN
equity_NOMZ
investments_NOMZ
._.
OGS_NN
investments_NOMZ
included_VBD
a_DT
4.3_CD
million_CD
stake_NN
in_PIN
Neogenesis_NN
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
down_RP
to_TO
nil_VB
see_VB [PRIV]
notes_NN
5_CD
and_CC
13_CD
._.
c_NN
Debtors_NN
have_VPRT [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
down_RP
to_PIN
recoverable_JJ
value_NN
._.
A_DT
significant_JJ
proportion_NOMZ
of_PIN
the_DT
OGS_NN
debtors_NN
were_VBD
prepayments_NOMZ
for_PIN
activities_NOMZ
and_PHC
projects_NN
which_WDT [WHSUB]
were_VBD [BYPA]
discontinued_VBN
by_PIN
Celltech_NN
._.
Consequently_CONJ
these_DEMP
had_VBD
no_SYNE
value_NN
to_PIN
Celltech_NN
._.
d_LS
OGS_NN
creditor_NN
and_PHC
accrual_NN
balances_NN
inherited_VBN [WZPAST]
were_VBD [PASS]
adjusted_VBN
in_PIN
the_DT
light_NN
of_PIN
the_DT
actual_JJ
settlements_NOMZ
made_VBD
post-acquisition_JJ
._.
e_LS
Fair_NN
value_NN
provisions_NN
have_VPRT [PEAS]
been_VBN [PASS]
established_VBN [PRIV]
for_PIN
onerous_JJ
obligations_NOMZ
inherited_VBN [WZPAST]
with_PIN
the_DT
acquisition_NOMZ
._.
These_DEMP
relate_VPRT
primarily_RB
to_TO
lease_VB
obligations_NOMZ
,_,
committed_JJ
development_NOMZ
spend_VPRT
on_PIN
non-valuable_JJ
projects_NN
and_CC
other_JJ
contractual_JJ
obligations_NOMZ
,_,
including_VBG
payments_NOMZ
to_PIN
former_JJ
senior_JJ
executives_NN
who_WP [WHSUB]
had_VBD
change_NN
of_PIN
ownership_NN
termination_NOMZ
clauses_NN
in_PIN
their_TPP3
service_NN
contracts_NN
._.
f_LS
The_DT
proteomics_NN
business_NOMZ
of_PIN
OGS_NN
was_VBD [PASS]
held_VBN [PRIV]
for_PIN
resale_NN
._.
The_DT
fair_JJ
value_NN
represents_VPRT
the_DT
estimated_JJ
result_NN
of_PIN
the_DT
business_NOMZ
prior_RB
to_PIN
any_QUAN
disposal_NN
together_RB
with_PIN
the_DT
anticipated_JJ
net_JJ
proceeds_NN
from_PIN
the_DT
assets_NN
inherited_VBN
._.
The_DT
table_NN
below_PLACE
sets_NN
out_PIN
the_DT
material_NN
balance_NN
aggregated_VBN [WZPAST]
on_PIN
to_PIN
the_DT
businesses_NOMZ
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
line_NN
on_PIN
acquisition_NOMZ
._.
m_NN
Net_NN
receipt_NN
from_PIN
termination_NOMZ
of_PIN
Confirmant_NN
Limited_NN
joint_JJ
venture_NN
see_VPRT [PRIV]
note_NN
23_CD
6.4_CD
Other_JJ
proteomics_NN
0.9_CD
Business_NOMZ
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
5.5_CD
At_PIN
the_DT
half_NN
year_NN
,_,
the_DT
businesses_NOMZ
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
line_NN
was_VBD [PASS]
reported_VBN [PUBV]
as_IN
being_VBG [BEMA]
8.0_CD
million_CD
,_,
the_DT
adjusted_VBN
fair_JJ
value_NN
at_PIN
31_CD
December_NN
2003_CD
reflects_VPRT [PRIV]
the_DT
unsuccessful_JJ
outcome_NN
of_PIN
efforts_NN
to_TO
dispose_VB
of_PIN
the_DT
business_NOMZ
see_VB [PRIV]
note_NN
23_CD
._.
Due_JJ
to_PIN
the_DT
businesses_NOMZ
no_RB
longer_RB
being_VBG [PASS]
held_VBN [PRIV]
for_PIN
disposal_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
remaining_VBG
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
proteomics_NN
business_NOMZ
and_PHC
Confirmant_NN
Limited_NN
are_VPRT [PASS]
included_VBN
within_PIN
the_DT
usual_JJ
statutory_JJ
headings_GER
._.
Information_NOMZ
on_PIN
OGS_NN
pre-acquisition_JJ
results_NN
The_DT
last_JJ
financial_JJ
statements_NOMZ
of_PIN
OGS_NN
were_VBD [PASS]
prepared_VBN
for_PIN
the_DT
year_NN
to_PIN
31_CD
December_NN
2002_CD
,_,
and_ANDC
were_VBD [BYPA]
audited_VBN
by_PIN
Ernst_NN
&_CC
Young_NN
._.
The_DT
summarised_JJ
profit_NN
and_PHC
loss_NN
account_NN
and_PHC
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
for_PIN
OGS_NN
for_PIN
the_DT
period_NN
from_PIN
1_CD
January_NN
2003_CD
to_PIN
the_DT
end_NN
of_PIN
April_NN
,_,
the_DT
period_NN
prior_RB
to_PIN
the_DT
effective_JJ
date_NN
of_PIN
acquisition_NOMZ
,_,
and_ANDC
for_PIN
the_DT
preceding_JJ
year_NN
are_VPRT
as_IN
follows_VPRT
:_:
1_CD
Jan_NN
to_PIN
30_CD
Apr_NN
unaudited_JJ
31_CD
Dec_NN
2002_CD
m_FW
m_FW
Turnover_NN
3.7_CD
14.0_CD
Net_JJ
operating_GER
costs_NN
16.8_CD
54.8_CD
Operating_GER
loss_NN
13.1_CD
40.8_CD
Share_NN
of_PIN
joint_JJ
venture_NN
loss_NN
1.6_CD
4.4_CD
Interest_NN
receivable_JJ
1.9_CD
6.4_CD
Amount_NN
written_VBN [PUBV] [WZPAST]
off_PIN
investments_NOMZ
2.4_CD
Loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
12.8_CD
41.2_CD
Tax_NN
on_PIN
loss_NN
on_PIN
ordinary_JJ
activities_NOMZ
3.3_CD
Loss_NN
on_PIN
ordinary_JJ
net_JJ
activities_NOMZ
after_IN
taxation_NOMZ
12.8_CD
37.9_CD
Due_JJ
to_PIN
the_DT
significant_JJ
restructuring_GER
undertaken_VBN [WZPAST]
on_PIN
OGS_NN
,_,
the_DT
above_PLACE
results_NN
are_VPRT [BEMA]
not_XX0
indicative_PRED
of_PIN
the_DT
impact_NN
of_PIN
the_DT
acquisition_NOMZ
on_PIN
Celltechs_NN
result_NN
._.
The_DT
turnover_NN
and_PHC
operating_GER
losses_NN
of_PIN
the_DT
business_NOMZ
,_,
before_IN
restructuring_GER
and_PHC
goodwill_NN
items_NN
,_,
consolidated_VBN [PASTP]
by_PIN
the_DT
Group_NN
for_PIN
the_DT
period_NN
since_OSUB
acquisition_NOMZ
are_VPRT
nil_NN
and_CC
3.9_CD
million_CD
respectively_RB
._.
In_CONJ
addition_NULL
,_,
a_DT
charge_NN
of_PIN
4.5_CD
million_CD
is_VPRT [PASS]
included_VBN
within_PIN
exceptional_JJ
items_NN
for_PIN
OGS_NN
in_PIN
respect_NN
of_PIN
integration_NOMZ
and_PHC
products_NN
that_TSUB
are_VPRT
being_VBG [PASS]
discontinued_VBN
._.
Both_DT
these_DEMO
amounts_NN
are_VPRT [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
cash_NN
flow_NN
analysis_NN
of_PIN
the_DT
impact_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
OGS_NN
shown_VBN [PRIV]
below_PLACE
._.
Acquisition_NOMZ
of_PIN
subsidiary_NN
undertakings_GER
continued_VBD
Impact_NN
of_PIN
OGS_NN
acquisition_NOMZ
on_PIN
cash_NN
flows_VPRT
OGS_NN
contribution_NOMZ
to_PIN
the_DT
Group_NN
cashflow_NN
since_OSUB
the_DT
date_NN
of_PIN
acquisition_NOMZ
can_POMD
be_VB [PASS]
summarised_VBN
as_IN
follows_VPRT
:_:
m_VB
Operating_GER
result_NN
3.9_CD
million_CD
operating_GER
loss_NN
,_,
integration_NOMZ
costs_NN
4.5_CD
million_CD
8.4_CD
Cashflow_NN
on_PIN
fair_JJ
value_NN
provisions_NN
22.5_CD
Working_JJ
capital_NN
movements_NOMZ
4.4_CD
Net_JJ
cash_NN
outflow_NN
from_PIN
operating_VBG
activities_NOMZ
35.3_CD
Interest_NN
received_VBD
2.1_CD
Taxation_NOMZ
3.6_CD
Cash_NN
funding_GER
in_PIN
respect_NN
of_PIN
businesses_NOMZ
held_VBN [PRIV] [WZPAST]
for_PIN
resale_NN
0.9_CD
Cash_NN
outflow_NN
before_IN
use_NN
of_PIN
liquid_JJ
resources_NN
30.5_CD
The_DT
total_JJ
impact_NN
on_PIN
cash_NN
and_CC
liquid_JJ
resources_NN
,_,
including_VBG
acquisition_NOMZ
flows_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
but_CC
excluding_VBG
the_DT
cost_NN
of_PIN
continuing_VBG
activities_NOMZ
,_,
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
m_VB
Cost_NN
of_PIN
shares_NN
102.3_CD
Transaction_NOMZ
costs_VPRT
3.8_CD
106.1_CD
Cash_NN
and_CC
liquid_JJ
resources_NN
inherited_VBN [WZPAST]
with_PIN
OGS_NN
126.6_CD
Cash_NN
outflow_NN
since_OSUB
date_NN
of_PIN
acquisition_NOMZ
30.5_CD
Net_JJ
Confirmant_JJ
cash_NN
acquired_VBD
6.4_CD
Costs_NN
in_PIN
relation_NOMZ
to_TO
continuing_VBG
activities_NOMZ
3.9_CD
Total_JJ
inflow_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
0.3_CD
23_CD
._.
Businesses_NOMZ
held_VBD [PRIV]
for_PIN
resale_NN
On_PIN
acquisition_NOMZ
of_PIN
OGS_NN
,_,
Celltech_NN
identified_VBD
the_DT
proteomics_NN
business_NOMZ
as_IN
being_VBG [PASS]
held_VBN [PRIV]
for_PIN
immediate_JJ
disposal_NN
._.
After_IN
significant_JJ
initial_JJ
interest_NN
the_DT
last_JJ
potential_JJ
buyer_NN
for_PIN
the_DT
proteomics_NN
business_NOMZ
withdrew_VBD
from_PIN
negotiations_NOMZ
in_PIN
late_TIME
November_NN
2003_CD
._.
At_PIN
that_DEMO
point_NN
,_,
a_DT
decision_NN
was_VBD [PASS]
taken_VBN
to_TO
terminate_VB
the_DT
operations_NOMZ
immediately_TIME
._.
Consequently_CONJ
,_,
from_PIN
that_DEMO
date_NN
onwards_NN
,_,
it_PIT
was_VBD
no_RB
longer_RB
appropriate_JJ
to_TO
treat_VB
the_DT
business_NOMZ
as_IN
a_DT
business_NOMZ
held_VBD [PRIV]
for_PIN
disposal_NN
and_CC
,_,
therefore_CONJ
,_,
as_IN
part_NN
of_PIN
the_DT
OGS_NN
closure_NN
costs_VPRT
a_DT
charge_NN
of_PIN
0.5_CD
million_CD
was_VBD [PASS]
made_VBN
in_PIN
respect_NN
of_PIN
proteomics_NN
redundancies_NN
._.
OGS_NN
was_VBD
party_NN
to_PIN
a_DT
50:50_CD
joint_JJ
venture_NN
with_PIN
Marconi_NN
,_,
in_PIN
a_DT
company_NN
known_VBN [PRIV]
as_IN
Confirmant_NN
Limited_NN
Confirmant_NN
._.
The_DT
purpose_NN
of_PIN
the_DT
joint_JJ
venture_NN
was_VBD
to_TO
integrate_VB
and_CC
leverage_NN
Marconis_NN
broadband_NN
data_NN
transmission_NN
capabilities_NOMZ
with_PIN
OGS_NN
proteomics_NN
database_NN
._.
Confirmant_NN
had_VBD
initial_JJ
funding_GER
of_PIN
30_CD
million_CD
contributed_VBD
equally_RB
by_PIN
Marconi_NN
and_PHC
OGS_NN
._.
Confirmant_JJ
operated_VBN
with_PIN
a_DT
separate_JJ
management_NOMZ
and_PHC
sales_NN
team_NN
._.
Following_VBG [PRESP]
the_DT
failure_NN
to_TO
dispose_VB
of_PIN
the_DT
proteomics_NN
business_NOMZ
,_,
agreement_NOMZ
was_VBD [PASS]
reached_VBN
with_PIN
Marconi_NN
to_TO
terminate_VB
the_DT
joint_JJ
venture_NN
and_CC
distribute_VB
the_DT
remaining_VBG
cash_NN
._.
This_DEMP
resulted_VBD
in_PIN
a_DT
payment_NOMZ
to_PIN
Marconi_NN
of_PIN
4.1_CD
million_CD
and_CC
OGS_NN
then_RB
acquired_VBD
full_JJ
rights_NN
over_IN
the_DT
remaining_VBG
10.5_CD
million_CD
of_PIN
cash_NN
and_CC
liquid_JJ
resources_NN
within_PIN
Confirmant_NN
._.
This_DEMO
net_JJ
6.4_CD
million_CD
receipt_NN
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
determining_VBG [SUAV] [PRIV]
the_DT
value_NN
of_PIN
businesses_NOMZ
held_VBN [PRIV] [WZPAST]
for_PIN
disposal_NN
in_PIN
note_NN
22_CD
above_PLACE
._.
The_DT
payment_NOMZ
to_PIN
Marconi_NN
took_VBD
account_NN
of_PIN
amounts_NN
owed_VBN [WZPAST]
to_PIN
OGS_NN
and_CC
its_PIT
share_NN
of_PIN
the_DT
Confirmant_NN
closure_NN
costs_NN
._.
The_DT
table_NN
below_PLACE
summarises_NN
the_DT
transactions_NOMZ
:_:
m_VB
Acquisition_NOMZ
of_PIN
remaining_VBG
50_CD
%_NN
of_PIN
Confirmant_NN
4.1_CD
Cash_NN
acquired_VBD
10.5_CD
Net_JJ
cash_NN
acquired_VBD
6.4_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
71_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
24_CD
._.
Shareholders_NN
funds_NN
Called_VBN
up_RP
Share_NN
Profit_NN
share_NN
premium_NN
Other_JJ
and_CC
loss_NN
capital_NN
account_NN
reserves_NN
account_VPRT
Total_NN
Group_NN
m_FW
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
1_CD
January_NN
2003_CD
141.3_CD
83.3_CD
621.4_CD
281.6_CD
564.4_CD
Preference_NN
shares_NN
redeemed_VBN
3.5_CD
2.4_CD
5.9_CD
Shares_NN
issued_VBN
to_TO
meet_VB
redemption_NOMZ
1.0_CD
4.9_CD
5.9_CD
Proceeds_NN
of_PIN
exercise_NN
of_PIN
Celltech_NN
share_NN
options_NOMZ
0.3_CD
0.3_CD
Currency_NN
translation_NOMZ
difference_NN
on_PIN
foreign_JJ
currency_NN
net_JJ
investments_NOMZ
and_CC
net_JJ
borrowings_GER
4.9_CD
4.9_CD
Preference_NN
share_NN
dividends_NN
transferred_VBN [WZPAST]
to_PIN
other_JJ
reserves_NN
0.1_CD
0.1_CD
Net_JJ
transfer_NN
to_PIN
profit_NN
and_PHC
loss_NN
account_NN
53.9_CD
53.9_CD
At_PIN
31_CD
December_NN
2003_CD
138.8_CD
88.5_CD
619.1_CD
340.5_CD
505.9_CD
Other_JJ
reserves_NN
arise_VPRT
from_PIN
the_DT
reorganisation_NOMZ
of_PIN
the_DT
Group_NN
structure_NN
on_PIN
1_CD
October_NN
1997_CD
and_CC
the_DT
acquisitions_NOMZ
of_PIN
Darwin_NN
Molecular_NN
Corporation_NOMZ
,_,
Medeva_NN
and_PHC
Cistron_NN
,_,
together_RB
with_PIN
merger_NN
adjustments_NOMZ
in_PIN
relation_NOMZ
to_PIN
the_DT
merger_NN
of_PIN
Celltech_NN
and_PHC
Chiroscience_NN
,_,
and_ANDC
the_DT
reserve_NN
transfer_NN
on_PIN
disposal_NN
of_PIN
ChiroTech_NN
._.
The_DT
cumulative_JJ
goodwill_NN
written_VBN [PUBV] [WZPAST]
off_PIN
directly_RB
to_PIN
reserves_NN
is_VPRT [BEMA]
60.5_CD
million_CD
2002_CD
:_:
60.5_CD
million_CD
._.
Called_VBN
up_RP
Share_NN
Profit_NN
share_NN
premium_NN
Other_JJ
and_CC
loss_NN
capital_NN
account_NN
reserves_NN
account_VPRT
Total_JJ
Company_NN
m_NN
m_FW
m_FW
m_FW
m_FW [BEMA]
At_PIN
1_CD
January_NN
2003_CD
141.3_CD
83.3_CD
2.4_CD
88.2_CD
315.2_CD
Preference_NN
shares_NN
redeemed_VBN
3.5_CD
2.4_CD
5.9_CD
Issue_NN
of_PIN
ordinary_JJ
shares_NN
1.0_CD
5.2_CD
6.2_CD
Net_JJ
transfer_NN
from_PIN
profit_NN
and_PHC
loss_NN
account_NN
4.9_CD
4.9_CD
At_PIN
31_CD
December_NN
2003_CD
138.8_CD
88.5_CD
93.1_CD
320.4_CD
Analysis_NN
of_PIN
shareholders_NN
funds_NN
Group_NN
Company_NN
2003 2002 2003 2002_CD
m_FW
m_FW
m_FW
m_FW
Equity_NOMZ
interests_NN
505.9_CD
558.6_CD
320.4_CD
309.4_CD
Non-equity_NOMZ
interests_NN
5.8_CD
5.8_CD
Shareholders_NN
funds_NN
505.9_CD
564.4_CD
320.4_CD
315.2_CD
In_PIN
2002_CD
non-equity_JJ
comprises_VPRT
6.9_CD
%_NN
convertible_JJ
redeemable_JJ
preference_NN
shares_NN
and_CC
accrued_VBN
preference_NN
share_NN
dividends_NN
._.
No_SYNE
voting_NN
rights_NN
were_VBD [PASS]
attached_VBN
to_PIN
these_DEMO
shares_NN
._.
Analysis_NN
of_PIN
share_NN
capital_NN
2003_CD
2002_CD
Authorised_NN
Number_NN
Number_NN
Ordinary_NN
shares_NN
of_PIN
50p_JJ
each_QUAN
373,064,416_CD
373,064,416_CD
6.9_CD
%_NN
convertible_JJ
redeemable_JJ
cumulative_JJ
preference_NN
shares_NN
of_PIN
1_CD
each_QUAN
3,467,790_CD
3,467,790_CD
Allotted_NN
,_,
called_VBD
up_RP
and_CC
fully_AMP
paid_VBN
2003 2002 2003 2002_CD
Number_NN
Number_NN
m_FW
m_FW
Ordinary_NN
shares_NN
of_PIN
50p_JJ
each_QUAN
277,654,453_CD
275,527,304_CD
138.8_CD
137.9_CD
6.9_CD
%_NN
convertible_JJ
redeemable_JJ
cumulative_JJ
preference_NN
shares_NN
of_PIN
1_CD
each_QUAN
3,467,790_CD
3.4_CD
Total_JJ
277,654,453_CD
278,995,094_CD
138.8_CD
141.3_CD
During_PIN
the_DT
period_NN
,_,
170,351_CD
ordinary_JJ
shares_NN
were_VBD [PASS]
issued_VBN
and_CC
fully_AMP
paid_VBN
upon_PIN
the_DT
exercise_NN
of_PIN
share_NN
options_NOMZ
._.
The_DT
cash_NN
consideration_NOMZ
received_VBD
amounted_VBD
to_PIN
0.3_CD
million_CD
and_CC
resulted_VBD
in_PIN
an_DT
increase_NN
in_PIN
the_DT
share_NN
premium_NN
account_NN
of_PIN
0.3_CD
million_CD
._.
On_PIN
31_CD
March_NN
2003_CD
,_,
3.5_CD
million_CD
convertible_JJ
redeemable_JJ
cumulative_JJ
preference_NN
shares_NN
were_VBD [PASS]
converted_VBN
into_PIN
ordinary_JJ
shares_NN
at_PIN
a_DT
price_NN
of_PIN
3_CD
per_PIN
share_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
cumulative_JJ
unpaid_JJ
interest_NN
accrual_NN
of_PIN
2.4_CD
million_CD
on_PIN
these_DEMO
preference_NN
shares_NN
was_VBD [SPAU] [PASS]
also_RB
converted_VBN
to_PIN
ordinary_JJ
shares_NN
at_PIN
a_DT
price_NN
of_PIN
3_CD
per_PIN
share_NN
._.
In_PIN
total_JJ
,_,
1,956,798_CD
new_JJ
ordinary_JJ
shares_NN
were_VBD [PASS]
issued_VBN
on_PIN
the_DT
conversion_NN
of_PIN
the_DT
preference_NN
shares_NN
,_,
equating_VBG [PRESP]
to_PIN
a_DT
redemption_NOMZ
of_PIN
5,870,394_CD
of_PIN
preference_NN
shares_NN
and_CC
related_JJ
interest_NN
._.
Shareholders_NN
funds_NN
continued_VBD
Share_NN
options_NOMZ
outstanding_JJ
to_PIN
employees_NN
of_PIN
the_DT
Group_NN
as_IN
at_PIN
31_CD
December_NN
2003_CD
are_VPRT
as_IN
follows_VPRT
:_:
i_FPP1
Celltech_NN
Executive_NN
Share_NN
Option_NOMZ
Schemes_NN
1,856_CD
employees_NN
hold_VPRT [PRIV] [THATD]
options_NOMZ
including_VBG [WZPRES]
unapproved_JJ
options_NOMZ
to_TO
subscribe_VB
for_PIN
up_RB
to_PIN
14,974,819_CD
shares_NN
at_PIN
prices_NN
ranging_VBG [WZPRES]
between_PIN
205p_CD
and_CC
1295p_CD
per_PIN
share_NN
exercisable_JJ
between_PIN
2003_CD
and_CC
2013_CD
._.
This_DEMP
includes_VPRT
both_DT
Chiroscience_NN
and_PHC
Medeva_NN
originating_VBG [WZPRES]
Executive_NN
options_NOMZ
._.
Included_VBN [PASTP]
in_PIN
this_DEMO
figure_NN
are_VPRT [BEMA]
43,806_CD
options_NOMZ
held_VBN [PRIV]
under_IN
the_DT
Chiroscience_NN
ESOP_NN
Trust_NN
._.
ii_FW
Celltech_NN
Savings_GER
Related_NN
Share_NN
Option_NOMZ
Schemes_NN
includes_VPRT
Celltech_NN
,_,
Chiroscience_NN
and_PHC
Medeva_NN
originating_VBG [WZPRES]
schemes_NN
947_CD
employees_NN
hold_VPRT [PRIV]
options_NOMZ
to_TO
subscribe_VB
for_PIN
up_RB
to_PIN
2,016,628_CD
ordinary_JJ
shares_NN
at_PIN
prices_NN
between_PIN
237p_CD
and_CC
948p_CD
per_PIN
share_NN
exercisable_JJ
between_PIN
2003_CD
and_CC
2010_CD
._.
iii_FW
Deferred_NN
Bonus_NN
Plan_NN
13_CD
employees_NN
hold_VPRT [PRIV]
options_NOMZ
to_TO
subscribe_VB
for_PIN
up_RB
to_PIN
455,350_CD
shares_NN
._.
The_DT
shares_NN
are_VPRT [PASS]
issued_VBN
and_PHC
are_VPRT [PASS]
held_VBN [PRIV]
in_PIN
the_DT
Celltech_NN
Group_NN
plc_NN
Employee_NN
Share_NN
Trust_NN
._.
Related_VBN
party_NN
transaction_NOMZ
During_PIN
the_DT
year_NN
,_,
Celltech_NN
entered_VBD
into_PIN
a_DT
related_JJ
party_NN
transaction_NOMZ
with_PIN
its_PIT
new_JJ
Chief_NN
Executive_NN
,_,
Dr._NN
Gran_NN
Ando_NN
._.
The_DT
transaction_NOMZ
involved_VBD
the_DT
acquisition_NOMZ
by_PIN
Celltech_NN
on_PIN
22_CD
October_NN
2003_CD
of_PIN
Dr._NN
Andos_NN
home_NN
in_PIN
Mendham_NN
Borough_NN
,_,
New_NN
Jersey_NN
,_,
USA_NN
._.
The_DT
purpose_NN
of_PIN
the_DT
transaction_NOMZ
was_VBD
to_TO
expedite_VB
Dr._NN
Andos_NN
relocation_NOMZ
to_PIN
the_DT
United_NN
Kingdom_NN
._.
The_DT
agreed_JJ
acquisition_NOMZ
price_NN
for_PIN
the_DT
property_NN
was_VBD
$_$
2_CD
million_CD
1.1_CD
million_CD
which_WDT
was_VBD [PASS]
based_VBN
on_PIN
the_DT
mid-point_NN
of_PIN
two_CD
independent_JJ
valuations_NOMZ
._.
The_DT
total_JJ
cost_NN
to_PIN
Celltech_NN
including_VBG [WZPRES]
acquisition-related_JJ
expenditure_NN
amounted_VBD
to_TO
$_$
2,026,842_CD
._.
The_DT
transaction_NOMZ
involved_VBN
full_JJ
transfer_NN
of_PIN
the_DT
rights_NN
to_PIN
the_DT
property_NN
to_PIN
Celltech_NN
:_:
no_SYNE
further_JJ
amounts_NN
become_VPRT
payable_JJ
to_TO
or_CC
from_PIN
Dr._NN
Ando_NN
._.
Full_JJ
settlement_NOMZ
of_PIN
the_DT
amounts_NN
due_JJ
to_PIN
Dr._NN
Ando_NN
was_VBD [PASS]
made_VBN
on_PIN
22_CD
October_NN
2003_CD
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
property_NN
is_VPRT [SPAU] [BYPA]
still_RB
held_VBN [PRIV]
by_PIN
Celltech_NN
and_CC
is_VPRT [PASS]
included_VBN
within_PIN
freehold_NN
tangible_JJ
fixed_JJ
assets_NN
,_,
see_VPRT [PRIV]
note_NN
12_CD
._.
Financial_NN
commitments_NOMZ
i_FPP1
Capital_NN
expenditure_NN
2003_CD
2002_CD
m_NN [PASS]
m_NN [PASS]
Contracted_VBD
7.8_CD
1.2_CD
ii_NN
Manufacturing_GER
capacity_NOMZ
The_NN
Group_NN
has_VPRT [PEAS]
entered_VBN
into_PIN
significant_JJ
manufacturing_GER
capacity_NOMZ
arrangements_NOMZ
as_IN
discussed_VBN
below_PLACE
:_:
Sandoz_NN
formerly_TIME
Biochemie_NN
GmbH_NN
Celltech_NN
has_VPRT [PEAS]
contracted_VBN
Sandoz_NN
,_,
a_DT
subsidiary_NN
of_PIN
Novartis_NN
,_,
as_IN
a_DT
long-term_JJ
source_NN
for_PIN
the_DT
manufacture_NN
of_PIN
its_PIT
microbially_RB
produced_VBN
antibody_NN
products_NN
including_VBG [WZPRES]
CDP870_NN
._.
Celltech_NN
has_VPRT [PEAS]
reserved_VBN
manufacturing_VBG
capacity_NOMZ
beginning_VBG [WZPRES]
1_CD
January_NN
2004_CD
and_CC
ending_VBG
31_CD
December_NN
2010_CD
._.
Celltech_NN
has_VPRT
potential_JJ
take_NN
or_CC
pay_NN
obligations_NOMZ
,_,
which_WDT [SERE]
are_VPRT [BEMA]
subject_PRED
to_PIN
mitigation_NOMZ
,_,
under_IN
this_DEMO
agreement_NOMZ
of_PIN
approximately_RB
41_CD
million_CD
._.
Lonza_NN
Celltech_NN
has_VPRT [PEAS]
contracted_VBN
Lonza_NN
as_IN
a_DT
long-term_JJ
manufacturing_GER
source_NN
and_CC
has_VPRT [PEAS]
reserved_VBN
manufacturing_VBG
capacity_NOMZ
until_IN
31_CD
December_NN
2010_CD
._.
Under_IN
the_DT
contract_NN
there_EX
are_VPRT
varying_VBG
sums_NN
payable_JJ
each_QUAN
year_NN
under_IN
take_NN
or_CC
pay_NN
obligations_NOMZ
._.
The_DT
total_JJ
obligations_NOMZ
over_IN
the_DT
period_NN
of_PIN
the_DT
contract_NN
,_,
which_WDT [SERE]
are_VPRT [BEMA]
subject_PRED
to_PIN
mitigation_NOMZ
,_,
amount_NN
to_PIN
14_CD
million_CD
._.
BioReliance_NN
Celltech_NN
has_VPRT
a_DT
contract_NN
with_PIN
BioReliance_NN
enabling_VBG [WZPRES]
the_DT
Group_NN
to_TO
reserve_VB
manufacturing_VBG
capacity_NOMZ
._.
The_DT
current_JJ
minimum_NN
commitment_NOMZ
is_VPRT [BEMA]
2.2_CD
million_CD
based_VBN
on_PIN
forecast_NN
requirements_NOMZ
which_WDT [WHSUB]
have_VPRT [PEAS]
been_VBN [PASS]
submitted_VBN [PUBV]
to_PIN
BioReliance_NN
._.
iii_FW
Leasing_GER
Operating_GER
and_PHC
finance_NN
lease_NN
commitments_NOMZ
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
note_NN
19_CD
._.
Celltech_NN
Annual_JJ
Report_NN
2003_CD
73_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
27_CD
._.
Pension_NN
arrangements_NOMZ
The_DT
Group_NN
operates_VPRT
a_DT
number_NN
of_PIN
pension_NN
schemes_NN
,_,
the_DT
majority_NOMZ
being_VBG [WZPRES] [PASS]
defined_VBN
benefit_NN
arrangements_NOMZ
._.
Details_NN
of_PIN
the_DT
Groups_NN
schemes_NN
are_VPRT
as_IN
follows_VPRT
:_:
i_FPP1
Pension_NN
schemes_NN
under_IN
SSAP_NN
24 2003 2002_CD
The_DT
charge_NN
for_PIN
the_DT
year_NN
comprises_VPRT
:_:
m_VB
m_FW
Celltech_NN
Pension_NN
and_PHC
Life_NN
Assurance_NN
Scheme_NN
and_PHC
Medeva_NN
Plans_NN
1.6_CD
2.2_CD
US_FPP1
qualified_VBD
scheme_NN
1.1_CD
US_FPP1
non-qualified_JJ
scheme_NN
0.2_CD
0.2_CD
Thiemann_NN
plan_NN
0.6_CD
0.5_CD
Defined_VBN
contribution_NOMZ
schemes_NN
US_FPP1
and_PHC
UK_NN
3.3_CD
1.6_CD
Total_JJ
5.7_CD
5.6_CD
The_DT
defined_VBN
contribution_NOMZ
schemes_NN
relate_VPRT
primarily_RB
to_PIN
the_DT
Celltech_NN
Group_NN
Personal_NN
Pension_NN
Plan_NN
CGPPP_NN
and_PHC
US_FPP1
401K_NN
plans_NN
._.
The_DT
CGPPP_NN
was_VBD [PASS]
introduced_VBN
as_IN
of_PIN
1_CD
January_NN
2000_CD
for_PIN
all_QUAN
new_JJ
UK_NN
employees_NN
of_PIN
the_DT
Group_NN
._.
The_DT
Celltech_NN
Pension_NN
and_PHC
Life_NN
Assurance_NN
Scheme_NN
CP&LAS_NN
,_,
the_DT
Medeva_NN
UK_NN
Pension_NN
Plan_NN
and_CC
the_DT
Medeva_NN
Senior_NN
Executive_NN
Pension_NN
Plan_NN
are_VPRT [BEMA]
all_QUAN
closed_VBN
to_PIN
new_JJ
members_NN
._.
Under_IN
the_DT
CGPPP_NN
the_DT
Group_NN
contributes_VPRT
8_CD
%_NN
of_PIN
salary_NN
to_PIN
individual_JJ
plans_NN
for_PIN
employees_NN
._.
The_DT
contribution_NOMZ
accrued_VBN [WZPAST]
at_PIN
the_DT
end_NN
of_PIN
the_DT
financial_JJ
year_NN
in_PIN
respect_NN
of_PIN
the_DT
Groups_NN
UK_NN
pension_NN
scheme_NN
was_VBD [BEMA]
0.1_CD
million_CD
._.
This_DEMP
was_VBD [PASS]
paid_VBN
in_PIN
accordance_NN
with_PIN
trust_NN
rules_NN
in_PIN
January_NN
2004_CD
._.
Details_NN
of_PIN
the_DT
Groups_NN
defined_VBN
benefit_NN
schemes_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
UK_NN
defined_VBD
benefit_NN
Scheme_NN
The_DT
last_JJ
full_JJ
actuarial_JJ
valuation_NOMZ
of_PIN
the_DT
UK_NN
schemes_NN
for_PIN
SSAP_NN
24_CD
purposes_NN
was_VBD [PASS]
undertaken_VBN
as_RB
at_PIN
30_CD
September_NN
2002_CD
._.
However_CONJ
,_,
an_DT
actuarial_JJ
review_NN
has_VPRT [PEAS]
been_VBN [PASS]
carried_VBN
out_PIN
as_IN
at_PIN
30_CD
September_NN
2003_CD
._.
The_DT
main_JJ
financial_JJ
assumptions_NOMZ
for_PIN
the_DT
30_CD
September_NN
2003_CD
review_NN
were_VBD
as_IN
follows_VPRT
:_:
Rate_NN
of_PIN
return_NN
6.8_CD
%_NN
Rate_NN
of_PIN
increase_NN
in_PIN
salaries_NN
4.0_CD
%_NN
LPI_NN
pension_NN
increases_NN
2.5_CD
%_NN
Revaluation_NOMZ
in_PIN
deferment_NOMZ
2.5_CD
%_NN
Asset_NN
valuation_NOMZ
method_NN
Market_NN
value_NN
Liability_NOMZ
valuation_NOMZ
Attained_VBN
age_NN
The_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
scheme_NN
were_VBD
as_IN
follows_VPRT
:_:
30_CD
Sep_NN
2003_CD
m_NN
Assets_NN
39.6_CD
Liabilities_NOMZ
44.6_CD
Deficit_NN
in_PIN
the_DT
scheme_NN
5.0_CD
The_DT
CP&LAS_NN
is_VPRT [SPAU] [PASS]
thus_CONJ
funded_VBN
at_PIN
89_CD
%_NN
of_PIN
the_DT
liabilities_NOMZ
._.
The_DT
attained_VBN
age_NN
methodology_NN
is_VPRT [PASS]
used_VBN
to_TO
obtain_VB
the_DT
actuarial_JJ
valuation_NOMZ
for_PIN
liabilities_NOMZ
._.
The_DT
attained_VBN
age_NN
methodology_NN
is_VPRT [BEMA]
the_DT
most_EMPH
appropriate_JJ
in_PIN
the_DT
circumstances_NN
of_PIN
this_DEMO
scheme_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
._.
The_DT
cash_NN
cost_NN
of_PIN
the_DT
scheme_NN
is_VPRT [BEMA]
identical_PRED
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
charge_NN
and_ANDC
consequently_CONJ
there_EX
is_VPRT
no_SYNE
SSAP_NN
24_CD
prepayment_NOMZ
nor_SYNE
provision_NN
._.
On_PIN
the_DT
basis_NN
of_PIN
the_DT
actuarial_JJ
reviews_NN
,_,
the_DT
current_JJ
average_JJ
contribution_NOMZ
rate_NN
paid_VBN [WZPAST]
by_PIN
the_DT
Group_NN
is_VPRT [BEMA]
14.7_CD
%_NN
of_PIN
pensionable_JJ
salaries_NN
2002_CD
:_:
14.7_CD
%_NN
._.
Pension_NN
arrangements_NOMZ
continued_VBD
US_FPP1
Qualified_NN
Scheme_NN
The_DT
most_EMPH
recent_JJ
valuation_NOMZ
of_PIN
the_DT
plan_NN
under_IN
US_FPP1
accounting_GER
standards_NN
was_VBD [PASS]
carried_VBN
out_PIN
on_PIN
31_CD
December_NN
2003_CD
._.
At_PIN
the_DT
valuation_NOMZ
date_NN
,_,
the_DT
market_NN
value_NN
of_PIN
the_DT
assets_NN
of_PIN
the_DT
plan_NN
was_VBD [BEMA]
8.9_CD
million_CD
and_CC
the_DT
liabilities_NOMZ
were_VBD [BEMA]
11.9_CD
million_CD
._.
Thus_CONJ
the_DT
assets_NN
of_PIN
the_DT
plan_NN
represented_VBD
75_CD
%_NN
of_PIN
the_DT
value_NN
of_PIN
the_DT
benefits_NN
that_TSUB
had_VBD [PEAS]
accrued_VBN
to_PIN
members_NN
._.
The_DT
projected_VBN
unit_NN
method_NN
was_VBD [PASS]
used_VBN
to_TO
derive_VB
the_DT
valuation_NOMZ
above_PLACE
and_CC
the_DT
key_JJ
actuarial_JJ
assumptions_NOMZ
are_VPRT [BEMA]
broadly_RB
in_PIN
line_NN
with_PIN
those_DEMP
set_VBN
out_PIN
in_PIN
ii_NN
below_PLACE
._.
The_DT
US_FPP1
Qualified_NN
Scheme_NN
was_VBD [PASS]
frozen_VBN
as_RB
at_PIN
31_CD
December_NN
2002_CD
and_CC
,_,
as_IN
such_JJ
,_,
no_SYNE
further_JJ
benefits_NN
accrue_VPRT
to_PIN
the_DT
members_NN
._.
US_FPP1
Unqualified_NN
Scheme_NN
The_DT
most_EMPH
recent_JJ
valuation_NOMZ
of_PIN
the_DT
plan_NN
under_IN
US_FPP1
accounting_GER
standards_NN
was_VBD [PASS]
carried_VBN
out_PIN
on_PIN
31_CD
December_NN
2003_CD
._.
The_DT
liabilities_NOMZ
of_PIN
this_DEMO
unfunded_JJ
scheme_NN
at_PIN
this_DEMO
date_NN
were_VBD [PASS]
valued_VBN
at_PIN
2.6_CD
million_CD
._.
However_CONJ
,_,
the_DT
Group_NN
is_VPRT
carrying_VBG
a_DT
liability_NOMZ
in_PIN
creditors_NN
of_PIN
2.5_CD
million_CD
against_PIN
this_DEMO
obligation_NOMZ
,_,
and_ANDC
also_RB
holds_VPRT [PRIV]
a_DT
RABBI_NN
account_NN
of_PIN
2.0_CD
million_CD
for_PIN
this_DEMO
liability_NOMZ
see_VB [PRIV]
ii_FW
below_PLACE
._.
The_DT
US_FPP1
Unqualified_NN
Scheme_NN
was_VBD [PASS]
frozen_VBN
as_RB
at_PIN
31_CD
December_NN
2002_CD
and_CC
,_,
as_IN
such_JJ
,_,
no_SYNE
further_JJ
benefits_NN
accrue_VPRT
to_PIN
the_DT
members_NN
._.
German_JJ
Thiemann_NN
Plan_NN
The_DT
most_EMPH
recent_JJ
valuation_NOMZ
of_PIN
the_DT
plan_NN
was_VBD [PASS]
carried_VBN
out_PIN
as_IN
at_PIN
31_CD
December_NN
2003_CD
under_IN
IAS_NN
19_CD
._.
At_PIN
the_DT
valuation_NOMZ
date_NN
,_,
the_DT
market_NN
value_NN
of_PIN
the_DT
assets_NN
of_PIN
the_DT
plan_NN
was_VBD [BEMA]
6.1_CD
million_CD
and_CC
the_DT
liabilities_NOMZ
were_VBD [BEMA]
12.2_CD
million_CD
._.
Thus_CONJ
the_DT
assets_NN
of_PIN
the_DT
plan_NN
represented_VBD
50_CD
%_NN
of_PIN
the_DT
value_NN
of_PIN
the_DT
benefits_NN
that_TSUB
had_VBD [PEAS]
accrued_VBN
to_PIN
members_NN
after_IN
allowing_VBG [SUAV]
for_PIN
expected_JJ
future_JJ
increases_NN
in_PIN
earnings_GER
._.
However_CONJ
,_,
the_DT
Company_NN
also_RB
holds_VPRT [PRIV]
separate_JJ
insurance_NN
assets_NN
of_PIN
6.0_CD
million_CD
outside_PLACE
of_PIN
the_DT
scheme_NN
to_TO
cover_VB
the_DT
deficit_NN
._.
Thus_CONJ
in_PIN
total_JJ
there_EX
are_VPRT
assets_NN
of_PIN
12.1_CD
million_CD
available_JJ
to_TO
cover_VB
the_DT
liability_NOMZ
of_PIN
12.2_CD
million_CD
as_IN
set_VBN
out_PIN
in_PIN
the_DT
FRS_NN
17_CD
disclosures_NN
._.
The_DT
key_JJ
actuarial_JJ
assumptions_NOMZ
that_TSUB
were_VBD [PASS]
used_VBN
are_VPRT
as_IN
set_VBN
out_PIN
in_PIN
ii_NN
below_PLACE
._.
ii_FW
FRS_FW
17_CD
disclosures_NN
The_DT
Group_NN
has_VPRT [PEAS]
adopted_VBN
FRS_NN
17_CD
,_,
Retirement_NOMZ
Benefits_NN
,_,
to_PIN
the_DT
extent_NN
of_PIN
the_DT
mandated_VBN
disclosure_NN
requirements_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
._.
FRS_NN
17_CD
is_VPRT [BEMA]
more_EMPH
prescriptive_PRED
than_PIN
SSAP_NN
24_CD
in_PIN
the_DT
assumptions_NOMZ
and_PHC
methodology_NN
that_TSUB
must_NEMD
be_VB [PASS]
used_VBN
in_PIN
order_NN
to_TO
assess_VB
actuarial_JJ
liabilities_NOMZ
._.
In_CONJ
particular_NULL
,_,
FRS_NN
17_CD
prescribes_VPRT
the_DT
use_NN
of_PIN
the_DT
projected_VBN
unit_NN
method_NN
of_PIN
valuation_NOMZ
and_CC
a_DT
discount_NN
rate_NN
obtained_VBN [WZPAST]
from_PIN
corporate_JJ
bonds_NN
rather_RB
than_PIN
equities_NOMZ
._.
Because_CAUS
of_PIN
the_DT
low_JJ
average_JJ
age_NN
of_PIN
the_DT
members_NN
of_PIN
the_DT
CP&LAS_NN
,_,
the_DT
Group_NN
considers_VPRT [PRIV]
the_DT
SSAP_NN
24_CD
valuation_NOMZ
to_TO
be_VB [BEMA]
more_EMPH
relevant_PRED
._.
The_DT
results_NN
of_PIN
the_DT
FRS_NN
17_CD
review_NN
are_VPRT [PASS]
presented_VBN
below_PLACE
._.
Qualified_VBN
independent_JJ
actuaries_NN
updated_VBN
the_DT
actuarial_JJ
valuations_NOMZ
of_PIN
the_DT
major_JJ
defined_VBN
benefit_NN
schemes_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
to_PIN
31_CD
December_NN
2003_CD
._.
The_DT
main_JJ
financial_JJ
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
this_DEMP
update_VB
were_VBD
as_IN
follows_VPRT
:_:
2003 2002 2001_CD
UK_NN
US_FPP1
Germany_NN
UK_NN
US_FPP1
Germany_NN
UK_NN
US_FPP1
Germany_NN
Assumptions_NOMZ
%_NN
%_NN
%_NN
%_NN
%_NN
%_NN
%_NN
%_NN
%_NN
Inflation_NOMZ
assumptions_NOMZ
2.8_CD
n_VBD
a_DT
2.0_CD
2.3_CD
3.0_CD
2.0_CD
2.6_CD
3.0_CD
2.0_CD
Rate_NN
of_PIN
increase_NN
in_PIN
salaries_NN
4.3_CD
n_VBD
a_DT
3.0_CD
3.8_CD
4.1-4_CD
.6_CD
3.0_CD
4.1_CD
5.0_CD
3.0_CD
Rate_NN
of_PIN
increase_NN
in_PIN
pension_NN
payment_NOMZ
2.1-2_CD
.7_CD
1.5_CD
1.9-2_CD
.3_CD
2.0_CD
2.0-2_CD
.6_CD
2.0_CD
Discount_NN
rate_NN
5.4_CD
6.0_CD
5.3_CD
5.5_CD
6.7_CD
6.0_CD
5.9_CD
7.0_CD
6.0_CD
Long-term_JJ
rate_NN
of_PIN
return_NN
expected_VBN [PRIV] [WZPAST]
at_PIN
31_CD
December_NN
Equities_NOMZ
7.8_CD
9.2_CD
n_NN
a_DT
7.5_CD
9.0_CD
n_IN
a_DT
7.2_CD
10.0_CD
n_IN
a_DT
Bonds_NN
5.4_CD
6.0_CD
n_IN
a_DT
4.5_CD
6.7_CD
n_NN
a_DT
5.0_CD
7.0_CD
n_NN
a_DT
Insurance_NN
4.8_CD
n_VPRT
a_DT
4.5_CD
4.5_CD
n_NN
a_DT
3.5_CD
n_NN
a_DT
n_NN
a_DT
3.5_CD
Pension_NN
fund_NN
deficit_NN
The_DT
pension_NN
fund_NN
deficit_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
under_IN
FRS_NN
17_CD
is_VPRT
as_IN
if_COND
this_DEMO
standard_NN
were_VBD [SPAU] [PASS]
fully_AMP
applied_VBN
._.
However_CONJ
,_,
under_IN
the_DT
current_JJ
accounting_GER
methodology_NN
SSAP_NN
24_CD
there_EX
are_VPRT
assets_NN
and_PHC
provisions_NN
within_PIN
the_DT
balance_NN
sheet_NN
at_PIN
31_CD
December_NN
2003_CD
that_DEMP
would_PRMD
offset_VB
the_DT
effect_NN
on_PIN
net_JJ
assets_NN
see_VPRT [PRIV]
below_PLACE
of_PIN
this_DEMO
deficit_NN
in_PIN
the_DT
event_NN
of_PIN
a_DT
restatement_NOMZ
under_IN
FRS_NN
17_CD
._.
If_COND
FRS_NN
17_CD
had_VBD [PEAS]
been_VBN [PASS]
adopted_VBN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
,_,
the_DT
Groups_NN
net_JJ
assets_NN
per_PIN
the_DT
balance_NN
sheet_NN
would_PRMD
be_VB [BYPA]
reduced_VBN
by_PIN
24.2_CD
million_CD
2002_CD
:_:
18.4_CD
million_CD
._.
Further_JJ
explanation_NOMZ
of_PIN
this_DEMO
adjustment_NOMZ
is_VPRT [PASS]
included_VBN
below_PLACE
._.
The_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
major_JJ
defined_VBN
benefit_NN
schemes_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
at_PIN
31_CD
December_NN
2003_CD
as_IN
calculated_VBN [PRIV]
in_PIN
accordance_NN
with_PIN
FRS_NN
17_CD
are_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
page_NN
76_CD
._.
Celltech_NN
Annual_JJ
Report_NN
2003_CD
75_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
27_CD
._.
Pension_NN
arrangements_NOMZ
continued_VBD
Pension_NN
fund_NN
deficit_NN
continued_VBD
The_DT
fair_JJ
value_NN
of_PIN
the_DT
schemes_NN
assets_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
not_XX0
intended_VBN [SUAV]
to_TO
be_VB [PASS]
realized_VBN [PRIV]
in_PIN
the_DT
short_JJ
term_NN
and_CC
may_POMD
be_VB [BEMA]
subject_PRED
to_PIN
significant_JJ
change_NN
before_IN
they_TPP3
are_VPRT [PASS]
realized_VBN [PRIV]
,_,
and_ANDC
the_DT
present_JJ
value_NN
of_PIN
the_DT
schemes_NN
liabilities_NOMZ
,_,
which_WDT [SERE]
are_VPRT [PASS]
derived_VBN
from_PIN
cash_NN
flow_NN
projections_NOMZ
over_IN
long_JJ
periods_NN
and_CC
are_VPRT
thus_CONJ
inherently_RB
uncertain_JJ
,_,
were_VBD
:_:
2003 2002 2001_CD
UK_NN
US_FPP1
Germany_NN
Total_NN
UK_NN
US_FPP1
Germany_NN
Total_NN
UK_NN
US_FPP1
Germany_NN
Total_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Scheme_FW
assets_NN
Equities_NOMZ
32.6_CD
5.5_CD
38.1_CD
29.5_CD
4.2_CD
33.7_CD
38.5_CD
5.7_CD
44.2_CD
Bonds_NN
8.8_CD
3.4_CD
12.2_CD
2.0_CD
3.4_CD
5.4_CD
1.6_CD
2.8_CD
4.4_CD
RABBI_NN
trust_NN
account_NN
2.0_CD
2.0_CD
2.1_CD
2.1_CD
2.5_CD
2.5_CD
Insurance_NN
0.9_CD
12.1_CD
13.0_CD
3.9_CD
11.1_CD
15.0_CD
10.0_CD
10.0_CD
Total_JJ
fair_JJ
value_NN
of_PIN
assets_NN
42.3_CD
10.9_CD
12.1_CD
65.3_CD
35.4_CD
9.7_CD
11.1_CD
56.2_CD
40.1_CD
11.0_CD
10.0_CD
61.1_CD
Present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
64.1_CD
14.5_CD
12.2_CD
90.8_CD
52.1_CD
13.3_CD
11.0_CD
76.4_CD
48.0_CD
15.7_CD
9.6_CD
73.3_CD
Deficit_NN
in_PIN
the_DT
scheme_NN
21.8_CD
3.6_CD
0.1_CD
25.5_CD
16.7_CD
3.6_CD
0.1_CD
20.2_CD
7.9_CD
4.7_CD
0.4_CD
12.2_CD
Related_VBN
deferred_VBN
tax_NN
credit_NN
1.5_CD
1.5_CD
1.5_CD
1.5_CD
Net_JJ
pension_NN
fund_NN
scheme_NN
deficit_NN
surplus_NN
under_IN
FRS_NN
17_CD
21.8_CD
2.1_CD
0.1_CD
24.0_CD
16.7_CD
2.1_CD
0.1_CD
18.7_CD
7.9_CD
4.7_CD
0.4_CD
12.2_CD
Adjustments_NOMZ
for_PIN
existing_VBG
assets_NN
and_PHC
provisions_NN
under_IN
SSAP_NN
24_CD
Assets_NN
,_,
net_NN
of_PIN
related_JJ
deferred_JJ
tax_NN
2.8_CD
2.8_CD
2.1_CD
0.5_CD
2.6_CD
2.5_CD
0.4_CD
2.9_CD
Provision_NN
,_,
net_NN
of_PIN
deferred_JJ
tax_NN
0.1_CD
2.5_CD
2.6_CD
2.9_CD
2.9_CD
1.0_CD
3.0_CD
4.0_CD
Adjustment_NOMZ
to_PIN
FRS_NN
17_CD
,_,
net_NN
of_PIN
related_JJ
deferred_JJ
tax_NN
21.7_CD
2.4_CD
0.1_CD
24.2_CD
16.7_CD
1.3_CD
0.4_CD
18.4_CD
6.9_CD
4.2_CD
11.1_CD
Net_JJ
assets_NN
as_IN
currently_RB
disclosed_VBN [PUBV]
n_IN
a_DT
n_NN
a_DT
n_NN
a_DT
505.9_CD
n_NN
a_DT
n_NN
a_DT
n_NN
a_DT
564.4_CD
n_NN
a_DT
n_NN
a_DT
n_NN
a_DT
619.2_CD
Net_JJ
assets_NN
as_IN
adjusted_VBN
if_COND
FRS_NN
17_CD
were_VBD [SPAU] [PASS]
fully_AMP
adopted_VBN
n_IN
a_DT
n_NN
a_DT
n_NN
a_DT
481.7_CD
n_NN
a_DT
n_NN
a_DT
n_NN
a_DT
546.0_CD
n_NN
a_DT
n_NN
a_DT
n_NN
a_DT
608.1_CD
The_DT
RABBI_NN
trust_NN
is_VPRT [PASS]
held_VBN [PRIV]
in_PIN
the_DT
Groups_NN
own_VPRT
name_NN
and_CC
is_VPRT [PASS]
shown_VBN [PRIV]
within_PIN
other_JJ
debtors_NN
in_PIN
note_NN
15_CD
._.
This_DEMO
account_NN
can_POMD [SPAU]
only_DWNT
be_VB [BYPA]
used_VBN
by_PIN
the_DT
Group_NN
to_TO
pay_VB
the_DT
pension_NN
liabilities_NOMZ
of_PIN
the_DT
US_FPP1
Unqualified_NN
Scheme_NN
,_,
except_PIN
in_PIN
the_DT
case_NN
of_PIN
bankruptcy_NN
when_RB
it_PIT
would_PRMD
become_VB
part_NN
of_PIN
the_DT
general_JJ
pool_NN
of_PIN
assets_NN
and_PHC
pensioners_NN
would_PRMD
rank_VB
as_IN
ordinary_JJ
creditors_NN
._.
Included_VBN [PASTP]
within_PIN
the_DT
insurance_NN
assets_NN
held_VBN [PRIV] [WZPAST]
in_PIN
Germany_NN
are_VPRT [BEMA]
6.0_CD
million_CD
of_PIN
insurance_NN
arrangements_NOMZ
in_PIN
the_DT
Companys_NN
own_JJ
name_NN
which_WDT [WHSUB]
were_VBD [PASS]
written_VBN [PUBV]
in_PIN
order_NN
to_TO
cover_VB
the_DT
pension_NN
deficits_NN
that_TSUB
would_PRMD [SPAU]
otherwise_CONJ
exist_VB
in_PIN
the_DT
pension_NN
scheme_NN
._.
There_EX
is_VPRT
no_SYNE
intention_NOMZ
to_TO
use_VB
these_DEMO
assets_NN
for_PIN
any_QUAN
purpose_NN
other_JJ
than_PIN
to_TO
cover_VB
the_DT
deficit_NN
and_CC
,_,
accordingly_RB
,_,
they_TPP3
have_VPRT [PEAS]
been_VBN [PASS]
shown_VBN [PRIV]
as_IN
part_NN
of_PIN
the_DT
available_JJ
assets_NN
._.
FRS_NN
17_CD
pension_NN
charge_NN
in_PIN
respect_NN
of_PIN
defined_VBN
benefit_NN
Schemes_NN
2003_CD
2002_CD
UK_NN
US_FPP1
Germany_NN
Total_NN
UK_NN
US_FPP1
Germany_NN
Total_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Operating_GER
profit_NN
Current_JJ
service_NN
cost_NN
1.4_CD
0.1_CD
0.2_CD
1.7_CD
2.0_CD
1.1_CD
0.2_CD
3.3_CD
Past_NN
service_NN
costs_VPRT
0.2_CD
0.2_CD
Gain_NN
on_PIN
curtailment_NOMZ
2.6_CD
2.6_CD
Loss_NN
on_PIN
RABBI_NN
trust_NN
0.2_CD
0.2_CD
Settlement_NOMZ
on_PIN
bulk_NN
transfer_NN
0.5_CD
0.5_CD
Total_JJ
operating_VBG
charge_NN
income_NN
1.4_CD
0.1_CD
0.2_CD
1.7_CD
1.7_CD
1.3_CD
0.2_CD
0.6_CD
Finance_NN
expense_NN
Expected_VBN [PRIV]
return_NN
on_PIN
pension_NN
scheme_NN
assets_NN
2.5_CD
0.6_CD
0.3_CD
3.4_CD
2.8_CD
0.7_CD
0.2_CD
3.7_CD
Interest_NN
charge_NN
2.9_CD
0.9_CD
0.7_CD
4.5_CD
2.9_CD
1.0_CD
0.6_CD
4.5_CD
Net_JJ
expense_NN
0.4_CD
0.3_CD
0.4_CD
1.1_CD
0.1_CD
0.3_CD
0.4_CD
0.8_CD
Loss_NN
gain_NN
before_IN
taxation_NOMZ
1.8_CD
0.4_CD
0.6_CD
2.8_CD
1.8_CD
1.0_CD
0.6_CD
1.4_CD
76_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
27_CD
._.
Pension_NN
arrangements_NOMZ
continued_VBD
2003_CD
2002_CD
UK_NN
US_FPP1
Germany_NN
Total_NN
UK_NN
US_FPP1
Germany_NN
Total_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Consolidated_NN
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Actual_JJ
return_NN
less_RB
expected_JJ
return_NN
on_PIN
pension_NN
schemes_NN
assets_NN
3.0_CD
0.9_CD
0.1_CD
3.8_CD
6.2_CD
1.9_CD
0.3_CD
7.8_CD
Experience_NN
losses_NN
gains_VPRT
arising_VBG
on_PIN
the_DT
schemes_NN
liabilities_NOMZ
0.9_CD
0.2_CD
0.6_CD
0.5_CD
0.3_CD
0.7_CD
0.4_CD
0.6_CD
Changes_NN
in_PIN
assumptions_NOMZ
underlying_VBG [WZPRES]
the_DT
present_JJ
value_NN
of_PIN
the_DT
schemes_NN
liabilities_NOMZ
7.0_CD
1.9_CD
0.6_CD
9.5_CD
3.8_CD
0.5_CD
4.3_CD
Actuarial_JJ
loss_NN
recognized_VBN [PRIV]
4.9_CD
1.2_CD
0.1_CD
6.2_CD
9.7_CD
1.7_CD
0.1_CD
11.5_CD
Additional_JJ
disclosures_NN
required_VBN [SUAV] [WZPAST]
by_PIN
FRS_NN
17 2003 2002_CD
UK_NN
US_FPP1
Germany_NN
Total_NN
UK_NN
US_FPP1
Germany_NN
Total_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Difference_NN
between_PIN
the_DT
expected_VBN [PRIV]
and_CC
actual_JJ
return_NN
on_PIN
scheme_NN
assets_NN
:_:
Amount_NN
3.0_CD
0.9_CD
0.1_CD
3.8_CD
6.2_CD
1.9_CD
0.3_CD
7.8_CD
Percentage_NN
of_PIN
scheme_NN
assets_NN
7_CD
%_NN
8_CD
%_NN
1_CD
%_NN
6_CD
%_NN
18_CD
%_NN
20_CD
%_NN
2_CD
%_NN
14_CD
%_NN
Experience_NN
gains_NN
and_PHC
losses_NN
on_PIN
scheme_NN
liabilities_NOMZ
:_:
Amount_NN
0.9_CD
0.2_CD
0.6_CD
0.5_CD
0.3_CD
0.7_CD
0.4_CD
0.6_CD
Percentage_NN
of_PIN
the_DT
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
1_CD
%_NN
1_CD
%_NN
5_CD
%_NN
1_CD
%_NN
1_CD
%_NN
5_CD
%_NN
4_CD
%_NN
1_CD
%_NN
Total_JJ
amount_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
:_:
Amount_NN
4.9_CD
1.2_CD
0.1_CD
6.2_CD
9.7_CD
1.7_CD
0.1_CD
11.5_CD
Percentage_NN
of_PIN
the_DT
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
8_CD
%_NN
8_CD
%_NN
1_CD
%_NN
7_CD
%_NN
19_CD
%_NN
13_CD
%_NN
1_CD
%_NN
15_CD
%_NN
The_DT
movement_NOMZ
in_PIN
deficit_NN
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
is_VPRT
as_IN
follows_VPRT
:_:
2003_CD
2002_CD
UK_NN
US_FPP1
Germany_NN
Total_NN
UK_NN
US_FPP1
Germany_NN
Total_NN
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
m_FW
Deficit_NN
surplus_NN
in_PIN
schemes_NN
at_PIN
beginning_GER
of_PIN
the_DT
year_NN
16.7_CD
3.6_CD
0.1_CD
20.2_CD
7.9_CD
4.7_CD
0.4_CD
12.2_CD
Current_JJ
service_NN
cost_NN
1.4_CD
0.1_CD
0.2_CD
1.7_CD
2.0_CD
1.1_CD
0.2_CD
3.3_CD
Contributions_NOMZ
1.6_CD
1.0_CD
0.4_CD
3.0_CD
2.7_CD
1.3_CD
0.4_CD
4.4_CD
Past_NN
service_NN
costs_VPRT
0.2_CD
0.2_CD
Other_JJ
finance_NN
income_NN
0.4_CD
0.3_CD
0.4_CD
1.1_CD
0.1_CD
0.3_CD
0.4_CD
0.8_CD
Gains_NN
on_PIN
curtailment_NOMZ
2.6_CD
2.6_CD
Settlement_NOMZ
on_PIN
bulk_NN
transfer_NN
0.5_CD
0.5_CD
Actuarial_JJ
loss_NN
4.9_CD
1.2_CD
0.1_CD
6.2_CD
9.7_CD
1.7_CD
0.1_CD
11.5_CD
Loss_NN
on_PIN
RABBI_NN
trust_NN
0.2_CD
0.2_CD
Exchange_NN
0.6_CD
0.1_CD
0.7_CD
0.5_CD
0.5_CD
Deficit_NN
surplus_NN
in_PIN
schemes_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
21.8_CD
3.6_CD
0.1_CD
25.5_CD
16.7_CD
3.6_CD
0.1_CD
20.2_CD
2003_CD
2002_CD
Total_JJ
Total_JJ
Reserves_NN
note_VPRT [PRIV]
m_FW
m_FW
Profit_NN
and_PHC
loss_NN
reserve_NN
excluding_VBG [WZPRES]
FRS_NN
17_CD
additional_JJ
pension_NN
liability_NOMZ
340.5_CD
281.6_CD
FRS_NN
17_CD
additional_JJ
pension_NN
liability_NOMZ
24.2_CD
18.4_CD
Profit_NN
and_PHC
loss_NN
reserve_NN
364.7_CD
300.0_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
77_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
28_CD
._.
Contingent_JJ
liabilities_NOMZ
a_DT
The_DT
Group_NN
has_VPRT
unsecured_JJ
and_PHC
undrawn_JJ
overdraft_NN
facilities_NOMZ
of_PIN
10_CD
million_CD
2002_CD
:_:
11_CD
million_CD
net_JJ
see_VPRT [PRIV]
note_NN
21_CD
._.
The_DT
Company_NN
has_VPRT [PEAS]
provided_VBN
guarantees_NN
to_TO
finance_VB
companies_NN
in_PIN
respect_NN
of_PIN
finance_NN
leases_NN
to_PIN
Celltech_NN
R&D_NN
Limited_NN
not_XX0
exceeding_VBG
2.5_CD
million_CD
2002_CD
:_:
2.5_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
1.0_CD
million_CD
2002_CD
:_:
1.4_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
utilised_VBN
._.
The_DT
Company_NN
has_VPRT [SPAU] [PEAS]
also_RB
provided_VBN
guarantees_NN
to_PIN
XL_NN
Winterthur_NN
International_NN
of_PIN
$_$
13.5_CD
million_CD
in_PIN
respect_NN
of_PIN
reinsurance_NN
liabilities_NOMZ
and_CC
8_CD
million_CD
to_PIN
Sandoz_NN
in_PIN
respect_NN
of_PIN
manufacturing_VBG
capacity_NOMZ
arrangements_NOMZ
._.
b_NN
The_DT
principal_JJ
litigation_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT [PEAS]
been_VBN [PASS]
involved_VBN
in_PIN
2003_CD
is_VPRT [PASS]
discussed_VBN
below_PLACE
._.
In_PIN
common_JJ
with_PIN
most_EMPH
trading_GER
companies_NN
,_,
Celltech_NN
and_CC
various_JJ
of_PIN
its_PIT
subsidiary_NN
undertakings_GER
are_VPRT [BEMA]
the_DT
subject_NN
of_PIN
a_DT
number_NN
of_PIN
legal_JJ
claims_NN
or_CC
potential_JJ
claims_NN
against_PIN
the_DT
Group_NN
,_,
the_DT
outcome_NN
of_PIN
which_WDT [PIRE]
can_POMD
not_XX0
at_PIN
present_JJ
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
._.
Provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
in_PIN
these_DEMO
accounts_NN
for_PIN
all_QUAN
liabilities_NOMZ
which_WDT [WHSUB]
might_POMD
be_VB [SPAU] [PASS]
reasonably_RB
expected_VBN [PRIV]
to_TO
materialise_VB
from_PIN
these_DEMO
claims_NN
._.
i_FPP1
Ionamin_NN
In_PIN
July_NN
1997_CD
,_,
significant_JJ
health_NN
concerns_NN
were_VBD [PASS]
raised_VBN
over_IN
the_DT
use_NN
of_PIN
the_DT
so-called_JJ
fen-phen_JJ
diet_NN
co-prescription_NOMZ
of_PIN
fenfluramine_NN
and_PHC
phentermine_NN
._.
These_DEMO
concerns_NN
resulted_VBD
in_PIN
the_DT
voluntary_JJ
withdrawal_NN
from_PIN
the_DT
market_NN
of_PIN
fenfluramine_NN
and_CC
a_DT
related_VBN
drug_NN
dexfenfluramine_NN
in_PIN
September_NN
1997_CD
._.
These_DEMO
withdrawals_NN
were_VBD [BYPA]
followed_VBN
by_PIN
the_DT
commencement_NOMZ
of_PIN
a_DT
significant_JJ
number_NN
of_PIN
lawsuits_NN
in_PIN
the_DT
US_FPP1
against_PIN
manufacturers_NN
and_PHC
prescribers_NN
of_PIN
fenfluramine_NN
,_,
dexfenfluramine_NN
and_PHC
phentermine_NN
._.
The_DT
most_EMPH
common_JJ
allegation_NOMZ
is_VPRT
that_DEMO
the_DT
fen-phen_JJ
diet_NN
caused_VBD
heart_NN
valve_NN
problems_NN
,_,
neurological_JJ
dysfunction_NOMZ
and_CC
,_,
much_QUAN
less_JJ
frequently_RB
,_,
primary_JJ
pulmonary_JJ
hypertension_NN
,_,
a_DT
rare_JJ
,_,
frequently_RB
fatal_JJ
disease_NN
of_PIN
the_DT
lungs_NN
._.
Celltech_NN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
in_PIN
close_NN
to_PIN
7,000_CD
of_PIN
these_DEMO
cases_NN
,_,
approximately_RB
1,500_CD
of_PIN
which_WDT [PIRE]
were_VBD
pending_VBG
as_RB
at_PIN
31_CD
December_NN
2003_CD
._.
The_DT
Groups_NN
involvement_NOMZ
derives_VPRT
from_PIN
the_DT
sale_NN
by_PIN
a_DT
Celltech_NN
subsidiary_NN
,_,
since_OSUB
2_CD
July_NN
1996_CD
,_,
of_PIN
lonamin_NN
,_,
the_DT
phentermine_NN
prescription_NOMZ
pharmaceutical_JJ
acquired_VBN
from_PIN
Fisons_NN
Corporation_NOMZ
Fisons_NN
on_PIN
that_DEMO
date_NN
._.
At_PIN
12_CD
February_NN
2004_CD
,_,
the_DT
Group_NN
had_VBD [PEAS]
been_VBN [SPAU] [PASS]
formally_RB
dismissed_VBN
from_PIN
approximately_RB
5,370_CD
of_PIN
these_DEMO
cases_NN
without_PIN
payment_NOMZ
of_PIN
any_QUAN
sums_NN
by_PIN
way_NN
of_PIN
damages_NN
or_CC
costs_NN
to_PIN
third_JJ
parties_NN
,_,
and_ANDC
dismissals_NN
of_PIN
more_EMPH
than_PIN
700_CD
additional_JJ
cases_NN
,_,
also_RB
without_PIN
payment_NOMZ
,_,
were_VBD [PASS]
agreed_VBN [SUAV] [PUBV]
to_TO
or_CC
filed_VBN
but_CC
were_VBD
not_XX0
yet_RB
effective_PRED
._.
Celltech_NN
denies_VPRT [PUBV]
liability_NOMZ
on_PIN
a_DT
number_NN
of_PIN
grounds_NN
,_,
including_VBG
,_,
fundamentally_RB
,_,
that_THVC
Ionamin_NN
does_VPRT
not_XX0
cause_VB
the_DT
health_NN
conditions_NOMZ
complained_VBD [PUBV]
of_PIN [STPR]
._.
Ionamin_NN
has_VPRT [PEAS]
been_VBN [PASS]
marketed_VBN
since_OSUB
1959_CD
and_CC
the_DT
FDA_NN
did_VBD
not_XX0
request_NN
that_TOBJ
Ionamin_NN
or_CC
any_QUAN
other_JJ
phentermine_NN
be_VB [PASS]
withdrawn_VBN
from_PIN
the_DT
market_NN
._.
Moreover_CONJ
,_,
Celltech_NN
believes_VPRT [PRIV] [THATD]
it_PIT
will_PRMD
be_VB [PASS]
indemnified_VBN
for_PIN
any_QUAN
unanticipated_JJ
liability_NOMZ
by_PIN
Fisons_NN
for_PIN
Ionamin_NN
sold_VBD
prior_RB
to_PIN
2_CD
July_NN
1996_CD
and_CC
by_PIN
Celltechs_NN
product_NN
liability_NOMZ
insurance_NN
carriers_NN
for_PIN
Ionamin_NN
sold_VBD
after_IN
2_CD
July_NN
1996_CD
._.
Celltechs_NN
defense_NN
costs_NN
are_VPRT
being_VBG [BYPA]
paid_VBN
by_PIN
Fisons_NN
and_CC
its_PIT
insurance_NN
carriers_NN
as_IN
required_VBN [SUAV]
by_PIN
their_TPP3
contractual_JJ
indemnities_NOMZ
._.
Fisons_NN
indemnity_NOMZ
obligations_NOMZ
are_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
Rhone_NN
Poulenc_NN
Rorer_NN
Inc_NN
,_,
now_DPAR
part_NN
of_PIN
Aventis_NN
Pharmaceuticals_NN
._.
Based_VBN [PASTP]
on_PIN
the_DT
merits_NN
of_PIN
its_PIT
defences_NN
and_CC
based_VBN
on_PIN
the_DT
third_JJ
party_NN
insurance_NN
coverage_NN
benefiting_VBG [WZPRES]
Celltech_NN
discussed_VBD
above_PLACE
,_,
Celltech_NN
believes_VPRT [PRIV]
that_THVC
the_DT
ultimate_JJ
outcome_NN
of_PIN
this_DEMO
litigation_NOMZ
will_PRMD
not_XX0
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
its_PIT
financial_JJ
position_NOMZ
and_PHC
results_NN
of_PIN
the_DT
operations_NOMZ
._.
ii_FW
MedImmune_NN
Litigation_NOMZ
relating_VBG [WZPRES]
to_PIN
Synagis_NN
In_PIN
1998_CD
Celltech_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
MedImmune_NN
Inc_NN
a_DT
worldwide_JJ
non-exclusive_JJ
licence_NN
to_TO
use_VB
certain_JJ
of_PIN
its_PIT
patents_NN
in_PIN
relation_NOMZ
to_PIN
its_PIT
humanised_JJ
antibody_NN
preparation_NOMZ
,_,
palivizumab_NN
sold_VBN [WZPAST]
by_PIN
MedImmune_NN
under_IN
the_DT
trade_NN
name_NN
Synagis_NN
._.
Celltech_NN
believe_VPRT [PRIV]
that_THVC
MedImmunes_NN
Synagis_NN
product_NN
comes_VPRT
within_PIN
the_DT
scope_NN
of_PIN
its_PIT
patents_NN
and_CC
that_DEMO
accordingly_RB
MedImmune_NN
owes_VPRT
significant_JJ
royalties_NN
to_PIN
Celltech_NN
._.
MedImmune_NN
disputes_NN
this_DEMP
and_CC
have_VPRT [PEAS]
refused_VBN
to_TO
pay_VB
any_QUAN
royalties_NN
._.
Accordingly_RB
Celltech_NN
commenced_VBD
two_CD
legal_JJ
actions_NOMZ
against_PIN
MedImmune_NN
one_CD
in_PIN
respect_NN
of_PIN
the_DT
US_FPP1
patent_NN
the_DT
major_JJ
market_NN
for_PIN
Synagis_NN
and_CC
the_DT
other_JJ
in_PIN
respect_NN
of_PIN
the_DT
German_JJ
patent_NN
where_RB
Synagis_NN
is_VPRT [PASS]
manufactured_VBN
._.
Both_DT
actions_NOMZ
are_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
jurisdiction_NOMZ
of_PIN
the_DT
UK_NN
Courts_NN
._.
The_DT
claim_NN
with_PIN
respect_NN
to_PIN
the_DT
US_FPP1
patent_NN
was_VBD [BYPA]
dismissed_VBN
by_PIN
the_DT
High_NN
Court_NN
in_PIN
November_NN
2002_CD
._.
Celltechs_NN
appeal_NN
to_PIN
the_DT
Court_NN
of_PIN
Appeal_NN
was_VBD [BYPA]
dismissed_VBN
by_PIN
a_DT
majority_NOMZ
decision_NN
in_PIN
July_NN
2003_CD
with_PIN
an_DT
Order_NN
that_TOBJ
Celltech_NN
pay_NN
MedImmunes_NN
legal_JJ
costs_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
MedImmunes_NN
claim_NN
for_PIN
legal_JJ
costs_NN
had_VBD [PEAS]
been_VBN [PASS]
settled_VBN
and_PHC
paid_VBN
by_PIN
Celltech_NN
._.
The_DT
claim_NN
with_PIN
respect_NN
to_PIN
the_DT
German_JJ
patent_NN
is_VPRT [PASS]
scheduled_VBN
for_PIN
hearing_GER
in_PIN
the_DT
High_NN
Court_NN
at_PIN
the_DT
end_NN
of_PIN
March_NN
2004_CD
._.
On_PIN
14_CD
October_NN
2003_CD
,_,
Celltech_NN
obtained_VBD
the_DT
grant_NN
of_PIN
a_DT
further_JJ
US_FPP1
patent_NN
which_WDT [WHSUB]
also_RB
falls_VPRT
within_PIN
the_DT
scope_NN
of_PIN
the_DT
licence_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
MedImmune_NN
._.
In_PIN
January_NN
2004_CD
,_,
MedImmune_NN
filed_VBD
a_DT
declaratory_JJ
action_NOMZ
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Columbia_NN
in_PIN
respect_NN
of_PIN
this_DEMO
patent_NN
seeking_VBG [WZPRES]
a_DT
declaration_NOMZ
that_TOBJ
its_PIT
Synagis_NN
product_NN
does_VPRT
not_XX0
infringe_VB
the_DT
patent_NN
and_CC
that_THVC
the_DT
patent_NN
is_VPRT [BEMA]
invalid_PRED
._.
This_DEMO
matter_NN
also_RB
forms_VPRT
the_DT
subject_NN
of_PIN
further_JJ
litigation_NOMZ
in_PIN
the_DT
UK_NN
._.
Since_OSUB
the_DT
scope_NN
of_PIN
MedImmunes_NN
claims_NN
are_VPRT [PASS]
limited_VBN
to_TO
seeking_VBG
a_DT
declaration_NOMZ
that_TOBJ
it_PIT
owes_VPRT
no_SYNE
royalties_NN
in_PIN
respect_NN
of_PIN
Synagis_NN
,_,
Celltech_NN
has_VPRT
no_SYNE
potential_JJ
liability_NOMZ
under_IN
any_QUAN
of_PIN
this_DEMP
pending_VBG
litigation_NOMZ
save_VB
in_PIN
respect_NN
of_PIN
MedImmunes_NN
legal_JJ
costs_NN
should_NEMD
Celltechs_NN
claim_NN
in_PIN
the_DT
UK_NN
Courts_NN
fail_VPRT
._.
Litigation_NOMZ
relating_VBG [WZPRES]
to_PIN
Boss_NN
Cabilly_NN
patent_NN
interference_NN
settlement_NOMZ
On_PIN
23_CD
December_NN
2003_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
for_PIN
the_DT
Central_NN
District_NN
of_PIN
California_NN
granted_VBD [SUAV]
summary_NN
judgement_NOMZ
in_PIN
favor_NN
of_PIN
Celltech_NN
and_PHC
Genentech_NN
that_TOBJ
the_DT
settlement_NOMZ
of_PIN
the_DT
Boss_NN
Cabilly_NN
patent_NN
interference_NN
between_PIN
Celltech_NN
and_PHC
Genentech_NN
was_VBD [BEMA]
immune_PRED
from_PIN
claims_NN
brought_VBN [WZPAST]
in_PIN
a_DT
lawsuit_NN
by_PIN
MedImmune_NN
under_IN
antitrust_JJ
and_PHC
unfair_JJ
competition_NOMZ
laws_NN
._.
On_PIN
19_CD
February_NN
2004_CD
the_DT
Court_NN
granted_VBD [SUAV]
final_JJ
judgement_NOMZ
in_PIN
favor_NN
of_PIN
Celltech_NN
and_PHC
Genentech_NN
on_PIN
those_DEMO
causes_NN
of_PIN
action_NOMZ
._.
Claims_NN
by_PIN
MedImmune_NN
against_PIN
Genentech_NN
that_TOBJ
the_DT
Cabilly_NN
patent_NN
is_VPRT [BEMA]
invalid_PRED
and_CC
not_XX0
infringed_VBN
are_VPRT
pending_VBG
in_PIN
the_DT
same_JJ
matter_NN
,_,
but_CC
those_DEMO
claims_NN
were_VBD [PASS]
not_XX0
asserted_VBN [PUBV]
against_PIN
Celltech_NN
._.
MedImmune_NN
has_VPRT [PEAS]
indicated_VBN [PRIV]
its_PIT
intention_NOMZ
to_PIN
78_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
appeal_NN
the_DT
judgement_NOMZ
._.
Should_NEMD
MedImmune_NN
appeal_NN
and_CC
ultimately_RB
prevail_VB
in_PIN
its_PIT
claims_NN
,_,
Celltech_NN
would_PRMD
be_VB [BEMA]
liable_PRED
to_TO
pay_VB
damages_NN
,_,
a_DT
reasonable_JJ
estimate_NN
of_PIN
which_WDT [PIRE]
can_POMD
not_XX0
be_VB [PASS]
made_VBN
at_PIN
this_DEMO
time_NN
._.
iii_FW
69kD_FW
Celltech_NN
is_VPRT [BEMA]
the_DT
owner_NN
of_PIN
patents_NN
for_PIN
69kD_NN
,_,
the_DT
Bordetella_NN
pertussis_NN
protein_NN
also_RB
known_VBN [PRIV]
as_IN
Pertactin_NN
._.
Celltech_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
GlaxoSmithKline_NN
an_DT
exclusive_JJ
worldwide_NN
licence_NN
to_TO
use_VB
the_DT
patents_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
licence_NN
,_,
Celltech_NN
has_VPRT
the_DT
first_JJ
option_NOMZ
to_TO
take_VB
proceedings_GER
to_TO
enforce_VB
the_DT
patents_NN
._.
Litigation_NOMZ
has_VPRT [PEAS]
arisen_VBN
in_PIN
Europe_NN
involving_VBG [WZPRES]
Celltechs_NN
patents_NN
and_CC
acellular_JJ
pertussis_NN
vaccines_NN
owned_VBN [WZPAST]
by_PIN
Chiron_NN
and_CC
its_PIT
subsidiaries_NN
._.
On_PIN
23_CD
July_NN
1998_CD
,_,
Celltech_NN
issued_VBD
infringement_NOMZ
proceedings_GER
in_PIN
Italy_NN
against_PIN
Chiron_NN
for_PIN
infringement_NOMZ
of_PIN
one_CD
of_PIN
Celltechs_NN
patents_NN
relating_VBG [WZPRES]
to_PIN
the_DT
69kD_JJ
antigen_NN
and_CC
is_VPRT
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Chiron_NN
from_PIN
marketing_VBG
its_PIT
product_NN
._.
Chiron_NN
is_VPRT
defending_VBG
that_DEMO
action_NOMZ
,_,
and_ANDC
has_VPRT [PEAS]
counterclaimed_VBN
for_PIN
a_DT
declaration_NOMZ
of_PIN
invalidity_NOMZ
of_PIN
the_DT
patent_NN
._.
Court_NN
experts_NN
have_VPRT [PEAS]
been_VBN [PASS]
appointed_VBN
,_,
but_CC
the_DT
date_NN
when_RB
their_TPP3
report_NN
will_PRMD
be_VB [PASS]
provided_VBN
is_VPRT [PASS]
not_XX0
known_VBN [PRIV]
._.
This_DEMO
patent_NN
is_VPRT [BEMA]
also_RB
subject_PRED
to_PIN
opposition_NOMZ
proceedings_GER
in_PIN
the_DT
European_JJ
Patent_NN
Office_NN
brought_VBN [WZPAST]
by_PIN
Chiron_NN
on_PIN
22_CD
January_NN
1997_CD
._.
The_DT
European_JJ
Patent_NN
Office_NN
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
,_,
in_PIN
a_DT
decision_NN
issued_VBN [WZPAST]
in_PIN
November_NN
2000_CD
,_,
that_THVC
the_DT
patent_NN
should_NEMD
be_VB [PASS]
revoked_VBN
._.
This_DEMO
decision_NN
of_PIN
the_DT
EPO_NN
is_VPRT [BEMA]
the_DT
subject_NN
of_PIN
an_DT
appeal_NN
by_PIN
Celltech_NN
which_WDT [WHSUB]
will_PRMD
be_VB [PASS]
heard_VBN [PRIV]
on_PIN
19_CD
March_NN
2004_CD
._.
iv_NN
Lonza_NN
On_PIN
14_CD
July_NN
2003_CD
,_,
Celltech_NN
announced_VBD [PUBV]
that_THVC
it_PIT
had_VBD [PEAS]
entered_VBN
into_PIN
a_DT
long-term_JJ
supply_NN
agreement_NOMZ
with_PIN
Lonza_NN
,_,
under_IN
which_WDT
Lonza_NN
will_PRMD
manufacture_VB
PEGylated_NN
antibody_NN
fragment_NOMZ
based_VBN
drugs_NN
for_PIN
Celltech_NN
at_PIN
its_PIT
microbial_JJ
production_NOMZ
facility_NOMZ
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
Celltech_NN
and_PHC
Lonza_NN
announced_VBD [PUBV]
a_DT
settlement_NOMZ
for_PIN
the_DT
termination_NOMZ
of_PIN
the_DT
CDP571_NN
manufacturing_GER
agreement_NOMZ
._.
The_DT
Group_NN
had_VBD [PEAS]
provided_VBN
as_RB
at_PIN
31_CD
December_NN
2002_CD
for_PIN
managements_NOMZ
best_JJ
estimate_NN
of_PIN
the_DT
amounts_NN
expected_VBN [PRIV]
to_TO
materialise_VB
from_PIN
the_DT
termination_NOMZ
of_PIN
this_DEMO
agreement_NOMZ
._.
The_DT
terms_NN
of_PIN
the_DT
settlement_NOMZ
have_VPRT [PEAS]
not_XX0
resulted_VBN
in_PIN
any_QUAN
additional_JJ
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
v_FW
Alpharma_NN
During_PIN
2002_CD
Celltech_NN
sold_VBD
its_PIT
Armstrong_NN
business_NOMZ
to_PIN
Andrx_NN
._.
This_DEMO
operation_NOMZ
had_VBD
a_DT
product_NN
supply_NN
contract_NN
with_PIN
a_DT
customer_NN
,_,
Alpharma_NN
._.
During_PIN
2003_CD
,_,
Alpharma_NN
voluntarily_RB
withdrew_VBD
the_DT
product_NN
from_PIN
sale_NN
claiming_VBG [PUBV] [WZPRES]
that_THVC
an_DT
element_NOMZ
of_PIN
the_DT
production_NOMZ
process_NN
did_VBD
not_XX0
have_VB
the_DT
required_JJ
FDA_NN
approval_NN
._.
They_TPP3
have_VPRT [PEAS]
filed_VBN
a_DT
suit_NN
against_PIN
Andrx_NN
and_PHC
Celltech_NN
has_VPRT [SPAU] [PEAS]
recently_TIME
been_VBN [PASS]
included_VBN
as_IN
a_DT
co-defendant_NN
in_PIN
respect_NN
of_PIN
liabilities_NOMZ
arising_VBG [WZPRES]
when_RB
Celltech_NN
owned_VBD
the_DT
Armstrong_NN
business_NOMZ
._.
Based_VBN [PASTP]
on_PIN
the_DT
merits_NN
of_PIN
its_PIT
defense_NN
,_,
Celltech_NN
believes_VPRT [PRIV]
that_THVC
the_DT
ultimate_JJ
outcome_NN
of_PIN
this_DEMO
litigation_NOMZ
will_PRMD
not_XX0
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
the_DT
financial_JJ
position_NOMZ
and_PHC
results_NN
of_PIN
the_DT
Company_NN
._.
However_CONJ
,_,
if_COND
the_DT
Company_NN
were_VBD [SPAU] [PASS]
ultimately_RB
held_VBN [PRIV]
liable_JJ
,_,
the_DT
damages_NN
that_TSUB
would_PRMD
be_VB [BEMA]
payable_PRED
could_POMD
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
a_DT
reasonable_JJ
estimate_NN
of_PIN
which_WDT [PIRE]
can_POMD
not_XX0
be_VB [PASS]
made_VBN
at_PIN
this_DEMO
time_NN
on_PIN
the_DT
financial_JJ
position_NOMZ
and_PHC
results_NN
of_PIN
operations_NOMZ
of_PIN
the_DT
Company_NN
._.
c_NN
Self_NN
insurance_NN
Since_OSUB
20_CD
September_NN
2001_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
been_VBN [PASS]
required_VBN [SUAV]
to_TO
increase_VB
its_PIT
levels_NN
of_PIN
self_NN
insurance_NN
in_PIN
respect_NN
of_PIN
methylphenidate_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
to_TO
retain_VB
a_DT
level_NN
of_PIN
self_NN
insurance_NN
in_PIN
respect_NN
of_PIN
all_QUAN
product_NN
liability_NOMZ
up_IN
to_TO
$_$
13.5_CD
million_CD
,_,
as_RB
well_RB
as_IN
self_NN
insurance_NN
in_PIN
respect_NN
of_PIN
methylphenidate_NN
of_PIN
up_RB
to_TO
$_$
20_CD
million_CD
._.
Whilst_OSUB
no_SYNE
methylphenidate_NN
claims_NN
have_VPRT [PEAS]
been_VBN [PASS]
received_VBN
since_OSUB
20_CD
September_NN
2001_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
provided_VBN
5.4_CD
million_CD
based_VBN
on_PIN
an_DT
external_JJ
review_NN
of_PIN
the_DT
likely_JJ
liability_NOMZ
associated_VBN [WZPAST]
with_PIN
incidents_NN
that_TSUB
may_POMD
arise_VB
from_PIN
past_JJ
sales_NN
of_PIN
methylphenidate_NN
prior_RB
to_PIN
20_CD
September_NN
2003_CD
and_CC
across_PLACE
all_QUAN
products_NN
after_IN
19_CD
September_NN
2003_CD
._.
Celltech_NN
Annual_JJ
Report_NN
2003_CD
79_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
29_CD
._.
Consolidated_NN
cash_NN
flow_NN
statements_NOMZ
Reconciliation_NOMZ
of_PIN
operating_VBG
loss_NN
to_PIN
net_JJ
cash_NN
outflow_NN
from_PIN
operating_VBG
activities_NOMZ
2003_CD
2002_CD
m_NN
m_NN
Operating_GER
loss_NN
63.6_CD
44.7_CD
Operating_GER
exceptional_JJ
items_NN
18.9_CD
Operating_GER
loss_NN
before_IN
exceptional_JJ
costs_NN
44.7_CD
44.7_CD
Depreciation_NOMZ
13.9_CD
13.3_CD
Goodwill_NN
amortisation_NOMZ
94.2_CD
93.7_CD
Intangibles_NN
amortisation_NOMZ
3.2_CD
1.0_CD
Increase_VPRT
decrease_NN
in_PIN
stocks_NN
3.6_CD
0.1_CD
Increase_VPRT
decrease_NN
in_PIN
debtors_NN
6.6_CD
0.9_CD
Increase_VPRT
decrease_NN
in_PIN
creditors_NN
28.9_CD
9.7_CD
Settlement_NOMZ
of_PIN
fair_JJ
value_NN
provisions_NN
22.5_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
before_IN
restructuring_VBG
costs_NN
62.8_CD
54.6_CD
Outflow_NN
relating_VBG [WZPRES]
to_TO
operating_VBG
exceptional_JJ
costs_NN
5.1_CD
5.2_CD
Outflow_NN
relating_VBG [WZPRES]
to_PIN
termination_NOMZ
of_PIN
operations_NOMZ
3.8_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
53.9_CD
49.4_CD
Analysis_NN
of_PIN
changes_NN
in_PIN
net_JJ
funds_NN
At_PIN
Cash_NN
Exchange_NN
At_PIN
1_CD
Jan_NN
2003_CD
Acquisitions_NOMZ
flow_NN
movements_NOMZ
31_CD
Dec_NN
2003_CD
m_FW
m_FW
m_FW
m_FW
m_FW
Cash_NN
81.1_CD
37.5_CD
5.1_CD
38.5_CD
Liquid_NN
resources_NN
24.0_CD
99.5_CD
7.0_CD
116.5_CD
Finance_NN
leases_NN
1.7_CD
0.7_CD
1.0_CD
Loans_NN
31.2_CD
28.5_CD
2.7_CD
Net_JJ
funds_NN
72.2_CD
99.5_CD
15.3_CD
2.4_CD
154.0_CD
80_CD
Celltech_NN
Annual_JJ
Report_NN
2003_CD
